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Thesis summary 
 
Introduction 
Sexual transmission of HIV-1 accounts for more than 80% of all the transmissions globally. 
After transmission, approximately 80% of the newly disseminated infections can be traced to 
a single variant, which comes from the minor HIV-1 population within the transmitting donor. 
This has led to the widely accepted idea of an HIV-1 transmission bottleneck. The nature of 
this bottleneck is not fully understood. Many studies working on understanding the nature of 
the transmitted virus have reported discordant traits of transmitted/founder viruses 
compared to viral isolates from chronically infected individuals. Such studies therefore lacked 
analysis of the intermediate step between these two populations: HIV-1 from the genital tract 
of the donors: where viruses are on their way to transmission to a new recipient. Importantly, 
numerous prior studies have shown that there is compartmentalization of HIV-1 populations 
between the general circulation and the genital tract, raising the possibility that the genital 
tract is an important selective environment. Collectively, prior studies of genital tract 
compartmentalization in males detected compartmentalization in about half of the donors 
studied, although by using techniques with limited depth of sampling than that employed in 
our study.  
 
The virus that establishes disseminated infection in a new recipient is selected. However, the 
extent to which this selection occurs before, during or after crossing the mucosal surfaces of 
the recipient is less clear – the period during which transmission selection could extend far 
back to the donor, and the donor’s genital tract. In other words, it is not clear as to what 
extent the transmission bottleneck occurs during compartmentalization of viral populations 
in the genital tract tissues. The design of an effective vaccine and other intervention strategies 
will rely upon the understanding the nature of the transmitted virus as this is the virus that 
must be targeted. 
 
This thesis 
Compartmentalization of minor variants cannot be tracked by techniques previously used to 
describe compartmentalization between the genital tract and the blood circulation. We 
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therefore used deep sequencing-based techniques to further understand 
compartmentalization of viral populations between blood and the male genital tract. In 
addition, we tested the sensitivity of variants to a range of entry and other inhibitors in order 
to explore possible changes in function that may arise when viral variants grow in the shifted 
selective milieu of the genital tract. We further hypothesized that this change of selective 
milieu as HIV-1 moves from blood into the genital tract may lead to viral variants in semen 
that are sensitive to autologous neutralization because such sensitive variants may be able to 
grow in the genital tract, which is presumably partially or completely shielded from 
antibodies. Because the viral populations in semen comes from a site that may be relatively 
protected from antibodies, they may be permitted to evolve differently in the relative 
absence of antibody pressure. It is possible that evolution of the virus within the genital tract 
is a significant part of the change the virus undergoes on its way to establishment of a new 
disseminated infection in the new recipient. We considered this possibility because even 
some small molecules like those of some antiretroviral drugs do not penetrate the genital 
tract effectively under some circumstances, raising the possibility that antibodies might not 
always penetrate in all areas of the genital tract.  
 
This thesis had three objectives: 
1. To evaluate HIV-1 compartmentalization in blood and the male genital tract using next 
generation sequencing to understand the nature of viral populations in these 
anatomical sites in greater detail.  
2. To identify the differences in sensitivity of blood and semen variants to entry inhibitors 
to obtain information about differences in function between HIV-1 populations in 
blood vs the male genital tract. 
3. To compare neutralization sensitivities of viral variants compartmentalized in blood 
and semen by testing their sensitivity to neutralization by autologous antibodies. As a 
control, we measured sensitivity to a pool of clade-matched heterologous sera to 
determine if any observed difference was due to global changes in neutralization 
sensitivity.  
 
Methods 
Study participants 
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Forty-four HIV-1 seropositive men were recruited and then requested to donate blood and 
semen samples at ANOVA Health’s Ivan Toms clinics at Woodstock and Green Point or 
through their mobile clinic in Khayelitsha, all in Cape Town, South Africa. Viral loads from 
blood and semen and CD4+ T cell counts from blood were measured. HIV-1 was enriched from 
semen using a Nycodenz gradient, and then concentrated using ultracentrifugation. 
 
Chapter 2: HIV-1 Compartmentalization in blood and semen 
Next generation sequencing on Illumina paired-end Miseq platform was performed. To our 
knowledge there is no published study that has used this technique to study male genital tract 
HIV-1 variants in chronically infected male donors, although there is one that does so for 
acutely infected donors.  We argue here that this is a superior method of sampling 
populations in blood and the male genital tract. In particular, it allowed us to more accurately 
track minor populations within each compartment. Additionally, the use of PrimerID 
approach allowed us to more clearly identify clonal amplification events in the HIV-1 
populations. Sequencing was performed on either the V3 or C3-V5 region of the HIV-1 
envelope gene from paired blood and semen samples from 11 donors.  
 
To evaluate compartmentalization, populations from blood and semen were compared using 
three standard techniques, Slatkin Maddison Test (SMT), Wrights measure of population 
subdivision (FST) and nearest neighbour statistic (Snn). Clonal amplification and results of 
modelling a lower depth of sampling are also presented.  
 
Chapter 3: Sensitivity of blood and semen variants to entry inhibitors and changes in 
function 
From three subjects who exhibited the highest extent of compartmentalization, full-length 
envelope clones derived from semen and blood RNA were made using limiting dilution PCR 
(single genome amplification), which provided the advantage of minimizing PCR-based 
artificial recombination. A high fidelity Taq polymerase was also used to minimize base-
substitution errors. An average of 10 clones were isolated per compartment. Pseudoviruses 
were then constructed from the full-length envelope clones from blood and semen. 
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The sensitivities of these pseudoviruses were tested against HIV-1 entry inhibitors; Maraviroc, 
PSC-RANTES, enfurvirtide (T-20) and JM2987. Maraviroc and PSC-RANTES are CCR5 inhibitors 
while JM2987 is a CXCR4 inhibitor. Enfurvirtide (T-20) is a fusion inhibitor blocking the virus 
from entering cells. The full-length clones used to make the pseudoviruses were also 
sequenced and genomic variations in variable loop characteristics (length and number of 
potential glycosylation sites) between blood and semen compared.  
 
Chapter 4: Sensitivity of blood and semen variants to autologous and heterologous 
antibodies  
To study the differences in sensitivity of blood and semen variants to antibodies, 
pseudoviruses cloned from semen RNA and blood RNA (above) were tested for their 
sensitivities to donor antibodies collected at the same time the samples were collected or to 
a pool of HIV-1 subtype C sera.  
 
Results 
Objective 1: Viral compartmentalization via next generation sequencing 
HIV-1 populations were compartmentalized in all the 11 donors studied but to varying 
extents. Donor SVB043 had the most compartmentalized viral populations between blood 
and the male genital compartment using all the three measures of compartmentalization. 
Further analysis of the phylogenetic trees revealed that some clusters contained either purely 
blood or semen sequences, even in trees generated from analysis of donors with weakest 
compartmentalization. This might explain the viral compartmentalization signal in these 
weakly compartmentalized donors.  
To mimic reduced sampling depth, subsampling of the Illumina Miseq data with a small 
number of sequences was done. This analysis revealed that viral compartmentalization 
between blood and male genital tract would likely (>50% estimated likelihood) have been 
detected in only 5/11 (45%) of the donors, a proportion which is very similar to the aggregate 
proportion from previous studies that had used single genome amplification (SGA) analysis. 
This means that the difference in detecting HIV-1 compartmentalization in this thesis vs 
previous studies can be explained by the depth of sequencing achieved here and that there 
is no evidence that the dynamics of the viral populations studied in this thesis were different 
from those previously studied.  
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In addition, the most recent common ancestor of semen variants was mostly located in blood, 
indicating the male genital tract was seeded by incoming variants from blood. Clonal 
amplification was also observed in all the 11 study participants and it was a characteristic of 
variants from blood and the male genital tract and its frequency did not obviously correlate 
with the severity of compartmentalization.  
 
In sum, blood and male genital tract HIV-1 compartmentalization and clonal amplification is 
present in most or all HIV-1 infected males but was not detected in all individuals in previous 
studies when using techniques with lower depth of sampling.  
 
Objective 2: Sensitivities of blood and semen variants to entry inhibitors and variable loop 
characteristics 
Viral variants from the most compartmentalized donors had variations in sensitivities to entry 
inhibitors; although the direction of the difference was inconsistent. Donor SVB043 who had 
the most severely compartmentalized viral populations between blood and semen, had 
semen viruses that were 1.67 (95%CI 1.08 – 2.56) times more resistant to maraviroc (p=0.024) 
while SVB008 which was the second most compartmentalized donor, had semen isolates that 
were 4.8 (95%CI 2.76 – 8.28) times more sensitive to inhibition by maraviroc (p < 0.0001). The 
meaning of this discrepancy is not entirely clear. It could mean that trait(s) that are selected 
for in genital tract variants over blood circulation variants are linked to the CCR5 binding 
region, and that the linked CCR5 genotype was carried along with the selected trait(s). There 
were no differences in sensitivity to maraviroc between blood and semen clones for donor 
SVB049 (p=0.847); although this donor on further investigation was found to have functional 
levels of efavirenz in his blood (3µg/ml, which were within the therapeutic range of 1-4µg/ml) 
indicating that he was likely on antiretroviral therapy (ART). This was not known to the clinic 
staff at the clinic at which he was known to receive care and was recruited to this study. 
 
The direction of sensitivities to PSC_RANTES (another CCR5 inhibitor) was concordant to that 
observed for maraviroc for donors SVB008 and SVB049 but not for donor SVB043 where 
semen variants were 1.67 (95%CI 1.08 – 2.56) times less sensitive than blood variants to 
maraviroc, with no detected difference in sensitivity to PSC_RANTES (p = 0.783). This 
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discrepancy for donor SVB043 probably reflects the difference in mode of action between 
Maraviroc and PSC_RANTES. The change in envelope conformation over movement from 
blood into the genital tract presumably affected the maraviroc binding site and not 
PSC_RANTES. All the clones from blood and semen for the three most viral 
compartmentalized donors were resistant to CXCR4 inhibitor suggesting that they were all R5 
tropic viruses. There were no differences in sensitivities of blood and semen viruses to fusion 
inhibitor T-20.  
 
The findings here suggest a changed viral envelope conformation/structure for the viruses in 
the male genital tract. The discordance suggests that the selected trait over movement of 
virus from blood into genital tract is linked or close to CCR5 binding site but itself does not 
involve binding to CCR5 co-receptor. 
 
Differences in length and number of glycosylation sites were found between variants from 
blood and those from the genital tract but the direction of the difference was also 
inconsistent. Donor SVB043 who had the most compartmentalized blood and seminal 
variants had semen variants that had longer and more glycosylated envelopes. Donor SVB008 
who had the second most compartmentalized blood and semen variants had no difference in 
variable loop length, but semen variants were less glycosylated. This therefore shows that 
selection for some of the previous reported traits of acute viral isolates may have started in 
the genital tract in a subset of the donors. 
 
Objective 3: Sensitivities of blood and semen variants to autologous and heterologous 
antibodies 
Viral populations compartmentalized in blood and the male genital compartment displayed a 
range of sensitivities to autologous and heterologous neutralization. Donor SVB043 who had 
the most compartmentalized viral populations between blood and the genital tract; had 
semen clones that were 1.75 (95%CI 1.11-2.78) times more sensitive to autologous 
neutralization compared to blood clones (p = 0.018). In contrast, donors SVB008 and SVB049 
who exhibited substantial compartmentalization, but to a lesser extent than that found in 
donor SVB043, showed no differences in sensitivities of blood and semen variants to 
autologous serum.  Neutralization sensitivity to a pool of heterologous subtype-matched sera 
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revealed no differences in sensitivities between clones from blood and semen for donors 
SVB043 and SVB008. Interpretation of results from donor SVB049 are clouded by the donor’s 
ART use. Overall, these results suggest that, in some individuals, a shift in selective milieu of 
the genital tract virus occurs. This is presumably due to partial or complete shielding of the 
genital tract tissue from circulating antibodies, and this shielding shape the populations of 
HIV-1 variants available for transmission from some but not all individuals.  
 
Overall conclusions 
Our data add to the existing knowledge of existence of distinct viral populations between 
blood and the male genital tract of chronically HIV-1 infected donors. Importantly, and for the 
first time, we present evidence that HIV-1 compartmentalization between blood and the male 
genital tract is present in most or all donors, and that some clones are severely 
compartmentalized even in donors who exhibit very mild compartmentalization. It appears 
that viral compartmentalization and clonal amplification in these anatomical sites may be 
present in most individuals but remained undetected in some individuals in previous studies 
due to the lower depth of sampling applied.  
 
We observed a discordance in entry inhibitor sensitivities and variable loop characteristics 
between blood vs semen variants among different donors. This may suggest a changed 
envelope conformation over importation of virus from blood into the genital tract. This 
change seems to be near or linked to the co-receptor binding site but does not appear to 
directly involve the co-receptor binding tested in this thesis. This interpretation also may 
explain the discordance in viral characteristics for the virus establishing infection reported in 
other studies. This thesis also shows that some of these traits of the transmitted/founder 
virus relating to neutralization sensitivity, sensitivity to entry inhibitors and variable loop 
characteristics may originate in and/or be enhanced by transition through the genital tract on 
the way to becoming a founder virus. 
 
These results are important in understanding how the populations in the genital 
compartment are selected, giving rise to the population of HIV-1 that is available for 
transmission to a new individual. An understanding of the dynamics of HIV-1 populations prior 
to and during transmission is important for vaccine design and other intervention strategies. 
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1.1 General Introduction to HIV 
1.1.1 Background 
Despite the concerted effort to manage HIV-1, it continues to be a devastating disease and 
one of the leading contributors to life years lost due to disability and premature deaths [1]. 
Since the beginning of the epidemic about 80 million people have been infected and about 
35 million have died from AIDS-related complications [2]. The disease continues to infect 
more people each year and in 2017 (the present statistics at the time of writing this thesis) 
1.8 million became infected and around 1 million people died of AIDS-related illnesses [2]. 
Presently there is increased use of anti-retroviral therapy (ART) that has markedly reduced 
the number of people dying from AIDS-related causes [3, 4]. The number increased from 8 
million in 2010 to about 22 million in 2017 which is a significant progress [2]. Despite these 
impressive results, HIV-1 severity in sub-Saharan Africa where the mode of transmission is 
primarily heterosexual [5] remains high and accounts for 66% of all transmissions [2]. The 
good news is that nearly all the countries in sub-Saharan Africa have adopted the test and 
treat strategy [6] and with the help of a broad range of stakeholders more lives will be saved. 
There is no HIV-1 vaccine yet and the only vaccine tested to date with positive efficacy 
(RV144) had only a modest efficacy of 31%, with the lower confidence interval extending to 
only 3% protection. The vaccine is being improved and is now being tested in a predominantly 
subtype C – infected population in South Africa under HVTN 702 phase III trial (NCT02968849). 
These challenges means that more work is needed to be done to reduce the HIV-1 infections. 
Understanding the HIV-1 transmission biology may help in design an effective vaccine and 
other intervention strategies.  
1.1.2 Discovery of HIV/AIDS 
The reports of symptoms of a debilitating disease which later came to be referred to as 
acquired immunodeficiency syndrome (AIDS) started around 1981  when the first patients 
with AIDS were identified in USA among men who have sex with men (MSM) [7]. It was later 
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found in intravenous drug users (IVDU), haemophiliacs [8], refugees, and Haitians [9]. It 
appeared as a long-lasting disease with an unusually long lag phase before the symptoms 
manifested. The early signs were weight-loss, fever, diarrhoea and lymphadenopathy. Later 
signs included opportunistic infections such as Pneumocystis carinii pneumonia, 
Mycobacterium avium intracellular and cytomegalovirus (CMV) [7, 10-14]. The profound state 
of immune suppression made the patients present with these opportunistic infections.  Little 
was known of retroviruses that had clinical effects upon humans. Importantly, assays for the 
presences of HIV-1 were poorly developed and of low sensitivity. Additionally, in the 
beginning, AIDS itself was defined by symptoms, leading to initial scepticism that it was 
caused by a single infectious organism, or even if it had an infectious cause at all [15]. Many 
other factors were proposed as causes; withholding of antiretroviral treatment after 
discovery  of antiretroviral drugs; on the basis of these arguments ultimately lead to death of 
hundreds of thousands of people, particularly in South Africa [16].   
It was particularly notable that there was a decrease in a particular subset of T cells that 
expressed CD4 surface antigen [17, 18], which had earlier been discovered by Milstein and 
Kohler using specific monoclonal antibodies [19]. This gave evidence that the agent 
concerned must be targeting the CD4+ T cells. At this time some laboratory techniques of 
isolating and growing lymphocytes in culture had been in place. In addition, some scientists 
at National Institute of Health (NIH) had discovered the T-cell growth factor (interleukin-2) 
which sufficiently helped increase time for growth of lymphocytes to allow expression of 
putative latent retroviruses. These techniques helped the few labs that were working with 
retroviruses at the time. Among these labs were those of Robert Gallo and Luc Montagnier. 
The two scientists discovered the human T-cell leukaemia virus (HTLV) type 1 and type 2 [20]. 
Luc  Montagnier’s lab is also credited with the discovery of HIV-1 as well [21], and one-half of 
the 2008 Nobel Prize in Physiology/Medicine was shared between Prof Barré Sinoussi and 
Prof Luc Montagnier for their discovery of HIV [22]. Human Immunodeficiency Virus and HTLV 
caused symptoms that were overlapping, sometimes leading to confusion [23]. For instance, 
some of the animal models for HTLV-1 and HTLV-2 not only showed leukaemia-like symptoms 
and lymphoma but also weight loss conditions which resembled those of AIDS. In addition, 
HTLV was transmitted through contaminated blood, sex and mother to child which were 
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consistent with the early epidemiology of AIDS. In fact, some of the early patients studied, 
were infected by both HTLV and HIV-1 which complicated interpretation further [13, 24].  
The evidence that AIDS was caused by a virus come from Centres for Disease Control (CDC) 
reports with haemophilia patients who presented with AIDS-like symptoms after receiving 
only filtered clotting factors [25]. The filtration eliminated other microorganisms that were 
larger than a virus. Subsequently, the first clear isolate of HIV was done at the Pasteur 
Institute in Paris in early 1983 [21]. The virus for the first time showed clear difference from 
HTLV in morphology and antigenicity. It was obtained from a patient presenting with 
lymphadenopathy which at the time was seen as a precursor to AIDS [21]. The lymph node as 
a site of discovery of HIV is not surprising since it is well known today that the virus thrives 
there during the asymptomatic period of infection [26].  
Working with an early transmitted virus (the virus was isolated from lymph nodes and it is 
known today that they are infected quite early after transmission) seemed problematic since 
it could only grow in fresh lymphocytes and not in permanent cell lines [26]. This delayed full 
characterization of the virus. In addition, the virus at this early stage of discovery was thought 
to be causative since in acutely-infected patients the immunosuppression was only mild. 
Breakthrough only came when the virus was isolated from a patient with Kaposi’s sarcoma in 
Paris which could now grow in permanent cell lines possibly because it came from a chronic 
infection. The long incubation periods before physical symptoms complicated the 
characterization of HIV-1 unlike other acute viruses whose symptoms manifest almost 
immediately. In addition, during symptomatic phase other opportunistic infections set in 
making it exceptionally very hard to link the causative agent to the disease. Later on, blood 
tests that were sufficiently sensitive were made which could now be used to directly link HIV 
to AIDS [27, 28].  With the advancement of laboratory techniques it was later possible to show 
that HIV-1 infection depended on certain chemokine receptors [29, 30]. Moreover, the 
surprising efficacy of the drugs against the reverse transcriptase enzyme of the virus all 
contributed as an indirect evidence of HIV being a causative agent of AIDS [31, 32]. These 
diagnostic tools opened the avenue for development of antiretroviral drugs and strong 
policies aimed at preventing the acquisition of HIV [33]. 
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1.1.3 Classification of HIV-1 and HIV-2 
Human Immunodeficiency Virus (HIV) is classified into two species, HIV-1 and HIV-2 according 
to differences in nucleotide sequences [34, 35]. In addition to the two types, HIV-1 is further 
classified into various groups: M (Main/major), O (Outlier), N (non-M, non-O), and P (Putative) 
[36]. HIV-1 group M (HIV-1M) is further subdivided into 9 subtypes annotated with letters A-
D, F-H, J, K and 98 circulating recombinant forms (CRFs) so far 
(https://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html). The CRFs are presumed 
to be a result of recombination between subtypes. It must be observed in at least three 
epidemiologically unlinked subjects, otherwise it is not presumed to have circulated, in which 
case it is called a unique recombinant form (URF) [37]. The CRFs are given names comprising 
of a number which is serialised according to the order of discovery and two letters indicating 
subtypes presumed to be present in the mosaic e.g. CRF01_AE (previously subtype E [38]) was 
the first and comprises of a mosaic of subtype A and E [37]. If more subtypes are presumed 
to be involved in making the mosaic, cpx (complex) is used to denote that CRF [37]. A recent 
study has shown that some of the sequence tracts within the CRFs might have been derived 
from older unclassified parental lineages rather than from the current classified HIV-1M 
subtypes [39]. These parental lineages may have been less infectious at the time to spread to 
many subjects or they may not have been present at strategic points during the spread of the 
HIV-1 to global epidemic [40]. Indeed these findings are consistent with the high number of 
subtypes and high degree of genetic diversity observed among the subtypes coming from 
Congo basin, the epicentre of HIV epidemic [41, 42].   
HIV-2 is inferred to have resulted from at least eight transmissions from sooty mangabeys 
(Cercocebus atys), a non-human primate found in west Africa [43]. These make up the 8 
groups of HIV-2 (A-H) and each is inferred to represent an independent cross-species monkey-
to-human transmission event. The epidemic has remained restricted in West Africa, with Mali, 
Guinea Bissau, Gambia, Mauritania, Nigeria, Sierra Leone, Cape Verde and Ivory coast having 
more than 1% of the general population infected . It is less virulent, less transmittable and 
usually characterized with lower viral loads compared to HIV-1 [44-47]. 
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1.1.4 Origin of HIV/AIDS 
Human immunodeficiency virus type 1 (HIV-1) has its roots in central Africa and it is thought 
that the avalanche of factors including railway transport (Figure 1) constructed by Belgian 
colonial rule, urban growth and change in sex lifestyles in Kinshasa fueled the spread of the 
virus to the global scale [48]. By the time HIV/AIDS was being discovered in the US, it had 
already been well established in central [49] and eastern [50] Africa.  Indeed, the oldest HIV-
infected human samples to have been discovered were both from central Africa; that of 1959 
African plasma (ZR59) that was found to have been HIV-1 seropositive [51] and a Bouin’s-
fixed paraffin-embedded lymph node biopsy specimen [52]. These two early samples come 
from Léopoldville, Belgian Congo (now Kinshasa, Democratic Republic of Congo (DRC)) [52].  
Figure 1: Factors that lead to exportation of HIV-1 group M from Congo basin include transportation network (railway and 
waterways). This map adopted from [48] shows the spatial movement of HIV-1 group M from Kinshasa following these 
transportation networks with gradient colours indicating the time scale of the movements. 
The relatives of HIV-1 and HIV-2 are found in non-human primates (NHP) who have an 
equivalent family of viruses called Simian Immunodeficiency Virus (SIV) (Figure 2). HIV is 
thought to have resulted from multiple zoonotic introductions into the human population 
29 
from these relatives possibly due to bush meat practice [53] and keeping NHP as pets [54]. 
Bites and contact with blood and other bodily fluids from the NHP during hunting and 
slaughter is the most plausible explanation for the cross-species transfer.  
Figure 2: HIV-1 and 2 involve a simian origin. These old world monkeys are naturally infected by simian immunodeficiency 
viruses (SIVs) which have crossed the species barrier to infect great apes and humans. (adapted from [55]) 
Each of the four groups of HIV-1 involve separate cross-species transfer from a particular NHP 
(Figure 3). HIV-1 group M (HIV-1M) has close SIV relatives in chimpanzees [56]. The SIV species 
that is closer to HIV-1M is SIVcpz isolated from chimpanzees Pan troglodytes troglodytes [53]. 
Through sequencing of gag and env genes of HIV-1, it was possible to identify that the last 
common ancestor of HIV-1M existed around 1930 [57]. 
Conversely, the HIV-1 group O (HIV-1O) has a SIV relative in Gorilla gorilla [58, 59]. Typical 
variants of HIV-1O (ANT70, MVP5180 and VAU) were first discovered in 1990s from 
30 
Cameroonian natives residing in Europe [60-62]. Today, HIV-1O is less widespread and is 
localized in Cameroon where it has infected one percent of the population. It is thought that 
HIV-1M and HIV-1O had similar epidemic histories in the 1960s, but HIV-1M managed to 
cause the global epidemic [40].  
The HIV-1 group N (HIV-1N) and HIV-1 group P (HIV-1P) are rare than HIV-1M and HIV-1O. 
The HIV-1N, (YFB30) was first discovered in 1998 from a Cameroonian woman who had died 
of AIDS three years earlier [63]. Her serum reacted to the envelope antigen of SIV isolated 
from chimpanzee and not antigens from HIV-1M and HIV-1O leading to classification of a new 
HIV-1 group. The typical variant of HIV-1P (RBF168) was discovered in yet another 
Cameroonian national arriving in France [36]. There are only three cases of HIV-1P so far 
discovered in the world [64]. 
HIV-2 on the other hand has a closest SIV relative called SIVsm from sooty mangabeys whose 
geographic regions still overlap in West Africa [55, 65].  
Figure 3: Phylogenetic tree indicating the origin of the two types of human immunodeficiency virus (HIV-1 and HIV-2). Photo 
obtained from https://www.pbs.org/wgbh/pages/frontline/aids/virus/tree.html  
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1.1.5 Epidemiology of HIV-1 group M 
Since the discovery of HIV-1 at around 1980, approximately 78 million people have been 
infected by the disease and 35 million so far succumbed to AIDS [66]. According to the UNAIDS 
estimates of 2018 [66], approximately 36.9 million people in all age groups were living with 
HIV in 2017 (lower bound estimate, 31.1 million, upper bound estimate, 43.9 million). Among 
these, 35.1 million were adults and 1.8 million children. Globally, approximately half of the 
people living with HIV were males and half were females. Overall, currently the number of 
new infections have been reduced by approximately 18% since 2010 (Figure 4). Sub-Saharan 
Africa is the most affected contributing to approximately 66% of all infections among people 
in all ages, and more women being infected (56%) than men. This notwithstanding, more men 
living with HIV die more than women mainly attributable to higher diagnosis rate and higher 
treatment coverage among women than men [67].  
With the advent of Highly Active Antiretroviral Treatment (HAART), there has been a steady 
decline in AIDS-related deaths globally with less than a million dying per year (approximately 
34% decline since 2010) [66]. This reduction in number of deaths since 2010 have been 
witnessed in many regions with the greatest decline in eastern and southern Africa (42% 
reduction). Other regions with sustained decline were; Asia and Pacific (39% reduction), 
western and central Europe and north America (36% reduction), western and central Africa 
(24% reduction) and Caribbean (23% reduction). Latin America had the lowest decline in the 
number of death (12% reduction), but this is mainly due to their long term programme of 
antiretroviral therapy. On the other hand, eastern Europe and central Asia had no reductions 
in AIDS-related deaths since 2010 while the number actually increased by 11% in North Africa 
and Middle East [66]. The production and use of opiate drugs in these two regions, which has 
led to increased HIV-1 infection rates within vulnerable groups, has been suggested to be the 
cause as well as gaps in the treatment cascade [66, 68]. In addition, lack of HIV-1 surveillance 
systems, little access to HIV-care facilities as well as the geopolitical situation of the region 
have contributed to deaths from HIV-1 related complications [69]. 
The UNAIDS 2018 estimates [66] shows that around 22 million people are currently on 
treatment which is a net improvement from 2.3 million people since 2016. There has also 
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been an 18% overall decline in new infections since 2010 [66]. Again the greatest decline was 
achieved in sub-Saharan Africa with eastern and southern Africa showing a 30% decline. 
Other regions also achieved reduction, Caribbean (18% decline), Asia and Pacific (14% 
decline), western and central Africa (8% decline) and western and central Europe and north 
America region having a 1% decline. Middle East and North Africa and eastern Europe and 
central Asia, the incidence has gone up instead [66]. Men account for most of the new HIV 
infections globally but in sub-Saharan Africa, more adult women account for new HIV 
infections than men (59%) [66]. The fact that the decline in number of AIDS-related deaths 
does not correspond with a similar decline in new HIV-1 infections means that the number of 
people living with HIV-1 will continue to grow and more resources are needed to keep them 
on treatment.  
An ambitious concept have been coined, branded “90-90-90” – with a target goal of year 
2020. This concept intends that by 2020, 90% of the people living with HIV will know their 
status, 90% of the diagnosed cases will be put on therapy and 90% of those on therapy will 
have viral suppression. This idea is part of the United Nation’s programme on HIV/AIDS 
ambitious goal to achieve a 90% reduction in new HIV infections and death by 2030 based on 
2010 baselines. It is based on “test and treat” principal in that if people can know their HIV 
status early enough, they can go on treatment immediately which in turn prevent onward 
transmission of the virus. This will have a net effect of reduction of new cases of HIV at the 
population level.  
With the current estimates of 36.9 million people living with HIV [66], it means 33.2 million 
will need need to be diagnosed, 29.9 be put on therapy and 26.9 achieve viral suppression to 
meet the 90-90-90 goals globally. Current estimates [70] show that 75% of the people living 
with HIV knew their status in 2017, of which 79% (59% of all people living with HIV) were 
accessing treatment and among these accessing treatment 81% (47% of all people living with 
HIV) were virally suppressed [2]. Around 9 million people still remain undiagnosed and among 
the diagnosed, 5.8 million have not yet initiated treatment. Around 20% of the people on 
treatment are not achieving viral suppression. This will have an effect on the onward 
transmission of HIV and risk of development of drug resistant mutations thereby affecting the 
choice of future treatments. 
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Key populations at risk of HIV needs a special focus for an  effective HIV eradication to be 
achieved. These special groups include men who have sex with men (MSM), intravenous drug 
users (IVDU), sex workers, transgender communities, prisoners among others. More recently 
immigrants have also been considered as part of the key HIV population with some of the 
people migrating due to persecution of their sexual identity (e.g. being gay or MSM) [71]. 
These groups have been shown to disproportionately concentrate the sub-epidemic of HIV in 
areas where overall prevalence within the general population is low [72]. In fact, a survey 
showed that new global HIV infections in 2017, were related to key populations and their 
sexual partners [73] with the epidemic driven by these groups in some regions than others. 
More than 75% of the new HIV infections in eastern and central Asia, middle east and north 
Africa, western and central Europe and north America, Latin America, Asia and the pacific, 
and the Caribbean were driven by these key populations and their sexual partners [66]. 
Notably, in 2017, intravenous drug users were the main drivers of the epidemic in eastern 
Europe and central Asia and in the Middle East and north Africa. In these two regions the HIV 
incidence has doubled in the last 20 years [66, 71]. In eastern and southern Africa, 16% 
percent of the new HIV infections were also driven by the key populations [70]. Therefore 
targeting these groups for diagnosis and treatment may be an important step in HIV 
eradication. 
 
 
Figure 4: The new HIV  in 2017 and the percentage change since 2010. Photo obtained from UNAIDS via 
https://www.avert.org/  
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1.1.6 Distribution of subtypes of HIV-1 group M 
HIV-1 group M subtypes and CRFs are distributed in diverse geographical regions of the world. 
Subtype C is the most abundant representing close to 50% of all global infections [74]. It is 
followed by subtype A at 18%, B at 11%, CRF02_AG at 8%, CRF01_AE at 5%, G at 5% and D at 
2% [74] (Figure 5). The rest of the subtypes have infected only a minority (<1%) of the 
population. All the CRFs and URFs represent a proportion of 20% of all the HIV-1 infections in 
the world [74]. The differential distribution of HIV-1 globally is as a result of founder effects, 
travel and migrations [75-77]. Southern African countries are almost entirely dominated by 
HIV-1 subtype C virus infecting countries like South Africa, Zimbabwe, Botswana, Zambia, 
Malawi and Swaziland. Subtype C also dominates in Burundi and Ethiopia which form part of 
Eastern Africa. In the other Eastern African countries; Tanzania, Rwanda and Kenya, subtype 
A predominates although C and D and their recombinants are also available. West African 
countries are dominated by CRF02_AG representing 50-80% of all infections, although 
CRF06_cpx represent up to 50% of the infections in Nigeria, Niger, Burkina Faso and Togo. 
North America and Western Europe countries are dominated by subtype B while in Eastern 
Europe subtype A as well as CRF03_AB dominate especially among the IVDUs [74]. In India, 
subtype C dominates although some regions are affected by subtype A as well. South 
American countries are dominated by subtype B and F while in Southeast Asia subtype B and 
CRF01_AE are prevalent. Oceania is dominated by subtype C while in Australia subtype B 
dominates. In China, CRF01_AE, CRF07_BC and CRF08_BC predominate [74]. 
Figure 5: Geographic distribution of HIV-1 group M (Major) subtypes and CRFs. Figure adapted from WHO-UNAIDS HIV 
Initiative 
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1.1.7 Pathogenesis 
The natural course of infection of HIV-1 is composed of three phases, acute, asymptomatic  
and symptomatic phase [78] (Figure 6) .  
 
1.1.7.1 Acute phase of HIV-1 infection 
The acute phase of infection starts with a single variant infecting a small subset of CD4+ T cells, 
macrophages and dendritic cells at the portal of entry and lasts between 3-6 weeks [79, 80]. 
HIV uses a combination of pathways for establishments at the portal of entry some of which 
include transcytosis, endocytosis and capture by mannose C-type lectins receptors such as 
DC-SIGN found on the surface of dendritic cells and macrophages [81]. The initial 
amplification happens at the draining lymph nodes before the variants enter the blood stream 
and secondary amplification happens at the gastrointestinal tract [26, 82]. The infected CD4+ 
T cells express a homing receptor called a4b7  which is known to facilitate the migration of 
infected cells into the gut-associated lymphoid tissue (GALT) [83, 84]. The CD4+ T cells are 
massively depleted in the GALT which also leads to accumulation of high viral loads in blood 
[85].  
 
This is followed in approximately half of the infected individuals by some flu-like symptoms 
(fatigue, night sweats, fever, chills, headache, muscle aches, sore throat, diarrhoea, joint 
aches, swollen lymph nodes, skin rash, etc) [86]. This condition is also known as primary HIV 
infection or acute retroviral syndrome [87]. This is also the most contagious phase of the 
infection since most individual are  unaware of their infection status and the initial indicators 
are usually ignored or confused with other mild infections [88]. The symptoms resolve on 
their own in a few weeks. This is the phase where peak viremia is observed at 106 - 107 viral 
RNA copies per millilitre (cp/ml) of blood which is one or two orders of magnitude higher than 
what is observed later during the chronic stage of infection [89, 90]. This phase is also 
accompanied by low prevalence of CD4+ T cells and there are usually no detectable antibodies 
meaning antibody-based tests are not able to detect the virus at this stage [89]. 
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1.1.7.2 Asymptomatic phase of HIV-1 infection 
During the asymptomatic phase, viral loads in plasma decline to a set point which comes to 
characterize chronic infection [91]. This reduction is mainly attributed to HIV-1 specific CD8+ 
cytotoxic cells which eliminate virally-infected target cells [92, 93]. In addition, antibodies 
against the virus start to build up and can now be detected in plasma [89]. The combined 
effort of humoral and cellular responses leads to partial recovery of CD4+ T-cells and their 
numbers are seen to slightly increase [91]. Despite the absence of symptoms, viral replication 
is still ongoing. The ongoing replication and regeneration of the CD4+ T-cells establishes a 
dynamic equilibrium hence a steady state viremia . The length of this phase varies; 1 – 2 years 
for fast progressors while slow progressors can take several years [78, 94].  
 
1.1.7.3 Symptomatic phase of HIV-1 infection 
Over time due to imbalanced replication of the virus and decreased regeneration of the CD4+ 
T-cells, a gradual decrease in the latter is observed if the patient is not on antiretroviral drugs 
[94]. This leads to the symptomatic phase of the infection [95]. At first mild symptoms are 
experienced with severity increasing with further reduction in CD4+ T-cells. This eventually 
leads to loss of immune function and an increase in viral replication at which Acquired 
Immune Deficiency Syndrome (AIDS) sets in. Opportunistic infections and rare cancers 
characterises this stage which eventually leads to fatalities [7]. 
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Figure 6: The dynamics of CD4+ cells and viral loads in a therapy naive HIV-1 infected subject over time. HIV pathogenesis 
sis characterized by four phases; primary infection, dissemination of virions in the body organs, clinical latency and 
symptomatic phase. (Image from Fauci and Desrosiers 1997 used with permission from Cold Spring Harbor Laboratory 
Press.) 
 
1.1.8 Virological characteristics of HIV-1 
 
1.1.8.1 The HIV-1 particle 
The HIV-1 virion has been studied extensively using the electron microscopy and consists of 
an envelope, a core and matrix (Figure 7), [96, 97].  The envelope is derived from the cell 
membrane of the infected cell and encompasses the matrix and the capsid [95] (Figure 7). 
The envelope is studded with Env glycoprotein projections (gp120) that are used for 
attachment onto the host target cell during fusion and entry. These glycoproteins are also an 
important target for the host immune system. The capsid on the other hand houses two 
identical positive sense RNA strands complexed with p7 nucleocapsid protein, several 
enzymes necessary for establishment in an infected cell as well as some accessory proteins 
(Figure 7). 
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Figure 7: The structure of the HIV-1 particle. The virion capsid is encompassed by the envelope. The capsid in turn  houses the 
viral genome as well as enzymes that are necessary for establishment in an infected cell. The figure was obtained from 
https://commons.wikimedia.org  
 
1.1.8.2 HIV-1 genome organization and roles 
The HIV-1 genome is ~9.8 kilobases [98] and encodes nine genes; gag, pol, vif, vpr, vpu, tat, 
env, rev, nef)  (Figure 8). The Long Terminal Repeats or LTR are regions flanking the viral 
genome in its DNA form and they contain transcription initiation and polyadenylation 
regulatory regions. The genes are organized into structural (gag and env), regulatory (tat, rev) 
and accessory genes (vif, vpu, vpr, nef). 
 
The structural proteins are first encoded into polyproteins that are then cleaved by protease 
to produce functional genes. Gag is the product of the HIV genome gag that encodes the 
capsid proteins (group-specific antigens). The precursor is the p55, a 55kDA myristoylated 
[99] protein that associates with the plasma membrane during the viral assembly. It (gag) is 
cleaved by viral protease into p7 (Nucleocapsid), p17 (Matrix), p24 (capsid) and p6 proteins 
[100]. The matrix particles are usually associated with the inner lipid bilayers of the viral 
envelope. In some particles however, it is also found deeper in the virion and participate in 
transport of the viral DNA into the host cell nucleus [101]. p24 forms the conical core of the 
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virus and is found associated with cycophilin A [102]. p6 mediates the interaction of p55 gag 
and the vpr accessory protein, aiding its inclusion into the virus particle [103]. It also helps 
efficient release of budding virus particles from host cells.  
 
The HIV-1 pol is another structural gene and encodes the viral enzymes, reverse transcriptase 
(RT), RNase H, integrase (IN), and protease (PR). The precursor is produced as a Gag-Pol [104] 
by frame shifting of the ribosome on the 3´end of gag [105]. HIV-1 protease occurs as a dimer 
to cleave the Gag and Gag-Pol polyproteins during the viral maturation. The RT has both RNA- 
and DNA-dependent DNA polymerase activities and forms the double-stranded DNA from the 
dimer of RNA present in the virion within the first 6 hours of infection. The RT polymerase 
does not have proofreading capacity and therefore introduces point mutations in the viral 
genome during each replication cycle at a rate of about 1 substitution for each 3 genomes 
synthesized. Integrase is a 34kDa protein consisting of three domains as analysed through X-
ray crystallography or NMR; the N-terminal domain, which chelates zinc, the core domain 
responsible the catalytic function and the C-terminal domain that binds DNA non-specifically. 
Integrase regulates the insertion of HIV provirus into the host genome, in complex with 
several host cell proteins. Integrase has three activities, an exonuclease activity by which it 
removes two nucleotides from the 3’ ends of the provirus, an endonuclease activity by which 
it cleaves the host DNA at the integration site and a process where the provirus is covalently 
linked to the ends of host DNA (strand-transfer reaction) [106]. 
 
The third structural gene is env which encodes the Env protein. Env is the viral glycoprotein 
produced as a gp160 precursor  from env gene then processed into two non-covalently bound 
proteins: a trans membrane part gp41 and an external part called gp120 (Figure 7). These 
non-covalently bound proteins form a trimer [107] on the viral envelope. The gp120 interacts 
with the CD4 [108] and chemokine receptors [109] on the surface of host cells during the 
infection process. The selective pressure of the antibody-mediated immune system of the 
host against the virus manifests against the Env [110]. As part of the adaptation of the virus,  
there is a co-receptor switch from CCR5 to CXCR4, which occur in 50% of the HIV patients 
infected with HIV sub-type B [111]. This switch, determined by the V3 region of the env gene 
is characterized with increased depletion of T-lymphocytes and rapid development of AIDS 
[110].  
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The HIV-1 genome has two regulatory genes tat and rev which encode the Tat and Rev 
proteinds respectively. Tat is the transactivator of HIV expression [112], one of the two 
important viral factors for the regulation of HIV gene expression. Tat binds to the 
transactivation response (TAR) in the RNA to activate elongation and as such prevents the 
5´LTR poly A signal from premature termination of transcription [113-115]. Short transcripts 
of around 100 nucleotides are produced in the absence of Tat. They occur persistently at low 
levels in nucleus or nucleolus of infected cells in two forms, the minor and the major forms. 
The minor form is a 72 amino acid protein also called Tat-1 exon while the major form is an 
86 amino acid protein also called the Tat-2 exon. 
 
Rev is the other important regulatory factor of HIV expression after Tat. Rev is a sequence-
specific phosphoprotein that helps in nuclear export and maintenance of the viral mRNA 
containing the Rev response elements (RRE) regions [116]. Rev binds to a bubble formed from 
non-Watson-Crick G-G base pairs [117] and transports unspliced or incompletely spliced 
mRNA from the nucleus to the cytoplasm which would ordinarily be retained in the nucleus. 
It is a 19kDA protein that binds to RRE, and like Tat, it is localized in the nucleus or nucleolus 
and mediates the transition from early to late phases of HIV gene expression. Rev contains 
three domains [118], arginine-rich region that binds RRE, multimerization domain [119] and 
effector domain with a nuclear export signal (NES) [120].   
 
The HIV-1 genome also contains several accessory genes that encodes the accessory proteins 
Vif, Vpu, Vpr and Nef. Vif is the Viral Infectivity Factor, which exists as a soluble cytosolic 
protein. This 23-kDA protein is important for viral replication in that it inhibits antiviral activity 
of a group of cellular enzymes, APOBEC (a cytidine deaminase that mutates viral nucleic acids) 
by targeting it for ubiquitination and cellular degradation. Most cell lines are permissive to Vif 
mutants of HIV and although the virus produced is able to infect non-permissive cell lines, the 
virus produced from the latter are non-infectious.  
 
Vpr is the Viral Protein R, a 14kDA protein incorporated in virions [121] by interacting with 
the carboxyl terminal, p6 of Gag [122]. Several roles have been proposed for this protein, 
which include, nuclear transport of pre-integrating complexes, which facilitates infection of 
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non-dividing cells [123]. This is achieved by tethering of the viral genome to the nuclear pore 
[124] facilitating nucleocytoplasmic transport. Other roles of this protein include the
transactivation of cellular genes, the induction of cellular differentiation and cell growth
arrest [125]. Vpu is the Viral Protein U, which is a type 1 integral membrane protein [126] that
functions in degradation of CD4 in the endoplasmic reticulum and enhancement of release of
the virion from the plasma membrane of the infected cells [127]. This 24kDA protein has been
found to antagonize host cells through binding to host proteins such as CD4 and targeting
them for degradation through recruiting of cellular multi-subunit ubiquitin ligases.
Additionally, it has also been seen to make ion channels on host cell membranes [128]. A new
target has been found to be an interferon induced trans membrane protein Tetherin/BST2
which allows retention of the nascent virions on the cell membrane and thereby restricting
viral replication [128].
Nef (an acronym of negative factor, which is an early error of describing its activity) is a 
myristoylated protein usually found associated with the plasma membrane using the 
myristoyl portion although cytoplasmic variants have also been observed [129]. When found 
in the nucleus, it is usually associated with the cytoskeleton. Nef is required in the 
maintenance of high viral loads and individuals with defective Nef emerge to be long time 
survivors. This 27kDA protein does this by down regulation of MHC-I reducing the killing of 
the infected cell by cytotoxic T cells [130] and down regulation of CD4 receptors by 
endocytosis and lysosomal degradation [131, 132]. Vpx is a 12kDA protein found in HIV-2 and 
some SIVs but not in HIV-1. It is a homolog of vpr gene in HIV-1. Its role is not yet fully 
elucidated but like Vpr it interacts with p6 of Gag. 
Figure 8: HIV-1 genome organization. Source: https://commons.wikimedia.org/  
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1.1.8.3 The replication cycle 
HIV-1 lifecycle involves a series of seven steps; binding, fusion, reverse transcription into 
double-stranded DNA, integration into the host genome, viral RNA synthesis and synthesis of 
the proteins, assembly and budding off infected cells (Figure 9). HIV-1 infection lifecycle starts 
when the virus attaches and enters the target cells [133]. HIV-1 needs a high density of CD4 
to infect cells and therefore, the main target cells are the CD4+ T cells [134]. HIV-1 has a 
trimeric GP120 on the envelope of the virus which initiates infection by binding to the CD4 
receptor on the surface of HIV target cells [135]. The binding of the viral glycoprotein leads to 
a conformational change of the glycoprotein hence exposing additional binding site for the 
host cell coreceptors [133]. HIV-1 can use either the CCR5 or the CXCR4 coreceptors available 
on the surface of the target cells. Based on the co-receptor utilization therefore HIV-1 can be 
classified as R5,  X4  or R5/X4 dual-tropic viruses, utilizing CCR5,  CXCR4 or both respectively 
[136]. CCR5 coreceptor utilization has been shown to be a characteristic of primary infecting 
viruses and also during chronic disease while CXCR4 are mainly observed during late 
infections [137]. This may be due to severe depletion of CCR5 target cells resulting from 
limited number of CD4+ T cells hence the macrophage-tropic phenotype [138].  
The fusion step begins after the co-receptor binding which leads to a second conformational 
change allowing the gp41 N-terminal fusion peptide to penetrate the cell membrane of the 
target cell [139]. On coreceptor binding, fusion of the HIV envelope and the CD4-containing 
cell membrane occurs therefore allowing the virus capsid core to enter the CD4+ cell. This is 
followed by reverse transcription of the dimeric viral RNA into double stranded DNA using the 
viral reverse transcriptase enzyme. During the reverse transcription process, RNAseH portion 
of the reverse transcriptase is used to degrade the RNA template strand from the RNA-DNA 
hybrid. The high diversity of the variants in an HIV-infected individual is attributed to the 
error-prone nature of the reverse transcriptase. In addition, the process of switching 
templates between two virion RNA strands results in recombination which is apparent when 
two species of RNA from different proviruses invade the same cell [140]. The DNA is 
complexed with other viral and cellular proteins to form what is called the pre-integration 
complex (PIC) [141]. The PIC enters the cell nucleus using the nuclear pore thereby starting 
the integration stage of the lifecycle.  The ability of HIV-1 to transport its genetic material via 
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an intact nuclear envelope makes it stand out from other retroviruses which rely on 
disintegration of the nuclear membrane during cell division [142].  
In the nucleus, the double stranded viral DNA is integrated into the host genome using the 
viral integrase enzyme [106]. The viral genome that is integrated may either be 
transcriptionally active or remain dormant within the host cell . HIV Latent reservoirs are 
composed of transcriptionally inactive proviral genomes but they may be transcriptionally 
active once host factors become upregulated. The Trans-Activator of Transcription (Tat) 
protein recruits the transcriptional factors to the HIV LTR region to begin the transcription 
process. Full-length mRNA primary transcripts and several spliced mRNAs encoding the 
various viral envelope and accessory proteins are produced. The transcripts are then 
translated into gag, pol, vpr, and vif and together with the full length mRNA transcript are 
assembled at the plasma membrane where they are packaged in viral particles. The 
assembled virus particles then bud off cholesterol-rich islands on the plasma membrane 
[143]. The cholesterol enrichment is thought to assist in the fusion of the virus envelope with 
the plasma membrane of the host cells during entry [143].  
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Figure 9: The lifecycle of HIV-1. Photo obtained from https://www.niaid.nih.gov/ 
1.1.9 The HIV-1 sexual transmission Biology 
1.1.9.1 HIV-1 infection routes and risks 
HIV-1 infection is acquired via several routes; sexual (male and female genital tracts), 
intestinal tract, placenta and bloodstream (contaminated blood and needles). Current 
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UNAIDS statistics show a reduction in HIV incidences although the decline is different among 
the risk groups [70]. Below are the brief summary of these routes. 
 
a. Sexual transmission 
Sexual transmission contributes to more than 80% of all the HIV-1 transmission globally [144]. 
Within this route, the risk of infections varies based on the directionality i.e. female to male 
transmission harbour a risk of exposure of 1 in 700-3000 contacts, male to female 1 in 200-
2000 and male to male transmission 1 in 10-1600 while Fellatio has a risk of 1 in 16 [145]. The 
virus that gets transmitted comes from semen, blood, rectal and cervicovaginal secretions.  
 
b. Bloodstream and contaminated equipment 
Transmission of HIV-1 also occurs through blood to blood contact with contaminated blood 
and needles. This route may occur in different ways with varying probabilities of infection per 
exposure event: blood transfusion (95 in 100), needle sharing (1 in 150) or needle stick injuries 
(1 in 200) [146].  In some parts of the world, the HIV-1 epidemic has traditionally been driven 
via needlestick injury by the key population of people who inject drugs (PWID) [66]. Some of 
these regions include eastern Europe and central Asia (EECA) [71, 147]. Today, cases of 
acquisition of HIV-1 through receiving contaminated blood during transfusion are rare due to 
proper screening. 
 
c. Placenta and intestinal tract 
The HIV-1 is transmitted from an infected mother to her baby though the placenta (vertical 
transmission) or through the intestinal tract during breastfeeding . This is also referred to as 
vertical transmission or mother-to-child transmission (MTCT) [148]. It is possible for HIV-
positive mothers to give birth to HIV-negative babies [149].  Without treatment of the mother, 
the risk of vertical transmission is at 1 in 4 births, which falls to <1 in 10 if the mother is on 
treatment [146]. This is achieved through treatment of the mother during gestation, labour 
and delivery and continuation of treatment after delivery [150]. In addition,  administration 
of neonatal and infant prophylaxis after delivery must also be done [149]. Neonatal 
prophylaxis acts as a pre-exposure prophylaxis so that the baby is not infected during 
breastfeeding and  post-exposure prophylaxis in case the baby got infected during delivery, 
labour or late gestation period [151]. This is however complicated in a resource poor settings 
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especially in sub Saharan Africa where sometimes the mothers don’t know their HIV-status, 
the delivery is done at home and infant survival depends on long term breastfeeding [152, 
153]. The WHO has a target of eliminating MTCT through its recommendation of adoption of 
Option B+ guideline of 2010/2012 which requires ART initiation for pregnant or breastfeeding 
mothers regardless of their CD4+T cell counts or clinical stage of disease, and continuation of 
treatment for life [154]. 
 
The transmission of HIV-1 can also happen through the intestinal tract (rectum and upper 
gastrointestinal tract) in adults [155, 156]. The transmission medium here is usually semen or 
blood and involves anal intercourse which can occur between men or between men and 
women [157-159].  
 
1.1.9.2 Female genital tract HIV-1 acquisition 
The majority of the HIV acquisitions in females happen through vaginal intercourse, semen 
being the main carrier [160]. Vaginal intercourse carries lower probability of successful 
infection compared to anal intercourse or parenteral inoculation [146]. Various organs of the 
female genital tract can be infected by HIV-1 (Figure 10). Using macaque models it has been 
shown that the labia, vagina, ectocervix, endocervix, uterus and ovaries  are all infected by 
SIV [161, 162]. The relative contribution of each of these tissues has not yet been fully 
elucidated. The virus from semen overcomes the huddles in the female genital tract related 
to presence of mucus, the female genital tract epithelial layers, defensive proteins and 
antibodies among others [163], collectively called the ‘mucosal barrier’ [164].   
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Figure 10: The HIV-1 invasion sites in the female genital tract. Photo adapted from [163] 
The lower female genital tract is composed of the vagina and the ectocervix (Figure 10). The 
ectocervix and the vagina provide a large surface area which the virus can potentially exploit 
for entry [163]. The fluid/exudate produced by the lower female genital tract covers the 
stratified vaginal epithelium and therefore provides the first barrier of protection preventing 
dissemination of the virus [165].  
Beneath the exudate is the multi-layered squamous epithelium of the vagina and ectocervix 
which provides a mechanical protective barrier against HIV-1 and other viruses (Figure 11). 
Even though this barrier is thought to be protective, the virus is still capable of bypassing it 
[166]. HIV-1 is thought to be captured here by Langerhans cells and translocated into deeper 
tissues [167, 168]. Other HIV-1 target cells available here are the CD4+ T cells and dendritic 
cells [134, 167]. When there is trauma on these surfaces, the acquisition of HIV-1 is even more 
probable. Trauma during intercourse is more common in women [169, 170] although there is 
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no clear definition of what really constitutes traumatic sex. This is partly believed to be the 
reason why more and more women seroconvert more than men [170]. Vaginal atrophy 
especially in post-menopausal women and those that use some vaginal tightening remedies 
especially in some Africa cultures [171, 172] exposes women to vaginal trauma that HIV-1 can 
exploit for entry. HIV-1 can be also be acquired solely through the vagina as evidenced in 
women who have undergone hysterectomy [173, 174].   
Figure 11: Scanning electron microscopy (SEM) photo of the vaginal epithelium showing the flattened and loosely attached 
epithelial cells. Photo adapted from https://fineartamerica.com  
The higher part of the female genital tract is comprised of the endocervix, fallopian tubes and 
ovaries. The endocervix has a single-layer columnar epithelium which is more vulnerable to 
HIV-1 infection due to its relative fragility [175]. It is also covered by mucus as previously 
mentioned whose main composition is the mucin which comes from two genes MUC4 and 
MUC5B [165]. Mucin in mucus is known to inhibit HIV infection [165]. In addition, the mucus 
also traps the viruses and cells thereby slowing its diffusion and therefore minimizing its 
infectivity [176, 177].  
The transformation zone between the endocervix and the ectocervix has been documented 
as the main portal of entry of HIV-1 [175]. This site is enriched with more HIV-1 target cells 
and therefore uniquely susceptible to viral entry [167, 175]. Besides, it is thought to be the 
region that is most susceptible to trauma during intercourse.  
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The endocervix mucosal surfaces have been thought to affect the R5 and X4 HIV-1 differently 
[178, 179]. It is thought to favour more the R5-tropic viruses than X4-tropic ones [180].  The 
cationic change on the V3 loop of X4 viruses is more than that of the R5 viruses [181]. This in 
turn would mean that X4 viruses would be more attracted to the polyanionic cervical mucin 
[182] and also to heparin sulphate proteoglycans that are found on the cervical mucosal
surfaces [183]. This in principle would favour R5 viruses and act as a sink for the X4 viruses.
Indeed, using flow cytometry techniques with dissociated cells, it has been shown that
cervical tissue is rich in CCR5 expressing CD4+ lymphocytes [184]. This corroborates with
earlier findings that showed the endocervix stromal papillae has more CCR5 mRNA compared
to CXCR4 [185]. During the menstral cycle, a window of vulnerability exists post-ovulation
when the endocervix defence is low thereby increasing susceptibility to HIV-1 infection [186,
187].
1.1.9.3 Male genital tract and HIV-1 in semen 
Semen contains fluid secretions from the male genital tract and the cellular fraction. The 
cellular fraction is composed of, spermatozoa, leukocytes, macrophages and some epithelial 
cells generally referred to as non-sperm cells [188]. Leukocytes include CD4+, CD8+, 
granulocytes and some B cells [189, 190]. The seminal plasma contains the fluid matrix 
produced by the epididymis, testes, prostrate, seminal vesicles, distal and proximal 
bulbourethral glands [191]. The largest fraction of the fluid however comes from the seminal 
vesicles and prostrate [191]. It also contains high amount of fructose and enzymes responsible 
for coagulation and dissolution of coagulation as well as citric acid, lipids and phosphates 
[192].  
Majority of HIV-1 acquisition in men result from vaginal intercourse with an infected female. 
Semen is also the main medium that carries the virus in transmissions involving men who 
have sex with men and in male-to-female transmission; making semen the single most 
contributor to transmission of HIV-1 [166]. The product of probability of transmission, 
duration of semen infectiousness and the number of sexual partners determine the basic 
reproductive number (R0) of male-associated forward transmission [193]. 
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The HIV-1 target cells in the male genital tract are more abundant in the foreskin. The outer 
foreskin is more keratinized than the inner one (Figure 12) and more HIV-1 target cells are 
found in the inner foreskin than the outer foreskin [163]. These cells include Langerhans cells 
and CD4+ T cells  on the lining and macrophages, T cells and dendritic cells (DC) in the 
underlaying stroma [194, 195]. The dendritic cells contain dendritic cell - specific C-type lectin 
(DC-SIGN) which capture the HIV-1 envelope allowing efficient infection of CD4+ cells in trans 
[196]. The vulnerability of the foreskin to HIV-1 infection is the basis for the protective effect 
after circumcision [197]. Circumcision however does not provide total protection against 
acquisition of the virus suggestion that other target sites are important too. The glans penis 
has squamous epithelium that is heavily keratinized like the outer foreskin making virus entry 
here impossible. On the other hand, the urethra is made up of columnar non-keratinized 
epithelium and has high concentration of CD4+ CD8+ T cells in the epithelium and underlaying 
lamina propria [198] which could be infected by HIV-1 and SIV [199]. 
Figure 12: The HIV-1 invasion sites in the male genital tract. Photo adapted from [163] 
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1.1.10 Crossing selective barriers 
The mucosal surfaces of the recipient’s gastrointestinal, female and male genital tracts are 
natural barriers that deter the virus from establishing and therefore most exposures do not 
lead to a productive infection [200-203]. The openings of these areas which also are the point 
of contact to the external environment are composed of stratified epithelia which is a 
multilayer of epithelial cells which offer the first mechanical protection against invading 
pathogens [163]. Besides being the physical barriers, the mucosal surfaces also produce 
substances that actively antagonizes the virus. For example production of mucins [204], 
innate and adaptive immunity factors [200, 205, 206]. Further protection is provided by the 
lower numbers of HIV-1-infected CD4+ T cells compared to the general circulation [207].  
On the other hand the rest of the mucosal surfaces are covered by a simple epithelia made 
up of a single layer of polarized epithelial cells with tight junctions between them [163]. This 
type of barrier only provides limited protection against infection. HIV-1 therefore exploits the 
physiological process of the mucosal surfaces including transcytosis to gain entry into the 
body [208]. At the stratified epithelium, binding and internalization of the virus is facilitated 
by the DC-SIGN and the Langerhans cells available in these regions where the virus is then 
directed into the draining lymph nodes [195]. Langerhans cells are professional antigen 
presenting cells and are usually the first line of encounter with the virus due to their proximity 
to the site of delivery [209]. In most cases when the viral load is low, the virus is successfully 
antagonized but if the viral load is high, the protective effect of langerin [210] is diminished 
and successful infection of T cells happens either at the local site or within the draining lymph 
nodes [166, 211].  
At the male genital tract, the foreskin has been implicated in facilitating the majority of the 
HIV-1 infections, and circumcision is known to protect men from acquiring infection [212, 
213]. In an explant tissue experiment, one study showed that some sections within the outer 
male genital tract are important in HIV-infection which include the meatus, urethra and glans 
all of which were found to favour more the R5 virus and block X4 viruses [214]. The presence 
of HIV-1 target cells at the urethra, foreskin and the rest of the epithelium increase the risk 
of acquisition of HIV-1. In yet another study with explant tissues, the inner foreskin was shown 
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to be more involved in HIV-1 acquisition suggesting that keratinization of the outer foreskin 
provided protection [208]. 
 On the other hand, at the simple epithelium of the endocervix, rectum and gastrointestinal 
surfaces, the main mechanism of internalization of the virus is through transcytosis [215]. This 
is where the infected and the epithelial cell come together in a polarized synapse enabling 
the budding virus to be quickly internalized without the epithelial cell being productively 
infected. 
1.1.11 HIV-1 prevention 
The risk of acquisition of HIV-1 from a single sexual exposure is very low [216] but staying with 
an infected person increases the risk of acquiring the infection due to multiple exposures 
[217]. In addition, other factors such as infectiousness of the sexual partner, their viral load 
[218], stage of disease [219] and susceptibility of the partner at risk including their sexually 
transmitted infections status [145] also increases the risk. Therefore prevention of 
transmission of HIV-1 involves both behavioural and biomedical strategies. 
1.1.11.1 Behavioural strategies 
Behavioural strategies include  modification of sexual and drug use behaviours in individuals 
or among social units. Though difficult to evaluate [220] intensive campaigns on behaviour 
change to reduce transmission of HIV-1 have been credited with reduction of HIV-1 incidences 
[70]. The approaches involved include skill-building approaches, peer-led campaigns, 
motivational activities and educational approaches. Success of such intervention strategies 
were realized in reduction in HIV-1 incidences among men who have sex with men in the USA 
[221]. Many countries attribute the success in reduction in HIV incidences to effective 
behavioural changes. Some of the behavioural strategies include condom use, monogamy and 
reduction of casual sex partners, sexual abstinence and debut delay, HIV counselling and 
testing, elimination of substance use or harm reduction strategies [222]. Among the countries 
where change of behaviour has influenced HIV-1 prevention include Kenya, Zimbabwe, 
Uganda, Malawi, Burkina Faso, Namibia and Swaziland [223].  
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1.1.11.2 Biomedical strategies 
Biomedical strategies include male circumcision, pre- and post- exposure prophylaxis, 
treating of STIs and vaccines.  
a. Male circumcision
Male circumcision is an old tradition in many communities in the world and it is estimated 
that around 35% of all the adult males in the world are circumcised [224]. In societies where 
the mode of HIV-1 transmission was heterosexual, male circumcision was negatively 
correlated with HIV-1 transmission [225]. Overall male circumcision have been reported to 
have a protective efficacy of between 50% - 88 % [213, 226-230] which is corroborated by a 
meta-analysis that showed an adjusted relative risk of 0.42 (95% CI 0.34 – 0.54) in all the 
circumcised males [231]. There are several biological explanation to the HIV-1 protection 
observed after circumcision: The inner foreskin which is exposed during erection has more 
HIV-1 target cells than the outer foreskin [230] and nine times more than the cervical tissues 
[232].  The outer foreskin has proportionately higher keratinization compared to the inner 
foreskin [195]. The foreskin is also susceptible to ulcerative sexually transmitted infections 
[233, 234]. Finally the uncircumcised penis is more susceptible to trauma during intercourse 
than a circumcised one.  
b. Treating sexually transmitted infections
Various sexually transmitted infections (STIs) are associated with increased relative risk of 
acquiring HIV-1 in longitudinal studies: genital herpes, syphilis, gonorrhoea, trichomonas and 
chlamydia [235-237]. The STIs cause urethritis, genital ulcers or cervicitis and may increase 
HIV transmission by creating entry points when the disease is ulcerative or increasing the HIV-
1 target cells if the disease creates an inflammatory situation [238, 239]. On the other hand 
the results from randomized clinical trials for treatment of STI for prevention of HIV-1 have 
reported mixed results [240, 241]. The incomplete understanding of the precise mechanism 
in action has led to the term ‘epidemiological synergy’ in explaining the role of STIs in HIV-1 
transmission [242]. In sum, STIs work to increase the infectiousness of the infected index case, 
increase the susceptibility of the recipient or both [242, 243]. 
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The presence of an STI has also been associated with increased shedding of the HIV-1 in the 
genital fluid [244-248] and treating STIs has been shown to reduce the viral shedding [247, 
249-251]. Therefore programs to diagnose and treat STIs are presumed to be important in
prevention of HIV-1.
c. Pre- and post-exposure prophylaxis (PreP and PEP)
Pre-exposure (PreP) and post-exposure (PEP) are recommended for occupational and non-
occupational exposures for people with a high risk of acquiring HIV-1 [252]. Though at present 
there is no randomized clinical trial for PEP, one case-control study showed 81% protection 
[253]. Other evidence for efficacy of PEP comes from animal models [254-256] and treatment 
of pregnant women [257, 258]. On the other hand there have been several randomized 
clinical trials for PreP done targeting men who have sex with men [259-261], heterosexual 
transmissions [262-265] and among intravenous drug users [266]. These studies showed 
between 44% - 86% reduction acquisition of HIV-1.  
d. HIV-1 Vaccines
With more than 70 million people and 35 million deaths since the beginning of the epidemic, 
there is a serious need for a HIV-1 vaccine. The road towards an effective HIV-1 vaccine has 
been long and winding since the traditional vaccine approaches of whole-inactivated or live-
attenuated virus did not work with HIV-1 [267]. Recombinant vaccines on the other hand 
provide some promise. Recently modest efficacy was observed with RV144 “Thai” vaccine 
trial in 2009 [268]. This vaccine is being modified in a current vaccine trial called HVTN 702 
launched in 2016 among South African Adults. The HVTN 702 vaccine is based on two previous 
experimental vaccines: a canarypox vector-based vaccine  ALVAC-HIV (Sanofi Pasteur) and 
AIDSVAX two-component gp120 protein subunit vaccine (GlaxoSmithKline) and MF59 
adjuvant (GlaxoSmithKline).  
Recently, the RV144 vaccine was adapted to subtype C virus which is the highly prevalent 
clade in South Africa under the HVTN 702 vaccine clinical trial. Fashioning an HIV-1 vaccine 
for every clade raises questions on licensure, i.e. each region seeking a licence for a HIV-1 
vaccine that targets their most prevalent subtype/subtypes. Janssen Phamaceutica vaccines 
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and their partners are working in developing a HIV-1 vaccine composed of several copies of 
each gene that captures a significant amount of the diversity of the HIV-1 subtypes. The phase 
1/2a trial called APPROACH with volunteers in Thailand, South Africa, Uganda, Rwanda and 
USA  showed safety and tolerability as well as high antibody titres [269]. In addition,  it 
showed 67% protection against SHIV-SF-162P3 in rhesus monkeys [269]. The phase 2b has 
already been launched (NCT03060629). 
In addition to recombinant vector vaccines, other researchers are infusing broadly 
neutralizing antibodies to test whether they can provide protection. The VRC01 monoclonal 
antibody as a passive immunotherapy is being tested in sub-Saharan Africa as well as in the 
USA, Peru and Brazil. The concern here is the rapid decay of antibodies hence repeated 
infusions will be mandatory to keep antibodies at protective levels. This brings also the issue 
of cost-effectiveness since it is expensive to produce the antibodies therefore these studies 
are rather a proof of concept to show that antibodies can offer protection and therefore 
inform vaccine development. 
e. Treatment as prevention of HIV-1 (TasP)
Initially, initiation of HIV-1 treatment was based on the level of CD4 counts [270]. Treatment 
as prevention (TasP) is a new concept which was derived from the observation that among 
discordant couples, the infected partner had undetectable or very low concentration of viral 
RNA [218, 271]. This led to randomized clinical control studies as well as mathematical 
modelling studies that showed near zero transmissibility if suppressed viral load was achieved 
[270, 272-274]. This was the basis for revision of the previous recommendations to treat 
based on CD4+ T cell counts and stage of disease [270] to the current universal ‘test and treat’ 
whose guidelines were drafted by World Health Organization (WHO) in 2016 [275]. If 
successful it will help achieve the UNAIDS Fast-Track target of 90-90-90 by 2020, where 90% 
of the people who are infected know their status, 90% of them to the receive the treatment 
and 90% of those on treatment to achieve viral suppression [276]. 
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1.2 HIV-1 compartmentalization 
HIV-1 compartmentalization is the restriction of movement of the virus between anatomical 
sites leading to formation of related yet distinct viral variants within these anatomical sites 
[277]. In an infected individual HIV-1 exists as quasispecies; which are related yet distinct 
variants.  The diverse population undergoes a founder effect when there is adaptation to a 
specific microenvironment that leads to the appearance of a compartmentalized population 
[278, 279]. The diversity results from the error prone-nature of the viral reverse transcriptase 
(RT) [280-282]. Additional causes of diversity comes from high recombination rates, the short 
viral replication cycle and the large population size [283]. The genetic diversity varies from 
one tissue to another thereby impacting on viral fitness and progression of disease [282, 284]. 
HIV-1 compartmentalization between blood and various anatomical sites have been 
documented with the most frequent compartmentalization occurring within the CNS 
(cerebral spinal fluid (CSF) or brain autopsy) compared to virus in the blood [277]. Other 
anatomical sites showing this phenomenon include the liver, breast, gut, lung [285], kidney 
and the male and female genital tracts [286-292]. Some of the proposed reasons for the 
existence of viral compartmentalization within these anatomical sites is the differential 
immune selective pressures, tissue and cell type differences in gene expression and 
replication, and other factors that alter the cellular or tissue environment [277]. Some of 
these alterations of cellular environment may include but not limited to antiretroviral 
concentrations for the subjects on therapy [293, 294]. These perturbations and selective 
pressures lead to some mutations that may impact phenotypic properties of the virus [277]. 
Some of these phenotypic attributes include cellular tropism, coreceptor utilizations, 
replicative fitness, transmission, neutralization properties, syncytium formation and 
cytopathic effects. Studying these compartmentalized viral populations enhances our 
knowledge of HIV-1 pathogenesis enabling designing of targeted remedies to prevent viral 
adaptation to these microenvironments. 
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1.2.1 Viral compartmentalization in leukocytes 
HIV-1 compartmentalization between peripheral blood mononuclear cells (PBMC) and 
plasma has been studied mainly using the pol or env sequences. These studies have revealed 
the existence distinct variants within these two sites [295]. In addition, differential drug 
resistance mutations between plasma and infected lymphocytes have been described [296]. 
In one study [297], out of the patients who were failing antiretroviral therapy, a quarter of 
them were due to drug resistance mutations in PBMC that were lacking in plasma. 
Compartmentalization has also been reported to exist between specific populations of 
lymphocytes e.g. monocyte/macrophages and CD8+ T cells [296, 298]. However other studies 
have also failed to demonstrate this compartmentalization [299, 300]. 
1.2.2    Viral compartmentalization in the brain and cerebral spinal fluid 
The brain and cerebral spinal fluid (CSF) have been reported to show more severe 
compartmentalization relative to what has been observed in other anatomical sites [301-
305]. This is probably due to the existence of a blood-brain barrier (BBB) [306-308] and the 
blood-CSF barrier (BCSFB) [304, 309]. These barriers are very selective, but seem to not only 
restrict virus trafficking but also other macromolecules circulating systemically [310]. The HIV-
1 infection in the brain and CSF leads to HIV-1-associated neurocognitive disorders (HAND) 
that occur during the advanced stage of disease [311-313]. HAND refers to a group of 
neurocognitive impairments including asymptomatic neurocognitive impairment (ANI), mild 
neurocognitive disorder (MND) and HIV-associated dementia (HAD) [314].  
The central nervous system is colonized during the primary infection [315] leading to brain 
injury and inflammatory responses [316, 317]. Even during the era of antiretroviral therapy, 
a less severe cognitive impairment exists suggesting that some ARVs don’t penetrate 
sufficiently into the BBB and BSCFB [318]. This means that the CNS could act as a latent virus 
reservoir which could present challenges in its elimination [82].  
Compartmentalization of HIV-1 between blood and the central nervous system has been 
evaluated in previous studies mainly from brain autopsy [319, 320]. In addition, viral 
compartmentalization, equilibration and clonal amplification in living subjects have been 
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observed between CSF and blood [305, 321-323]. The compartmentalized viral populations in 
CSF and CNS were found to exhibit some characteristics that were distinct from the viruses 
circulating systemically [305, 324-326]. Schnell et al reported existence of both R5 T cell tropic 
and macrophage-tropic viruses circulating in the CSF of patients exhibiting signs of  HIV-
associated dementia (HAD) [327]. On therapy initiation, the R5 viruses were associated with 
rapid decay in the CSF while the macrophage-tropic ones were associated with slow decay 
indicating that the macrophage tropic phenotype arose as an adaptation to grow in cells 
expressing low levels of CD4 in the CNS [327]. Indeed the team showed that the macrophage 
phenotype was restricted to CNS/CSF and did not exist in blood plasma of the same subjects. 
Testing them in affinofile cells which have an inducible CD4 and CCR5 levels, it was confirmed 
that macrophage tropic viruses were better at infecting cells with low levels of CD4 than their 
T cell tropic counterparts [328]. Development of X4 and m-tropic variants expands the host 
target cells when the CD4+, CCR5+ T cells become limiting. 
1.2.3 Viral compartmentalization in the gastro-intestinal tract 
The Gut-Associated Lymphoid Tissue (GALT) contains the majority of the body’s lymphocytes 
compared to the general circulation [78, 329]. The mucosal CD4+, CCR5+ T cells are the 
predominant lymphocytes, thereby facilitating the replication of the virus during the first few 
weeks of infection [83, 330, 331]. Extensive depletion of the CD4+ T cells occurs in the gut, 
and evidence shows significant loss still persist even after years of therapy [85].  The proximity 
of the gut to the external environment, and access to gut microbial antigens and food add to 
the characteristics that make the gut hospitable to replication of HIV-1 [331]. These factors 
cause the CD4+ T cells to be in a perpetual activated state and also some having differentiated 
into the memory state. In addition the access to microbial antigen leads to inflammation and 
injury resulting in HIV-1 stimulatory cytokines [332].  
Within the various organs of the gut; stomach, duodenum, oesophagus and colon, differences 
in viral HIV-1 diversity have been observed [333]. Distinctive viral populations  have also been 
observed in the rectum relative to those in blood [334]. This can be due to founder effect, but 
it can also indicate that the virus experiences differential selective pressure depending on 
local selective milieu of the organ is resides in. Further studies analysing the virus in tissues in 
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autopsies have also come to a similar conclusion of distinct viral populations within tissues in 
the gut [334, 335]. Interestingly, distinct viral populations have also been reported between 
HIV-1 in faecal samples and that in blood samples [336-338] further supporting viral 
compartmentalization between blood and the gut. 
Compartmentalization has also been observed in other bodily anatomical sites. These include 
the breasts [339-342] where also mastitis was associated with increased viral replication 
[341]. Like with other anatomical sites, not all the studies have reported 
compartmentalization of HIV-1 between breast milk and blood [340, 342, 343]. HIV-1 genetic 
differences have been observed between the liver cells and blood in a subset of the donors 
[344, 345]. Coinfection with HIV have been reported to exacerbate other liver conditions such 
as hepatitis C, liver cirrhosis and fibrosis [346] hence affecting treatment response and 
causing premature death.  Within the lung increased replication of HIV-1 has been reported 
in people coinfected with tuberculosis [347, 348], while other studies also showed 
independent evolution of HIV-1 within the lung compared to the general blood circulation 
[285, 349]. Other tissues with evidence of HIV-1 compartmentalization include kidneys [350-
352], lymph nodes [353, 354] and spleen [355-358].   
1.2.4 HIV-1 compartmentalization in the female genital tract 
HIV-1 is able to replicate independently in the female genital tract resulting in viral 
compartmentalization [359]. Initial studies had observed discrepancies in viral loads between 
the systemic circulation and the female genital tracts [291, 360, 361]. These differences gave 
initial evidence that the two compartments were distinct and HIV-1 can replicate 
independently in each of them [292]. In the era of antiretroviral therapy some scientists were 
also quick to notice that some female patients on antiretroviral treatments still continued to 
shed the virus in the genital tract [362]. These observations lead to studies on the genotype 
and the phenotype of the viruses compartmentalized between blood and the genital tract.  
Within the female genital tract, compartmentalization has been observed in about half of the 
donors studied [287, 288, 290, 291, 363-368]. Most of these studies were cross-sectional. 
Longitudinal studies revealed that viral compartmentalization between blood and the female 
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genital tract was transient, meaning with time blood and genital tract viruses mixed; it is in 
only a minority of the cases where viral compartmentalization between blood and the female 
genital tract was sustained over substantial periods of time. HIV-1 compartmentalization in 
the female genital tract was also observed to be a result of clonal amplifications of monotypic 
populations rather than unique genotypes [286, 369]. In addition, several factors  have been 
shown to correlate with the extent of viral compartmentalization within the female genital 
tract; CD4+ T cell counts [288, 290], availability of coreceptors on host cells [185], selective 
immune pressures [370], inflammation, antiretroviral selective pressure or presence of a 
sexually transmitted infection [145].  
1.2.5 HIV-1 compartmentalization in the male genital tract 
HIV-1 in semen has been reported to appear very early during infection [371, 372] and has a 
significant contribution to the global burden of disease [373]. The viral load in the genital fluid 
is a very important risk factor in the transmission of HIV-1 [374]. Acutely infected individuals 
are more likely to transmit the virus since the viral titres are higher during this time and mostly 
they are unaware of their HIV status. [375].  
The male genital tract has previously been reported to have partially distinct viral 
compartments in around 50% of the cases and in different subtypes [189, 190, 205, 251, 289, 
292, 303, 372, 374, 376-420]. This has been shown in several ways including discordance in 
viral load levels [392]. There is a weak association of viral load in blood and semen [373]. A 
study carried out in an African cohort established a spearman’s correlation coefficient rho of 
0.55 between the seminal and blood plasma viral RNA and the risk of virus transmission [359]. 
They were able to establish that for every log increase in seminal RNA copies, there was a 
corresponding 0.79 fold increase in risk of HIV-1 transmission [421]. However the quantities 
were higher in blood than in semen. It has been reported that the higher the viral load in 
semen, the higher the chances of the virus getting transmitted [373].  
Sub-compartmentalization of HIV-1 between seminal plasma and seminal cells has been 
reported [380, 422-424] and provides insight as to the source of the virus found in semen 
[380]. Originally it was thought the HIV-1 in semen came from infected cells that got imported 
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from blood [425]. However, more recent studies have shown that the genital tract is a distinct 
viral compartment able to locally produce the virus and infected cells [292, 386]. Anderson 
and colleagues identified three sources of the viral populations in semen, direct import of the 
virus, clonal amplification and compartmentalization [381]. Before this study, previous ones 
had observed that HIV-1 is still detectable in the ejaculate of men who have undergone 
vasectomy [426] and also in the pre-ejaculatory fluid [427]. This gave insight of the source of 
HIV-1 in semen to be from more distal sources of the male genital tract.  
Recently, a detailed tissue origin of the SIV in semen has been reported [191]. Simian 
immunodeficiency virus (SIV) is a relative of HIV that infects non-human primates and the 
results therefore can be extrapolated to explain the source of the latter as well. Using a 
phylogenetic approach the team was able to show that the virus in semen comes from various 
organs that make up the male genital tract [191]. The team also showed that virus from 
different organs of the male genital tract is phylogenetically compartmentalized [191]. In 
addition, viral populations from the epididymis, seminal vesicles and vas deferens were 
genetically similar to the virus found in semen [191] suggesting that they contribute more to 
the virus found in seminal plasma. This is at odds with older studies that had reported that 
the source of the virus in semen came from prostrate and urethra [428]. Because the male 
genital tract in humans is generally inaccessible to direct sampling, some of these earlier 
studies resulted in quantification of viral loads in semen [428-432].  
Not all studies have observed differences in viral shedding in various organs of the male 
genital tract. One example is Fieni et al study that used a macaque model to study the viral 
shedding in various organs of the male genital system [433]. The team did not find 
compartmentalization of the viral populations between various organs of the genital tract 
[433]. The differences could possibly be explained by the different modes of inoculation of 
the virus, intravenous vs penile inoculation. Further, sampling was also not done in some 
organs like urethra and vas deferens. The persistent viral shedding of virus in semen long after 
symptoms were cleared in the recent attacks by Ebola [434] and Zika [435] viruses have 
revealed existing gaps in our understanding of the virus in semen [436, 437].  
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Compartmentalization of HIV-1 between blood and the male genital tract has also been 
shown to have some compartment-specific traits related to reduced positive selection, lower 
diversity, altered glycosylation, less dependence on CXCR4 [409]. These altered traits of 
genital tract virus relative to the one in blood is driven by the need for the virus to adapt to 
the prevailing environment in the genital tract. These differences also reflected on the 
phylogenetic differences between blood and male genital tract viruses [377, 380, 386, 396, 
409]. 
HIV-1 is first shed into the genital compartments of donors before it is subsequently 
transmitted to the recipients during sexual transmission. One known predictor of forward 
transmission of HIV-1 during sexual transmission is the level of viral load in blood [218]. This 
does not suggest blood-to-blood transmission but the viral load in the genital compartment 
also correlate with the levels in blood although it is at least a log lower [376, 413].  The levels 
of virus shed into the genital compartments of donors varies from individual to individual 
[413]. It is not yet clear why this is so, but it appears  there is a critical blood viral load 
threshold (above 10000 cp/ml) when shedding into semen happens at increased probability 
[205].  
1.2.5.1 HIV-1 compartmentalization: Antiretroviral drugs and HIV shedding into semen 
The advent of highly active antiretroviral drugs has reduced the number of HIV-associated 
deaths globally [66]. The drugs are able to control the virus in blood to undetectable levels 
thereby drastically decreasing transmission [270, 438]. There is a corresponding decrease in 
viral loads in  semen as well [439, 440]. However it has been observed that even in patients 
who have suppressed virus in blood, between 2% - 48% of them still shed the virus in semen 
[375, 393, 402, 414, 441-443]. This is possibly due to the drugs not penetrating efficiently to 
critical parts of the genital tract [444, 445]. In addition it could also be a consequence of 
stimulation of viral replication in the genital tract by a sexually transmitted infections, 
inflammation [412, 414, 442, 446] or seminal cytomegalovirus replication [401]. HIV-1 
compartmentalization can also be due to clonal amplification where an infected cell produces 
some virus that is homogenous but not replicating. 
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1.2.5.2 HIV-1 in semen and sexually transmitted infections 
Sexually transmitted infections promote the acquisition and transmission of HIV-1 in a 
number of ways. These include interfering with the physical or mechanical barrier, causing 
inflammation or attracting more HIV-1 target cells [447].  
Sexually transmitted infections (STIs) that breach the physical barrier cause ulceration and 
also non-ulcerative conditions and have been implicated with an increased risk of contracting 
HIV-1 [447]. Human herpes simplex virus type 2 (HSV-2) is the most common ulcerative 
genital coinfection and has been reported to increase the HIV-1 transmission efficiency [448] 
and shedding in semen [449, 450]. HSV-2 interacts with the host proteins causing 
inflammation thereby making the environment conducive for HIV-1 replication [451]. In 
addition, the genital ulcer is made into a  portal from which HIV-1 is actively shed. Further, 
cytokine release due to HSV-2 has been shown to stimulate HIV-1 expression [452]. Other 
ulcerative STI that result in an increase in viral shedding in semen include syphilis [453].  
Non-ulcerative urethritis has also been linked with up to 8 times more virus shedding in 
semen when groups of HIV-infected people were compared to their uninfected controls 
[251]. Among the non-ulcerative urethritis investigated in this study, Gonorrhea was 
observed to result in the highest shedding of HIV-1 in semen [251]. The viral burden was 
significantly reduced in semen within a week of treatment of the sexually transmitted 
infection but remained unchanged in blood further supporting the role of STI in HIV shedding 
in semen. [251]. Non-ulcerative sexually transmitted infections result in inflammation. 
Mucosal tissues are enriched with HIV-1 target cells when an inflammation-inducing STI like 
gonorrhea is involved. These infected cells are recruited by the inflammatory cytokines such 
as interleukins and tumour necrosis factor which intern lead to more viral shedding in the 
semen [454, 455]. 
1.3 Bottlenecks in HIV-1 transmission 
Transmission of HIV-1 is known to involve a transmission bottleneck where a single variant is 
transmitted in around 80% of the cases [456-458]. Earlier evidence came from cross-sectional 
studies involving discordant couples that showed that early transmission of HIV correlates 
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with viral population bottleneck [459-462]. Studying the viral transmission bottlenecks and 
the pressures involved during selection in the donor, genital fluids and recipients helps to 
understanding the nature of the transmitted founder viruses, information that can be used 
for the design of vaccines and other intervention strategies. 
1.3.1 Transmission bottleneck based on mode of HIV-1 transmission 
It has been appreciated for a number of years that a stringent bottleneck occurs during HIV-
1 transmissin, where the HIV-1 infection in the recipient is established by a single variant or 
by a limited number of founder viruses [463-466]. More recently, it has become more and 
more clear that the observed narrowing is very sharp even in parenteral HIV-1 transmission 
[467, 468]. This phenomenon has been termed “transmission bottleneck” and is the subject 
of our current study (Figure 13). The biological mechanisms behind this observed population 
bottleneck are poorly understood but physical conditions at the mucosal surfaces of the 
recipient [469], level of  immune activation [145, 470] and availability of HIV-1 target cells 
[471] are some host factors seen to influence it.
Traditionally, the number of the transmitted founder (T/f)  had been shown to vary depending 
on the mode of HIV-1 transmission i.e. sexual [457], mother-to-child transmission [464] or 
parenteral [466]. During the heterosexual transmission of HIV-1, 80% of the transmitted virus 
is due to a single virus [457, 458, 469, 472-474]. The risk of transmission of multiple viruses 
increases in virus transmissions involving men-who-have sex with men and in intravenous 
drug users (IVDU) [475]. However more recently, it has become apparent that the 
transmission of the virus in men-who-have sex with men, involves single variant transmission 
in 75% of the recipients [469, 476]. Transmission of single variants in mother-to-child 
transmission is approximately 70% [477] and 40-80% in injecting drug users [72, 467, 478]. 
These levels are identical to those observed in heterosexual transmissions. This indicates that 
even though the narrowing seems to be stochastic mediated by the mucosal surfaces of the 
recipient or low titre inoculum encountering a rare target cell, some narrowing steps are 
heavily selective. This shows that the mucosal surfaces of the recipient are not the only source 
of selection but more selection happens systemically as well and therefore the T/F virus may 
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have some features different from chronic virus that provide necessary advantage during 
transmission.  
Figure 13: Depiction of the HIV-1 transmission bottlenecks from an infected donor to the recipient. (adapted from [468]) 
1.3.2 Transmission bottleneck among intravenous drug users 
Drug use is a complex, chronic behaviour usually difficult to uproot due to development of 
dependence. Unfortunately, several disease agents including HIV-1 are transmitted through 
this route resulting from sharing injection apparatus and risky sexual behaviour while under 
influence. Intravenous drug use involves introduction of a drug systemically via exposed blood 
veins on the skin through a needle and syringe. In some parts of the world, like Eastern Europe 
and Central Asia, the HIV-1 epidemic was driven by intravenous drug users and their sexual 
partners [147, 479]. In Russia, the clone circulating among some intravenous drug users has 
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sequence divergence constraints meaning that it was a clonal introduction into the 
population in more recent times followed by spread from this single introduction [480].  
HIV-1 has been shown to involve a substantial bottleneck irrespective of the mode of 
transmission. The bottleneck had been reported to be more in heterosexual transmission 
[472], intermediate in MSM [481] and least in blood-to-blood transmission. However, recent 
studies have shown that there is substantial bottleneck that exist among intravenous drug 
users [72, 475]. The virus that established the infection in these studies was derived from 
single variants in 40-75% of the donors. The two cohorts studied were independent of one 
another and came from different settings, one from North American [475] and another from 
Russia [72]. In the north American cohort, 6/10 (60%) of the transmissions involving IVDU 
were traced to multiple variants while 40% were traced from single variants [475]. In the 
Russian IVDU cohort, 69% (9/13) involved transmission of single variants [72]. Combining this 
with unpublished data from the same cohort involving 6 out of 7 single variant transmissions 
[482], then 15/20 (75%) of IVDU HIV-1 transmissions involved single variants in this cohort. 
This data indicates that substantial bottleneck exists in blood-to-blood transmissions where 
no mucosal barriers are involved. Unexpectedly, this was very similar to the proportion that 
is observed in sexual transmissions [467].  
A potential limitation to interpretation of these studies however, is in sizing the inoculum 
involved. The donor viral load and amount of blood left in the needle are variable. During the 
acute phase of infection, the viral loads are usually very high and since IVDUs share needles 
in a network and more frequently, the virus can spread fast. In some simulations [483], 
without syringe rinsing, approximately 84µl and 2µl of donor blood is left in the high and low 
dead volume syringes respectively. These residue donor blood volumes could be used to 
approximate the size of the inoculum. However, this can be confounded by practices such as 
booting; where blood is redrawn into the syringe a second time to rinse residual drug left in 
the dead space [484]. With syringe rinsing, approximately 1µl and <0.001µl is left in high and 
low dead volume syringes respectively [485-487]. Other practices that could complicate sizing 
of the inoculum include heating the drug before injection, rinsing of the needles after and 
before use and time between needle sharing.  
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Another limitation could be that these transmissions that are thought to occur through 
intravenous drug use could have been transmitted sexually. However, for the Russian cohort, 
transmission is more likely to be through intravenous drug use since the IVDU-linked 
transmissions are mostly subtype A while sexual transmissions are subtype B [480]. Overall, 
the rate of single variant transmissions involving IVDU seems to be higher than it would be 
expected. These observations are corroborated by a study showing reduction in viral diversity 
after controlled intravenous inoculation of macaques with SIVmac251 or SIVmac660 [488]. 
These studies suggest that the mucosal surfaces of the recipient are not absolutely 
responsible for the observed transmission bottleneck but rather it involves multiple selective 
barriers within the donor genital tract, donor and recipient genital fluid as well as within the 
recipient blood (Figure 13). 
1.3.3 A fitness bottleneck during HIV-1 transmission 
Transmission of HIV-1 selects for fitter viruses at the transmission bottleneck where 
establishment could easily be extinguished [489]. The fitness bottleneck is observed during 
the establishment of HIV-1 at the portal of entry during the infection of the first cell and more 
cells thereafter, usually measured by the number of virus particles produced by an infected 
cell or the infectiousness of these particles. Despite the complexity and diversity of HIV-1 
across the epidemic and within an infected individual, heterosexual transmission mostly 
selects a single founder outgrowth virus which comes from the minor variant in the donor 
[490]. Carlson et al observed a selection towards  transmission of amino acids that correlate 
with increased fitness of the virus [489]. Thus the probability of transmission was influenced 
by the viral fitness.  
The concept describing the virus establishing infection is based on the reproductive number 
(R0) which is the average number of cells infected from an infecting single host cell. The 
infection spreads only when this number is greater than 1 and dies out if the number is less 
than 1 [193]. Studies done during the early events before expansion show that the R0 is 
initially low but it increases with time as more cells get infected [193, 491]. Carlson et al also 
reported more polymorphism being transmitted in male-to-female transmission than female-
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to-male transmission meaning less fit virus transmission were more common in male-to-
female transmission than vice versa [489]. This severe bottleneck during female-to-male 
transmission can be mitigated by a genital urinary infection in the recipient or if the viral load 
was high in the donor [489]. 
1.3.4 Multivariant HIV-transmissions and sexually transmitted infections (STIs) 
Recent observations that HIV-1 transmission among the intravenous drug users involves a 
single variant raises questions about the role of sexually transmitted infections (STIs) in 
transmission of multiple variants. Acquisition of multiple variants has previously been linked 
to faster diseases progression evidenced by higher viral loads and lower CD4 counts among 
these individuals [492]. Some STIs such as syphilis [243, 493], chlamydia [494] gonorrhea [495] 
lead to increased risk of HIV-1 infection [446] as well as multiple variant transmission [469, 
496]. These results are usually attributed to the breaks in the mucosal surfaces [497], 
recruitment of target cells or production of inflammatory cytokines [498].  In some studies, 
however, the presence of an STI in the donor or recipient was neither associated with risk of 
HIV-1 infection [499, 500] nor multivariant transmission [469]. It is possible that these studies 
were underpowered to detect the association between STI and increased multivariant 
transmission.  Even for the two studies linking HIV with risk of multivariant transmission [469, 
496], association with any particular STI was not shown. Instead vaginal/urethral discharges 
[469] or grouping all STIs together [496] were associated with multivariant transmission,
possibly because there were too few events in the study of any one STI to be able to easily
detect a specific association. Therefore, perhaps the effect of an STI in promoting HIV-1
infection is only to provide a modifying effect without necessarily compromising the integrity
of the mucosal barriers. These effects provide the synergy necessary for increased HIV-1
infection and risk of multivariant transmission [242, 447, 501]. Also, the observations of an
elevated risk of infection establishment by a single variant among intravenous drug users [72,
467, 475, 482], disfavour the idea of the mucosal surfaces or defences being solely
responsible for the transmission bottleneck.
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1.3.5 Features of the transmitted/founder virus 
Observation that the transmitted/founder virus involves a transmission bottleneck from a 
highly diverse swarm in chronically infected individuals has led to a holy grail of characteristics 
associated with this outgrowth virus. Several attributes both genotypic and phenotypic seem 
to correlate with the transmitted founder virus. Most of these attributes seem to be 
inconsistent among the studies. Utilization of CCR5 co-receptor by the T/F virus [502-506] is 
consistent among many studies but other attributes are observed in one study while absent 
in another. While these features support the idea of the transmitted/founder virus being 
selected for during transmission [468, 489, 490, 507, 508], other processes involve stochastic 
narrowing of the viral population at the transmission bottleneck.  
Since the features of transmitted/founder virus selection might extend to the donor as well, 
this thesis will examine the differences in phenotype of the variants found systemically and 
those found in the male genital tract since they are the viruses that are potentially 
transmitted to the recipients. In the next sections both the genotypic and phenotypic features 
relevant to our current study that have been shown to characterise the transmitted/founder 
virus are discussed.  
1.3.5.1 Genotype of the transmitted/founder virus 
Several genotypic features have been observed in transmitted/founder viruses compared 
with chronic viruses found in the transmitting partner. These features have been gathered 
from studies comparing genotypes between transmitting pairs or general comparisons of 
sequences collected at chronic and acute phases of HIV-1 infection. Some of these features 
include variable loop characteristics, i.e. number of potential N-linked glycosylation sites 
found on the HIV-1 envelope and length of the envelope variable loops. These features are 
individually discussed below. 
a. Transmitted/founder virus has shorter hypervariable loops of the HIV-1 env
It is thought that the long hypervariable loops of the HIV-1 envelope could be 
disadvantageous to the virus that is initiating transmission. One explanation is that the long 
loops which result from insertions may limit the virus access to CD4 receptor and CCR5 
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coreceptor. On the other hand, longer variable loops are advantageous to the chronic virus 
as they can mask neutralizing antibody epitopes facilitating escape. This is necessary in 
chronic infections where immune pressure increases. Even with the said benefits, the finding 
of shorter envelope loops as a property of the transmitted/founder viruses has been 
inconsistent among studies.  
Studying HIV-1 subtype B for example, Gnanakaran and colleagues confirmed that early 
infecting viruses had shorter V4 loops compared to chronic infections [509]. This however 
was not seen in other studies involving HIV-1 subtype B during early infection [510-512]. 
However transmission of viruses with shorter hypervariable loops has been consistent among 
subtype A [510], D and C [459]. This therefore suggests that transmission in these subtypes 
favours compact envelope glycoproteins that interact better with target cells at the mucosal 
surfaces of the recipients [513]. During disease progression, the variable loops grow in length 
towards chronic infection. This is however sustained up to a particular limit where they 
shorten again in late stage of disease [514]. This might be due to release of immune pressure 
as the host is severely immune compromised at the later stage of infection. Indeed, this is 
supported by a study showing slower evolution of the virus in patients with low CD4+ T cell 
counts [515].  
b. Transmitted/founder virus carry fewer potential N-linked glycosylation sites
(PNGS)
HIV-1 envelope protomer is comprised of approximately 30 N-linked glycoproteins sites 
(Asparagine) whose role is to anchor the carbohydrates to the HIV-1 envelope. Consequently, 
the carbohydrate protects the underlying protein from recognition by circulating antibodies 
[516]. Viruses in chronic infections are selected partly on increase in number or varying the 
position of the carbohydrates on them. This has led to development of the term ‘glycan shield’ 
although some neutralizing antibodies can recognize these carbohydrates [517]. With the 
disease progression also, the HIV-1 loop lengths become longer as they adapt to immune 
pressure [514]. But as previously indicated, the T/F virus favours variants that have shorter 
loops. It is therefore also possible to expect fewer glycosylation in the T/F virus as well.  
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Traditionally, the role of these glycans was thought to only influence immune escape. But 
more recent studies are showing that glycans have more roles than that. One of these is their 
involvement in HIV-1 transmission as will be detailed in this section. In addition, they are 
involved in providing some structural characteristics as they are found as part of the epitopes 
and are targeted by some broadly neutralizing antibodies [518].  
Among the original studies, Deydeyn and colleagues observed that among the 8 transmitting 
pairs that they studied, five of the pairs involved transmission of variants that had smaller 
number of PNGS compared to the median number in the donor [459]. However, taken 
together the number of either donor or recipient sequences did not differ significantly from 
HIV-1 subtype C viruses available in the Los Alamos database which has sequences from all 
infection stages. Similar findings were also observed among HIV-1 subtype A viruses [510] and 
in another subtype C virus study [506]. Interestingly, one study showed that under-
glycosylation was observed more when comparing sequences from acutely infected men with 
chronically infected women [506].  
Though the advantages of fewer PNGS for the T/F virus has not been fully elucidated, one 
study has shown that having fewer glycosylation sites is important in enhancing the 
interaction of the virus with α4β7 integrin [519]. This is a homing marker available on CD4+ T 
cells that directs them to the gut-associated lymphoid tissues (GALT). This is the reason the 
GALT is among the first to amplify the virus following successful establishment.  Despite this, 
fewer PNLGS as a feature of T/F virus has not been consistent among subtypes suggesting 
that the phenotype resulting from it might be beneficial for one subtype and not the other. 
For example, it is absent in HIV-1 subtype B [510, 520]. Even with the inconsistency, it appears 
that the differences might be small or even unnoticeable in some subtypes, but they might 
affect key structural characteristics of the HIV-1 envelope necessary to provide the needed 
property to establish. These properties might include among others enhanced binding to 
α4β7 as previously mentioned.  
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1.3.5.2 Phenotype of the transmitted/founder virus 
Among the phenotypic features that have been observed to be favoured during HIV-1 
transmission include difference in utilization of the coreceptors and neutralization 
sensitivities to donor antibodies.  These are individually discussed in the below sections. 
a. Transmitted/founder virus preferentially utilize CCR5 coreceptors
Among all the features of the transmitted/founder viruses studied, the utilization of the CCR5 
coreceptor is the only characteristic that has been a consistent feature [503, 521]. There is a 
selective transmission of CCR5-utilizing viruses and less of the X4 tropic viruses, possibly due 
to the fact that X4 tropic viruses develop later in the infection. Dependency on CCR5 
coreceptor in subtype B is higher during early infection and coreceptor switch to CXCR4 or 
utilization of both is seen with disease progression. Recently it has been reported that some 
chronic viruses are able to utilize a maraviroc-bound conformation of CCR5 [504] or a 
conformation that is not usually bound by maraviroc when CCR5 expression levels were high. 
This trait of promiscuous utilization of CCR5 coreceptors by chronic viruses was selected 
against by transmitted/founder (T/F) viruses in both subtype B and C viruses [504].  
b. Transmitted/founder virus is sensitive to the transmitter’s antibodies
Transmitted/founder virus has been seen to favour epitopes that are lost during chronic 
infection as the virus tries to escape the immune pressure from the infected host. This is 
possibly due to absence of autologous antibodies in the recipient until later [522, 523] or the 
associated cost is detrimental to establishment and therefore selected against. The latter is a 
more plausible explanation since it has been established that some low titre neutralizing 
antibodies are available as early as two weeks of infection [524]. At the population level, 
broadly neutralizing antibodies do not provide protection against HIV-1 but they do provide 
substantial selective pressure on the viral populations. This selective pressure makes viruses 
in later stages of infection more resistant to neutralization by antibodies. 
Transmission of autologous neutralizing antibody-sensitive viruses has been reported to be a 
feature of HIV-1 T/F viruses [459, 525, 526]. The study by Derdeyn et al showed that recipient 
pseudoviruses were 10 times more sensitive to donor plasma compared to their donor 
counterparts [459]. These results were also corroborated by similar ones by Deymier and 
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colleagues using infectious molecular clones [526]. The explanation comes from another 
feature of a compact V1-V4 region of the T/F virus [459]. This tendency of compact V1-V4 
region would lead to enhanced exposure of the CD4 binding site. This increased exposure has 
often been associated with sensitivity to neutralization [527, 528]. In addition, sensitivity of 
recipient viruses to donor antibodies was also shown in a subset of cases in HIV-1 subtype B 
transmission in a cohort involving men who have sex with men [525]. It appears that the 
envelope conformations favoured at chronic infections are selected against at the 
transmission bottleneck. This means that the HIV-1 transmission favours envelope 
conformations that are accessible to receptors on the target cells.  
1.4 HIV phylogenetics 
HIV- popolations expand from an initial small populations during transmission and diversity 
increases towards chronic infection [457]. Therefore viral phylogenetic becomes a good tool 
to study HIV populations. Traditonally, phylogenetic approach has been used in study HIV-1 
compartmentalization [377, 380, 394, 400, 529] and phylogenetic compartmentalization has 
for long been the gold standard. HIV Bayesian phylogenetics have also been used in HIV- 
studies especially in epidemiology. This is because is combines several factors  such as viral 
movement dynamics, demgraphics and epidemiological factors that can be encoded into the 
molecular sequence data [48]. Bayesian phylodynamcis have also been used in studying HIV-
1 movement between anatotomical sites [303, 325, 530]. These analyses provide information 
that is beneficial in evidence-based solutions for prevention, management and control of 
disease. 
1.5 Motivation and rationale for the study 
Sexual transmission of HIV-1 remains the most predominant mode of spread contributing to 
70-80% of all the transmissions [81]. Despite the high diversity that characterizes the donor
population and transmission fluids, it has been observed that only one variant gets
transmitted in 80% of the cases in heterosexual [457, 472], 75% in homosexual [467, 481] and
60-80% in intravenous drug users [467, 468]. This suggests that transmission of HIV-1 involves
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one or more selective events within the path of transmission from the donor to the recipient. 
The biological mechanisms of this bottleneck remains largely unknown. 
The majority of this genetic bottleneck is thought to be mediated by the mucosal surfaces of 
the genital tract [469]. It is not clear to what extent the intact mucosa of the recipients selects 
for the transmitted virus over and above the physical obstruction of the virus. More studies 
showing that a substantial bottleneck exists during HIV-1 transmission among intravenous 
drug users, show that the mucosal surfaces are not solely responsible for observed bottleneck 
[72, 467]. Availability of HIV-1 target cells [471], genital inflammation [145] and level of 
immune activation [470] are other host factors suggested to play a role. Previous studies that 
worked to understand the transmission bottleneck compared isolates from chronic and acute 
HIV-1 infections [459, 489, 525, 526]. By doing this, they cannot address at what stage 
selection happens, anywhere from the path from donor blood to disseminated infection of 
the recipient, with selection at multiple steps very possible.  
One potentially very important step in this bottleneck may be associated with the 
compartmentalization of HIV-1 in the genital tract which has been shown to be a distinct 
compartment separate from systemic circulation [289, 377, 386, 396]. In addition to being 
compartmentalized, the virus in the genital compartment has also been shown to sometimes 
be clonally amplified [381]. Techniques that have been used previously to study HIV-1 
compartmentalization and clonal amplification cannot detect minor variants robustly. Deep 
sequencing on the other hand gives the advantage of sampling the HIV-1 populations 
represented in minor proportions. The current deep sequencing technique has been 
improved to include primerID [531-537] thereby mimicking the viral composition in vivo as 
opposed to collapsing the sequences into haplotypes. 
Even though today antiretroviral drugs are available that have substantially reduced the 
morbidity and mortality resulting from HIV-1 related infections, understanding the molecular 
mechanism of sexual transmission is needed in order to design some precise, targeted, more 
specific and potent prevention strategies.  
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Several studies have studied the variations that exist between the seminal and blood virus 
variants [367, 380, 409, 433, 490] but their findings have not extended to neutralization 
studies, nor has deep sequencing been employed. Deep sequencing would afford us the 
opportunity to get a fuller picture of the selective pressure on the viruses and to employ more 
sophisticated statistical methods to analyse our data.  
1.6 Study objectives 
Since compartmentalization of minor variants cannot be tracked using techniques used 
previously to describe compartmentalization between blood and the male genital tract, deep 
sequencing was used in this study. In addition, the changes in function for clones derived from 
blood and semen were evaluated by testing them against HIV-1 entry inhibitors,   We further 
hypothesized that the change of selective milieu as HIV-1 moves from blood into the genital 
tract may lead to viral variants in semen that are sensitive to autologous neutralization. Hence 
the virus in semen comes from a site that is relatively protected from antibodies and may be 
permitted to evolve differently relative to absence of antibody pressure. This evolution of the 
virus within the genital tract may be a significant part of the change the virus undergoes on 
its way to establishment in the new recipient. We considered this possibility because even 
some small molecules like those of some antiretroviral drugs do not penetrate the genital 
tract effectively. The objectives were; 
4. To evaluate HIV-1 compartmentalization in blood and the male genital tract using next
generation sequencing to understand the nature of viral populations in these
anatomical sites in greater detail.
5. To identify the differences in sensitivity of blood and semen variants to entry inhibitors
to obtain information about differences in function between HIV-1 populations in
blood vs the male genital tract.
6. To compare neutralization sensitivities of viral variants compartmentalized in blood
and semen by testing their sensitivity to neutralization by autologous antibodies. As a
control, we measured sensitivity to a pool of clade-matched heterologous sera to
determine if any observed difference was due to global changes in neutralization
sensitivity.
76 
2 CHAPTER 2 
Compartmentalization and clonal 
amplification of HIV-1 between blood 
and the male genital tract shown using 
next generation sequencing 
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2.1 Abstract 
Compartmentalization of HIV-1 between blood and the male genital tract may have 
substantial impact on which viruses gets transmitted during sexual transmission. Knowledge 
and characterization of these variants is important for the design of vaccine and other 
intervention strategies. Here the power of next generation sequencing was utilized to study 
compartmentalization and clonal amplification in a greater detail. A total of 44 study 
participants were recruited and in the end, a subset of 11 with sufficient viral load in semen 
to allow deep sequencing. Illumina Miseq was used in combination with PrimerID approach 
which groups together all the PCR products derived from each cDNA molecule during the 
reverse transcription process. This combination of approaches allowed us to achieve a high 
sequence depth including minor populations and the ability to account for PCR artefacts of 
PCR-based recombination and base substitutions.  
Compartmentalization was analysed using three standard techniques, Slatkin-Maddison test, 
nearest neighbour statistic and Wright’s measure of population subdivision. Clonal 
amplification was evaluated by collapsing the sequences at 99% similarity using Vsearch. 
Viral sequence compartmentalization between blood and the male genital tract was observed 
in all the 11 study participants, unlike in previous studies where compartmentalization was 
reported in about half of the donors. The extent of compartmentalization however varied 
among the study participants. Simulation of lower depth of sampling (i.e. like used in single 
genome analysis) suggested that compartmentalization could have been detected on only 
about half of the study individuals. Thus, the difference in detecting HIV-1 
compartmentalization in this thesis vs previous studies can be explained by the depth of 
sequencing achieved here and that there is no evidence that the dynamics of the viral 
populations studied in this thesis were different from those previously studied. 
Importantly, the location of the most recent common ancestor (MRCA) of semen sequences 
was located in blood suggesting that the genital reservoir is seeded from the incoming 
variants from blood. Clonal amplification was observed in all the study participants and it was 
a characteristic of both blood and semen viral populations which support the idea of 
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independent replication of variants within blood and the male genital tract. In addition, the 
proportion of clonally amplified variants that traffic poorly between compartments varied 
among the donors.  
These findings will help in better understanding the dynamics that affect the composition of 
viral populations that are available for transmission in the HIV-1 infected male donors. 
 
2.2 Background 
Compartmentalization of HIV-1 i.e. restriction of viral movement between the genital tract 
and the general blood circulation is important in understanding sexual transmission of HIV-1. 
An estimated 80% of the HIV-1 transmission occur through the sexual route especially via 
contaminated genital tract secretions [160]. Indeed, during male-to-female transmission and 
to some extent in men-who-have-sex-with-men (MSM), the main carrier of the virus is semen. 
In addition, the compartmentalized viral variants in the genital tract could become a reservoir 
from where the blood compartment is reseeded after a successful but interrupted 
antiretroviral treatment (ART) [444] or be a site of generation of drug resistance mutations 
[538]. Compartmentalization of HIV-1 can be promoted by physical barriers, differential 
selective pressure, host cell types and immune pressure. 
 
The diversity of HIV-1 in an infected person is immense and has previously been compared to 
the entire flu diversity in the world  [539]. This therefore means that innovative tools are 
needed to study it and to design potential vaccines and other intervention strategies.  
Previous studies working on HIV-1 compartmentalization between blood and the male genital 
tract had relied upon either single genome amplification (SGA) technique [289, 303, 381, 394, 
490, 529, 540] or cloning from bulk [377, 541]. Each of these methods have their advantages 
and disadvantages. For Example, SGA is advantageous over bulk PCR by allowing less PCR-
induced recombination and resampling which can result in underestimation of the sequence 
diversity of the target population [542]. The technique is however expensive and labour-
intensive, thereby limiting the number of isolates that can be studied. With the above 
constraints also, the few isolates possible, mostly come from the dominant variant in the HIV-
1 population of an infected individual. On the other hand, cloning form bulk PCR is subject to 
cloning bias where some variants are preferentially cloned than others [543]. In addition, it is 
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prone to artificial, PCR-based recombination between different templates.  Older studies had 
relied upon Heteroduplex Tracking assay (HTA) [367, 461, 544, 545] but that technique does 
not provide the sequence information; rather it provides qualitative information only. 
 
Next generation sequencing minimizes these artefacts and more recent studies have 
employed it to study HIV-1 populations in infected individuals [546-549]. A more recent 
improvement of deep sequencing is the introduction of PrimerID approach [532, 534, 537] 
which involves introduction of a random 9-15 nucleotide sequence at the 5’ end of the PCR 
products.  The primerID therefore, enables grouping of sequences according to the single 
cDNA molecule from which they were amplified. This makes it possible to account for 
resampling, recombination and minimise the risk of reading point mutations into the final 
sequence [550]. Thus, primerID approach is a critical improvement to minimize the error rate 
of the existing next generation sequencing techniques [534]. 
 
 In this second chapter of the thesis, the increased power afforded by next generation 
sequencing is utilized to study viral compartmentalization between blood and the genital 
tract in HIV-1 infected male donors in more detail than studied previously. In addition, 
utilization of primerID allowed analysis of clonal amplification in the two compartments in 
greater detail than previously possible. 
 
2.3 Methods 
2.3.1 Study participants and samples 
A total of 44 HIV-1 positive therapy-naïve men were recruited from a clinic that gives care to 
predominantly HIV-1 infected men at Woodstock, Cape Town, South Africa. Individual written 
consent was obtained from every study participant before blood and semen samples were 
collected. The inclusion criteria included: male, HIV—infected, adults of over 8 years and not 
on antiretroviral treatment (ART). The enclusion criteria included: past or current history of 
antiretroviral treatment, those with poor venous access, transgender individuals or any other 
individual who, in the opinion of the clinician giving care or recruiting staff, is unsuitable for 
participation in the study due to poor health. Demographic information relating to age, 
80 
nationality and racial group was collected. In addition, history of infection relating to current 
or previous sexually transmitted Infection (STI) was also obtained through an interview with 
the clinician and from the participants’ medical records. To estimate the duration of infection, 
the last HIV-1 negative test and earliest HIV-1 positive test dates were recorded, if they were 
available. The details of the study participants are described in Table 2.  
Blood was obtained via venous puncture and collected in 4 tubes; 5ml PPT tube for viral load 
assay, 4ml EDTA tubes for CD4+ cell counts, 9ml EDTA tubes for plasma and in serum separator 
tubes without anticoagulant. The 9ml EDTA plasma and serum separator tubes were then 
centrifuged at 2000rpm for 15 minutes. Blood plasma and serum were aliquoted in cryovials 
vials and Eppendorf tubes respectively and  immediately stored at -80oC.   
Semen was collected through self-masturbation at the clinic, immediately transported to the 
lab and processed within four hours of collection. Briefly, following a 30-60 minutes wait (for 
semen liquefaction) at room temperature in a laminar flow hood, the semen specimen was 
transferred to a 15ml sterile polypropylene conical tube with a wide-mouth plastic transfer 
pipette and then diluted with an equal volume of PBS containing penicillin (100U/ml) and 
streptomycin (100µg/ml). The diluted semen specimen was underlaid with 2ml of 19% 
cushion of Nycodenz (Axis-Shield PoC AS, Oslo, Norway) reconstituted in PBS with penicillin 
and streptomycin added. The tube was then capped, placed on a centrifuge bucket with a 
cap, and centrifuged at 1000xg for 20 minutes. The non-seminal-cell (NSC) layer was atop the 
cushion, the sperm pellet to the bottom of the tube (Figure 14). Supernatant seminal plasma 
was removed to within approximately 1cm of the NSC layer and filter sterilized through a 
0.8µm filter. The seminal plasma virus was then concentrated by centrifugation at 100,000xg 
for 1 hour at 4oC. After ultracentrifugation, the supernatant was discarded, and the pellet 
resuspend in 200µl of PBS. From the 200µl volume, 40µl was diluted 12.5 times using PBS and 
taken for viral load assay. The rest was aliquoted in two volumes of 70µl and one of 20µl and 
stored at -80oC.  
The NSC layer was removed with a wide bore transfer pipette, transferred to a fresh 15ml 
conical tube, and diluted with five times volume of PBS with penicillin, streptomycin and 
nystatin (100 to 200 U/ml). The NSC was then recovered by centrifugation at 500g for 10 
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minutes, the supernatant removed and discarded, and the process repeated twice. The 
Washed NSC pellet was then preserved at -80oC. These samples were not analyzed as part of 
this thesis. 
A subset of 11 study participants with sufficient viral loads (above 4000 copies per sample)  in 
semen were selected for deep sequencing; all had sufficient viral loads in both blood and 
semen to be suitable for analysis: SVB008, SVB012, SVB021, SVB025, SVB026, SVB029, 
SVB030, SVB039, SVB041, SVB043 and SVB049.  
Figure 14: Schematic representation of semen processing. After liquefaction, semen was underlaid in 19% Nycodenz gradient 
and centrifuged at 1000xg for 20 minutes. After centrifugation, the sperm pellet was at the base of the tube, the non-seminal 
cells (NSC) on top of the gradient cushion followed by semen plasma (SP). Semen plasma was then concentrated through 
ultracentrifugation while the NSC was washed several times and both specimen stored. 
2.3.2 Primers and the sequencing region 
The sequenced region was either the C3-V5 region encompassing 423 bp (HXB2 7179-7602) 
or the V3 region encompassing 416 bp (HXB2 6909-7325). The primers used for deep 
sequencing of the viral RNA from blood and semen are summarized in Table 1. The cDNA 
gene-specific long primers covering either the C3-V5 or V3 were designed such that the gene-
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Cell free
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Ultracentrifugation
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specific part that primed the production of cDNA was at the 3’ end (Figure 15). It was 
preceded by the PrimerID which comprised a 15-nucleotide region. The PrimerID was then 
preceded by a region where the universal reverse primer for the first round PCR bound. This 
design allowed the use of one universal PCR primer irrespective of the region sequenced. The 
sequencing region was designed in such a way that the PCR amplified region allowed the use 
of paired end sequencing with no information lost in the intertwining region between the 
forward (R1) and reverse (R2) after sequencing. The PrimerIDs were designed in such a way 
that they are always sequenced at the reverse end (R2). 
Figure 15: Design of the cDNA primer used for generation of cDNA from either the V3 or C3-V5 of the RNA extracted from 
blood and semen samples. The cDNA primer contained a gene specific primer at the 3’ end preceded by the 15-nucleotide 
PrimerID and then the binding site of the reverse primer during the PCR reaction.  
Table 1: The list of primers used for the cDNA synthesis and amplification of either the V3 or the C3-V5 region of the blood 
and semen viruses. The ‘N’ in the cDNA primer represent the PrimerID section that was used to combine the sequences that 
were generated from the same cDNA. 
2.3.3 RNA extraction and cDNA synthesis 
The viral RNAs from blood and semen samples were extracted using QIAmp Viral RNA mini 
Kit (Qiagen) following the manufacturer’s instructions. The extracted RNA was eluted in a final 
NNNNNNNNNNNNNNN
Gene-specific primer  PrimerID PCR primer site
5’3’
Primer name Sequence (5’-3’) Purpose Region
Env_C5_cDNA GAGATGTGTATAAGAGACAGNNNNNNNNNNN
NNNNGTCCYTCATATYTCCTCCTYCAGG
cDNA 
primer
C3-V-5
Env_V3_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG
NNNNNNNGGACCAGGGAGAGCATTTGTTAC
Forward 
primer
C3-V5
Env_C3_cDNA GAGATGTGTATAAAGAGACAGNNNNNNNNNN
NNNNNTGTGTTGTAAYTTCTAGRTC
cDNA 
primer
V3
Env_C2_F TGGACGGCAGCGTCAGATGTGTATAAGAGACAG
NNNNNNNGCTGGTTATGCGATTGTAAACTG
Forward 
primer
V3
Univ_i7_Rev GTCTCGTGGGCTCGGAGATGTGTATAAGAGACA
G
Reverse 
primer
Universal 
reverse
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volume of 50µl. The RNA was then reverse transcribed into cDNA using a gene-specific cDNA 
primer (Table 1) using SuperScript III First Strand System for RT-PCR (Invitrogen) and following 
the manufacturer’s instructions. Briefly, the extracted RNA was heated to 65°C for 5 minutes 
to denature the RNA secondary structures. This was followed by addition of 35µl of a mixture 
made of 1x of 5x buffer, 5mM Dithiothreitol (DTT), 2 U/ul RNAse inhibitor and 10 U/ul 
Superscript III reverse transcriptase.  The reaction mixture was then incubated in a 
thermocycler with two step temperatures of 45°C and then at 50°C for an hour each. After 
reverse transcription, the enzyme was denatured by incubating the reaction mixture at 70oC 
for 15 minutes before holding at 4oC. The generated cDNA was removed from the DNA-RNA 
hybrid by digestion using RNaseH (Invitrogen) by incubation at 37oC for 20 minutes.  
2.3.4 PCR amplification of the region of interest 
The cDNA generated from the previous step was divided into 5µl aliquots and first round PCR 
performed using Platinum HIFI Taq polymerase (Invitrogen). First round PCR for the C3-V5 or 
V3 regions was done using forward primers env_V3_subC_F and env_C2_subC_F (Table 1). A 
universal reverse primer (Univ_i7_REV, Table 1) which binds to the primer binding site on the 
cDNA long primer (Figure 15) was used. The PCR reaction mixture was comprised of 2mM 
MgSO4, 0.5mM dNTPs, 0.2µM each of reverse and forward primers and HIFI buffer. The PCR 
conditions involved an initial incubation of 2 minutes at 94oC followed by 25 cycles of 94oC 
(30 sec), 58oC (15 sec), and 68oC for 2 minutes. A final extension at 68oC for 10 minutes was 
done followed by holding at 4oC.  
2.3.5 Addition of Illumina indices 
Addition of Illumina indices was done using PCR, which was performed from 5µl of the first 
round PCR product using the Platinum HIFI Taq (Invitrogen). The primers comprised of a 6-
nucleotide index region complementary to the illumina sequencing adapters fixed on the 
sequencing chip. Multiple combinations of indexing primers were used for each sample to 
allow multiplexing of the samples within the same sequencing chip. The sequenced region 
was designed to exploit paired end sequencing without information being lost at the 
intertwining region between first (R1) and second (R2) reads.  The primer ID region was 
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designed to always be sequenced at the second end (R2). The PCR reaction mixture contained 
1X of the 10X Buffer, 2mM MgSO4, 0.5mM DNTPs and 0.2µM of each of the indexing primers. 
The PCR cycling conditions involved an initial temperature of 94oC for 2 minutes followed by 
25 cycles at 94oC (30 sec) denaturation, 58oC (15 sec) annealing and extension at 68oC for 2 
minutes. A final extension at 68oC for 10 minutes was also performed before holding at 4oC.  
2.3.6 Bead purification 
Before performing the first round PCR, the cDNA was purified using the Agencourt RNAClean 
XP beads (Beckman Coulter).The first round PCR and indexing PCR products were also purified 
using SPRISelect beads (Beckman Coulter) following the manufacturer’s instructions. For both 
types of beads, a bead to PCR-product ratio of 0.6 was maintained and washing done using 
70% ethanol. The purified products were eluted in 50µl of nuclease-free water. 
2.3.7 Illumina sequencing 
The size of the C3-V5 env amplicon was approximately 423bp, covering HXB2 7179-7602 [551] 
on the HIV-1 genome while that of V3 region was approximately 416bp covering 6909-7325 
of HXB2. Paired-end (2x300bp) multiplex Illumina Miseq was used to sequence the 
constructed libraries.  
2.3.8 Sequence processing pipeline 
An in-house R-based pipeline (MotifBinner2.0), (accessible at GitHub: 
https://github.com/HIVDiversity/MotifBinner2) was used to process the fastq format files 
into primerID-consensus sequences as described by Jabara et al, 2011 [537]. The pipeline 
comprised a combination of tools for assessing the quality of both the reverse and forward 
reads as well as ambiguous nucleotides and primer dimers. Following PCR and sequencing, 
each sequence should be from the same input template if they contain same primerID. The 
cleaning of the sequences was done by scanning each sequence for primerID. The sequences 
bearing the same primerID were binned together. The bins  made up of sequences whose 
primerIDs possibly contains sequencing errors were removed by use of a consensus cutoff 
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approach as described by Zhou et al, 2015 [533]. To remove these offspring primerIDs, a 
computation was performed to determine the likelihood that more than a certain percentage of the 
contents of a small bin was the result of sequencing errors in the bigger bin. If it is more likely that 
the contents resulted from sequencing errors in a larger bin’s primerIDs than it is for the bin to 
naturally exist (i.e. its primerIDs to have been sampled from the pool of available primerIDs), then the 
bin was discarded. If it is unlikely that the prespecified percentage of the bin is the result of sequencing 
error in the primerIDs of the larger bin, then the bin was kept provided that it was larger than a certain 
minimum size. For the purposes of flagging bins as potential offspring bins, the cuttoff was doubled. 
Bins smaller than double the consensus cutoff were referred to as small bins while bins larger than 
double the consensus were referred to as large bins. 
The pipeline utilized tools for assessing the quality of the read data from both R1 and R2 reads 
supplied. The reads that didn’t match the required read lengths, and sequences that contains 
more than 2% of ambiguous nucleotides or obvious primer dimers were discarded. The 
sequences were then trimmed to high quality reads. The second end reads (R2) were then 
searched for the primerID and the number of reads with these primerIDs tabulated. The 
forward R1 and reverse R2 reads were consequently matched, paired together and another 
quality trim performed followed by another binning together of the sequences with the same 
primerID. The total number of sequences obtained defined the depth of sampling. Finally, 
gaps were removed from the primerID-consensus sequences. The number of consensus PID 
(PrimerID) sequences obtained after employing the pipeline are summarized in Table 3. 
2.3.9 Phylogenetic analysis 
The processed PID-consensus sequences or haplotypes (variants) from blood and semen 
sequences were combined into one fasta file. The alignment was then performed using 
MAFFT [552]  and visually inspected and edited in Aliview [553]. Maximum likelihood trees 
were constructed from the PID-consensus sequences using FastTree [554] employing the GTR 
model. Fasttree was chosen because it can handle large alignments with reasonable 
computational memory and time. In addition, Bayesian phylogenetics were performed from 
equal number of  haplotypes (variants) from blood and semen constructed using a Vsearch 
[555] haplotyper tool that allowed 99.75% similarity.
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To study the HIV-1 movement between blood and semen, Bayesian Evolutionary Analysis by 
Sampling Trees version v1 (BEASTv1.10.4) was used  [556]. Blood-semen alignments were run 
using a subsitition model suggested by jmodeltest [557], employed the uncorrelated  relaxed 
molecular clock and assumed a Bayesian Skyline population model for the tree priors of the 
virus population change over time. To infer the acenstral state reconstruction, Bayesian 
stochastic search variable selection (BSSVS) approach was used [558]. Based on the 
compartment (blood or semen) of origin, symmetric diffusion model was used which allow 
equal probability of movement of the virus between blood and semen compartments. These 
parameters were specified within the XML file generated by Bayesian Evolutionary Analysis 
Utility (BEAUTI). Five hundred million generations were run, and trees sampled at every 
100,000th tree and convergence inspected in Tracer [559] for Estimated sample size (ESS) of 
above 200. The Maximum Clade Credibility trees were then constructed from the sampled 
trees using TreeAnnotator. If the ESS were below 200 i.e. convergence was not reached, the 
analysis was repeated again using the same XML file. The logs from the replicates were then 
combined using LogCombiner and resampled at a lower frequency. The convergence was 
then inspected in Tracer and if achieved, the trees were sampled using the same frequency 
and MCC tree constructed as earlier explained. The MCC trees were edited and visualized in 
FigTree [560]. Location (compartment) state randomization was done by introducting a tip-
swap operator in the XML file and repeating the Bayesian analysis and indicated above. The 
inferred location state of the most recent common ancestor should be purely as a result of 
sampling bias when tip-swap is performed. The root state posterior probabilities of each 
compartment was then plotted against those of the tip-swap analysis. 
2.3.10 Compartmentalization analysis 
The PID-consensus sequences were used in the evaluation of compartmentalization. To 
prevent sampling bias, equal number of sequences were first randomly selected from blood 
and semen. To do this, the sequences from the compartment (blood or semen) with the 
smaller number of sequences were retained. The same number was then randomly sampled 
from the other compartment with high number of PID-consensus sequences using a python 
library script. Compartmentalization was assessed by using three statistical-based tools. Two 
distance-based methods, nearest neighbour statistic (Snn) [561], Wright’s Measure of 
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Population Subdivision (FST) [562, 563] and one tree-based method Slatkin Maddison Test 
(SMT) [564]. These methods are all implemented in a software package called HYPHY [565]. 
The FST computes mean genetic distances between and within the compartments using the 
Tamura Nei-93 algorithm and computes the F-statistic. The closer to 1 the F-statistic is, the 
more compartmentalized the viral populations and vice versa. The Snn statistic compares the 
observed mean genetic distances with a hypothetical randomly distributed neighbour. On the 
other hand, SMT counts the number of inferred migration events between the compartments 
and compares this count with what would be expected in a fully mixed (panmictic) population. 
2.3.11 Distribution of identical sequences in the phylogenetic trees 
To study the distribution of variants in blood and genital compartment, phylogenetic trees 
were first constructed from the PID-consensus sequences using RaxML [566]. An R-based 
package (Analyses of Phylogenetics and Evolution, “APE”) [567] was used to extract the 
terminal node leaves of the phylogenetic trees. The number of blood and semen sequences 
from nodes with 10 or more sequences were then counted and tabulated in bubble plots. 
2.3.12 Clonal amplification 
Clonal amplification analysis was performed from the haplotypes constructed after collapsing 
the PID-consensus sequences at 99.75% similarity using Vsearch [555]. The frequency was 
tagged to the name of the haplotype (variant) which allowed to determine the minor and 
major variants. This way clonal expansion of a single cell was accounted for. The 99% 
frequency was also utilized to draw bubble plot trees with the size of the bubble proportional 
to the number of sequences used to make that particular variant. RaxML [566] was used for 
constructing trees while python library ete3 [568] was used to plot the bubble trees.  
2.3.13 Diversity analysis 
From the unique sequences made by collapsing identical sequences, HIV-1 diversity between 
blood and semen sequences was analysed. The median pairwise genetic distances were then 
determined using Molecular Evolutionary Genetics Analysis (MEGA) software version 7 [569]. 
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2.3.14 Inference on migration events between blood and semen 
We estimated the minimum number of viruses moving between the blood and semen 
compartments after normalizing for equal numbers of sequences using the Slatkin-Maddison 
test which allows the counting of the number of inferred migration events from blood to 
semen and vice versa. The difference between the migration events from blood to semen and 
semen to blood were analysed using non-parametric Wilcoxon signed rank test. The inferred 
migration events from SMT have previously been shown to correlate with Bayesian Markov 
Jump counts [303]. 
2.3.15 Statistical Analyses 
Data was analysed using non-parametric methods as implemented in GraphPad prism 8 (La 
Jolla California USA, www.graphpad.com) or Stata statistical software v15 (College Station, 
Tx: StataCorp LLC) 
Results 
2.3.16 Study participants 
A total of 44 HIV-1 infected therapy naïve men were recruited for the study who donated a 
paired blood and semen samples. Their characteristics are summarized in Table 2 . The 
median log10 viral load in the blood was 4.10 cps/ml (IQR 2.69-4.56) while that in semen was 
2.72 cps/sample (IQR 1.3-3.71). Viral load in blood and semen were weakly associated 
(adjusted R2 = 0.28, p < 0.0005) and semen viral loads were generally detected when the blood 
viral load was above 10,000 copies/ml (Figure 16 A). Of the 21/44 study participants (48%) 
who had detectable viral loads in both semen and blood, 11 were picked for deep sequencing 
(Figure 16 B). There was no difference in median age for the 11 donors (median = 28yrs, IQR 
26-33yrs) versus those that were not deep-sequenced (median = 29yrs, IQR 25-35yrs) (Mann-
Whitney test p = 0.792).  The CD4+ T cell counts for the 11 selected study subjects (median =
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390 cells/µl (IQR 233-467 cells/µl) ) was  slightly lower than that of the entire population 
(median = 514 cells/µl (IQR 371-626 cells/µl) (Mann-Whitney test p = 0.0416). This is probably 
due to the choice of study participants who had higher viral loads in semen who by association 
also had higher viral loads in blood (Figure 16 B). Blood viral load is negatively associated with 
CD4+ T cell count in HIV-1-infected adults [570, 571]. 
Table 2: Study participants details. 
SampleID Age (years) 
CD4 
count 
(cells/ml) 
Blood 
viral 
load 
(cps/ml) 
Semen viral 
load 
(cps/sample) 
Reported 
time since 
known to be 
HIV positive 
(yrs) 
Recent STI history 
SVB001 43 494 21993 4082.5 6 none 
SVB002 37 743 28001 <50 15 none 
SVB003 34 1123 20 482.5 6 none 
SVB005 29 622 20289 890 5 none 
SVB006 55 727 1648 <50 5 none 
SVB007 37 200 42072 915 7 Syphilis treated >1yr ago, Genital warts treated >1 yr ago 
SVB008 42 257 309388 38640 5 none 
SVB009 29 855 20 <50 5 Syphilis treated >1 yr ago 
SVB010 46 639 13993 <50 4 Gonorrhoea treated >1 yr ago 
SVB012 27 586 145745 6365 2 
Gonorrhoea and Chlamydia 
both treated more than 1 yr 
ago 
SVB013 25 603 31838 2152.5 2 Gonorrhoea and Chlamydia both treated >1 year ago 
SVB014 52 615 3637 <50 3 none 
SVB015 34 668 12500 <50 2 Syphilis 
SVB016 32 960 81 <50 1 Genital Herpes treat<1yr 
SVB017 20 491 4070 <50 1 none 
SVB018 27 669 692 <50 2 Gonorrhoea treated <1yr ago 
SVB019 26 519 114 <50 1 Unknown 
SVB020 25 783 30261 79247.5 4 Genital warts 
SVB021 34 148 183339 4435 1 Syphilis-not treated 
SVB022 57 264 9369 420 1 Gonorrhoea -  on treatment 
SVB023 20 460 20889 <50 0 Unknown 
SVB024 25 425 448 <50 4 Unknown 
SVB025 25 368 440969 23357.5 0.25 Unknown 
SVB026 31 209 46202 4842.5 1 Gonorrhoea-treated >yr ago 
SVB027 21 543 41616 1985 1 Unknown 
SVB029 28 149 20947 273305 2 Unknown 
SVB030 27 390 25781 235710 0.08 Unknown 
SVB032 29 505 11624 450 10 Unknown 
SVB033 0 372 81702 7810 0 Genital warts 
SVB034 24 589 333 1157.5 0 Genital Herpes HSV 
SVB036 34 147 57052 1152.5 7 Syphilis - on treatment 
SVB037 32 789 115 <50 3 Unknown 
SVB038 25 1104 11073 3232.5 1 Genital warts 
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SVB039 18 425 43191 132605 1 none 
SVB040 24 542 1809 <50 1 syphilis, gonorrhoea, genital warts 
SVB041 25 567 89090 27540 0.08 none 
SVB042 50 403 20 530 14 none 
SVB043 59 509 122297 5556597.5 2 none 
SVB044 32 152 2455 <50 15 none 
SVB045 29 300 20691 5470 1 none 
SVB046 23 529 529 <50 1 none 
SVB047 20 325 6871 <50 0 Genital warts 
SVB048 47 570 348 <50 1 Gonorrhoea 
SVB049 30 423 85711 7915 1 none 
Figure 16: The viral loads from the 44 study participants (A). Blood viral loads were weakly associated with the semen viral 
loads (Adjusted R2 = 0.28, p < 0.0005). In addition, viral load in blood was generally only detectable when the viral loads in 
semen were above 10,000 copies/sample with three donors having detectable viral loads in semen but undetectable or low 
in blood (A). Eleven participants who had sufficient viral load in semen were selected for deep sequencing (B). 
2.3.17 Relationship between blood and semen viral loads and sexually transmitted infections (STIs) 
There was no difference in viral loads between semen and blood for participants who 
recorded to have a concomitant or recent sexually transmitted infection (STI < 1 yr) or had an 
STI treated more than a year before (STI > 1 yr) (Figure 17). The CD4+ T cell count for the 
subjects with concomitant or recent STI did not differ from those without a concomitant STI 
as well (Mann-Whitney test p = 0.6435).  
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Figure 17: Relationship between viral loads in blood and sexually transmitted infections (STIs). 
2.3.18 Deep sequencing output and selection of sequences for compartmentalization evaluation 
A total of 22352 PID-consensus sequences were obtained after processing and clean-up of 
the sequences (median = 1130 (IQR = 481-1257 per compartment and donor) (Table 3). There 
were more PID-consensus sequences from blood than those from semen (median blood = 
1259 (IQR 1130 – 1699 sequences), median semen = 448, (IQR 206 – 1039 sequences, p = 
0.004). Consequently there were more unique variants in blood than in semen (median blood 
= 319 (IQR 259 – 599 sequences) vs median semen = 127 (IQR 63 – 183 sequences) (Table 3). 
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Table 3: Summary table with the PID-consensus sequences obtained after sequencing and sequence processing. The table 
also indicates the number of unique sequences obtained from each compartment as well as the sequences used to analyse 
compartmentalization. 
SampleID PID-consensus sequences
Number used for 
compartmentalization 
analysis
Unique 
sequences
SVB008_BP 1643 448 848
SVB008_SP 448 448 160
SVB012_BP 1139 81 286
SVB012_SP 81 81 26
SVB021_BP 1645 165 667
SVB021_SP 165 165 45
SVB025_BP 1753 246 164
SVB025_SP 246 246 52
SVB026_BP 2209 394 919
SVB026_SP 394 394 96
SVB029_BP 580 580 256
SVB029_SP 892 580 255
SVB030_BP 1259 1201 378
SVB030_SP 1201 1201 247
SVB039_BP 2234 1193 351
SVB039_SP 1193 1193 191
SVB041_BP 1121 912 267
SVB041_SP 912 912 140
SVB043_BP 707 707 185
SVB043_SP 1165 707 113
SVB049_BP 1251 114 258
SVB049_SP 114 114 19
Total 22352 12082 5923
Median (IQR) 1130 (481 – 1257) 448 (185 – 861) 219 (133 – 302)
Median blood 
(IQR) 1259 (1130 – 1699) 319 (259 – 599)
Median Semen 
(IQR) 448 (206 - 1039) 127 (63 – 183)
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2.3.19 Compartmentalization was found in all the study subjects 
Compartmentalization analysis was done using three statistical techniques with same number 
of PID-consensus sequences from each compartment (average = 448 sequences). 
Compartmentalization was said to occur when all the three standard tests reached 
significance ( p < 0.05). Compartmentalization was observed in all the 11 study participants 
(Figure 18). However, the severity of the compartmentalization varied among the 11 donors. 
Donor SVB043 had the most severe blood and genital tract viral compartmentalization while 
SVB041 had the least, as measured by Wright’s FST and Snn (Figure 18 A,B). There was no 
apparent association between the severity of compartmentalisation and either viral load or 
CD4+ T cell count (Figure 18 D). 
Figure 18: Compartmentalization of viral populations between blood and the genital compartment was observed in all the 
study participants using three statistical techniques; Wright’s FST (A), Nearest neighbour statistic (Snn) (B) and Slatkin 
Maddison test (SMT) (C). The extent of compartmentalization varied among the donor. Figure C also shows the number of 
inferred migration events from blood to semen and vice versa. There were more inferred migration events from blood to 
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semen than from semen to blood (Mann-Whitney p = 0.0098). There was no relationship between extent of viral 
compartmentalization between blood and the male genital tract with the viral loads or CD4+ T cell counts. 
To investigate whether sample bias could be the cause of the observed compartmentalization 
in all the 11 donors, tip-label randomization analysis was performed [572, 573]. This was done 
using a Python library script that shuffled the sequences names 100 times and then randomly 
reallocated them to two groups in the same proportion as there were blood vs semen 
sequences in that sequence set. The resulting alignment was then used to test 
compartmentalization using the three statistical tests. This test is intended to reveal sampling 
bias in the structure of the overall sequence set or its tree that might erroneously score as 
compartmentalisation. None of the tip swapped sequence sets of any of the donors achieved 
compartmentalization (i.e. no significant p values in all the three tests) (Figure 19). This shows 
that sampling bias was highly unlikely to explain the compartmentalization signal that was 
observed among the donors studied. 
Figure 19: Tip-label randomization test. Swapping the tip label designations to investigate if sampling bias was responsible 
for the observed viral compartmentalization in all donors. None of the donors achieved compartmentalization. Overall this 
shows that sampling bias was not the cause of the compartmentalization that was observed among these donors. 
We noticed that Slatkin Maddison (SM) method was particularly sensitive to the number of 
sequences analyzed. To control potential bias due to the number of sequences analysed, a 
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SVB049 0.009 0.348 0.502 0.456 16 1
SVB021 0.007 0.319 0.524 0.116 18 0.149
SVB026 0.002 0.815 0.497 0.569 40 0.231
SVB012 0.026 0.025 0.492 0.643 13 1
SVB025 0.022 0.002 0.526 0.014 21 1
SVB030 0.001 0.391 0.494 0.872 124 1
SVB029 0.001 0.657 0.512 0.091 73 1
SVB039 0.001 0.355 0.499 0.6 131 0.228
SVB041 0.001 0.218 0.514 0.004 90 0.22
A
DC
B
95 
single compartment with the highest number of sequences was tested for statistical 
compartmentalization using the SM method. First, sequences from the largest compartment 
were split randomly into two sets. One hundred of such subsamples were done and each time 
compartmentalization was assessed using SM method. Since the sequences comes from the 
same compartment, theoretically, compartmentalization is not supposed to be observed. 
Therefore, the rate of false positive was determined from the 100 subsamples. None of the 
100 subsamples showed compartmentalization for all the 11 donors Table 4. 
Table 4: Number of migration events and p-values from Slatkin-Method test of compartmentalization using 100 subsamples 
from the same compartment 
subsample
migration 
count p-value
migration 
count p-value
migration 
count p-value
migration 
count p-value
migration 
count p-value
migration 
count p-value
migration 
count p-value
migration 
count p-value
migration 
count p-value
migration 
count p-value
migration 
count p-value
1 711 1 517 1 519 1 837 0.998001998001998 977 1 398 1 572 1 1035 1 510 1 557 0.998001998001998 579 1
2 708 1 509 0.997002997002997 510 1 835 0.993006993006993 978 1 390 1 562 1 1045 1 522 1 557 1 576 1
3 721 1 519 1 503 1 837 1 968 1 400 1 561 1 1051 1 522 1 543 0.8771228771228772 586 1
4 701 1 517 0.999000999000999 510 1 840 0.999000999000999 961 1 395 1 561 1 1044 1 509 1 561 1 578 1
5 706 1 521 1 513 1 843 1 965 1 389 0.994005994005994 549 0.975024975024975 1042 1 521 1 547 0.8001998001998002 591 1
6 716 1 524 1 501 1 843 1 970 1 391 0.995004995004995 560 1 1053 1 509 0.999000999000999 546 0.8651348651348651 571 0.995004995004995
7 699 1 515 0.999000999000999 520 1 840 1 976 1 393 1 549 0.995004995004995 1058 1 515 1 557 0.993006993006993 572 0.995004995004995
8 711 1 528 1 513 1 837 1 964 1 393 1 560 1 1025 0.938061938061938 510 0.995004995004995 544 0.9530469530469531 582 1
9 706 1 526 1 513 1 825 0.965034965034965 970 1 396 0.999000999000999 561 1 1045 0.999000999000999 517 1 553 0.997002997002997 580 1
10 700 1 518 1 512 1 846 1 973 1 383 0.98001998001998 572 1 1058 1 518 1 558 0.994005994005994 576 1
11 716 1 516 1 513 1 835 0.998001998001998 971 1 402 1 576 1 1028 0.988011988011988 519 1 538 0.7462537462537463 570 0.999000999000999
12 705 1 524 1 509 1 834 0.997002997002997 970 1 396 1 565 1 1047 1 513 1 553 0.996003996003996 578 0.999000999000999
13 710 1 517 0.999000999000999 508 1 842 1 974 1 401 1 578 1 1030 0.994005994005994 516 0.998001998001998 554 0.998001998001998 575 0.998001998001998
14 719 1 519 0.999000999000999 519 1 840 1 969 1 394 1 572 1 1051 1 508 0.991008991008991 552 0.975024975024975 567 0.991008991008991
15 712 1 514 1 511 1 837 1 960 1 402 1 567 1 1048 1 516 1 551 0.985014985014985 576 1
16 715 1 519 1 515 1 843 1 960 1 400 1 563 1 1030 0.975024975024975 515 1 544 0.7982017982017982 585 1
17 700 1 523 1 505 0.999000999000999 833 0.997002997002997 969 1 396 1 569 1 1036 0.999000999000999 518 1 552 0.978021978021978 564 0.981018981018981
18 709 1 506 0.984015984015984 509 1 834 0.995004995004995 952 1 403 1 568 1 1043 1 498 0.958041958041958 553 0.991008991008991 569 0.996003996003996
19 692 1 517 1 493 0.997002997002997 813 0.4585414585414586 959 1 405 1 559 1 1059 1 517 1 558 0.999000999000999 574 0.997002997002997
20 706 1 511 0.995004995004995 514 1 828 0.975024975024975 951 1 405 1 569 1 1050 1 517 1 564 1 579 1
21 714 1 500 0.974025974025974 502 0.999000999000999 846 1 977 1 397 1 570 1 1061 1 517 1 553 0.9920079920079921 584 1
22 714 1 517 1 520 1 836 0.999000999000999 960 1 400 1 564 1 1058 1 517 1 555 0.993006993006993 573 1
23 715 1 514 1 499 0.996003996003996 833 0.999000999000999 974 1 404 1 559 0.999000999000999 1048 1 518 1 537 0.4545454545454545 565 0.999000999000999
24 714 1 521 1 494 0.9920079920079921 836 0.998001998001998 961 1 389 1 572 1 1046 1 520 1 544 0.8951048951048951 573 0.999000999000999
25 716 1 502 0.968031968031968 511 1 848 1 958 1 398 1 557 0.999000999000999 1028 0.987012987012987 508 0.997002997002997 558 0.999000999000999 580 1
26 707 1 518 0.997002997002997 510 1 830 0.987012987012987 971 1 395 1 560 0.999000999000999 1039 0.996003996003996 516 1 547 0.984015984015984 578 1
27 718 1 502 0.988011988011988 497 0.998001998001998 830 0.974025974025974 954 1 395 0.999000999000999 575 1 1043 1 518 1 553 0.986013986013986 555 0.8031968031968032
28 715 1 518 1 516 1 823 0.8801198801198801 967 1 393 0.999000999000999 564 1 1047 1 513 1 555 0.998001998001998 572 1
29 720 1 512 0.999000999000999 488 0.962037962037962 837 1 956 1 397 0.998001998001998 560 0.999000999000999 1037 0.9820179820179821 505 0.985014985014985 548 0.967032967032967 569 0.991008991008991
30 702 1 510 0.986013986013986 508 1 836 0.999000999000999 971 1 395 1 567 1 1053 1 516 1 561 1 572 0.999000999000999
31 707 1 522 1 506 1 836 0.999000999000999 949 1 390 0.999000999000999 558 1 1051 1 517 1 559 1 585 1
32 709 1 513 0.997002997002997 512 1 820 0.7342657342657343 972 1 397 1 575 1 1050 1 508 0.995004995004995 556 0.999000999000999 575 1
33 695 1 514 0.999000999000999 509 1 833 0.999000999000999 968 1 400 1 556 1 1054 1 519 1 558 0.999000999000999 564 0.9920079920079921
34 710 1 519 1 520 1 843 1 968 1 396 1 569 1 1046 1 505 0.985014985014985 554 0.998001998001998 579 1
35 698 1 510 0.998001998001998 506 1 831 0.989010989010989 975 1 392 0.997002997002997 577 1 1044 0.999000999000999 507 0.998001998001998 545 0.9400599400599401 583 1
36 712 1 506 0.984015984015984 506 1 825 0.9140859140859141 983 1 393 1 566 1 1037 0.999000999000999 518 0.999000999000999 548 0.8851148851148851 574 0.995004995004995
37 708 1 524 1 512 0.999000999000999 836 0.999000999000999 963 1 408 1 558 1 1059 1 520 1 540 0.7482517482517482 579 1
38 712 1 518 1 510 1 838 0.997002997002997 963 1 396 1 566 1 1058 1 512 0.999000999000999 552 0.995004995004995 575 0.998001998001998
39 710 1 514 1 507 1 843 1 970 1 400 1 568 1 1046 1 518 1 548 0.9210789210789211 589 1
40 721 1 522 1 509 1 830 0.989010989010989 973 1 392 0.999000999000999 573 1 1054 1 509 1 541 0.8491508491508492 579 1
41 725 1 520 1 520 1 833 1 968 1 394 0.999000999000999 569 1 1047 1 519 1 548 0.9590409590409591 577 1
42 718 1 497 0.955044955044955 513 1 832 0.994005994005994 965 1 383 0.994005994005994 572 1 1041 0.999000999000999 521 1 546 0.8761238761238761 571 1
43 725 1 520 1 501 0.999000999000999 832 0.994005994005994 968 1 408 1 574 1 1051 1 510 0.991008991008991 562 1 570 0.988011988011988
44 713 1 520 1 501 1 838 0.999000999000999 958 1 397 1 561 0.999000999000999 1047 1 509 0.999000999000999 554 0.99000999000999 582 1
45 719 1 515 1 500 0.997002997002997 825 0.8751248751248751 968 1 391 1 568 1 1052 1 513 0.999000999000999 545 0.8381618381618382 567 0.9920079920079921
46 717 1 513 0.996003996003996 502 1 841 1 968 1 399 1 554 0.999000999000999 1039 1 511 1 543 0.952047952047952 572 1
47 697 1 518 0.999000999000999 505 1 822 0.9230769230769231 965 1 399 1 553 0.996003996003996 1045 1 487 0.7422577422577422 563 0.999000999000999 572 0.998001998001998
48 712 1 518 1 508 1 828 0.9430569430569431 969 1 400 0.998001998001998 565 1 1040 0.998001998001998 516 1 557 0.999000999000999 569 0.997002997002997
49 708 1 524 1 494 0.987012987012987 837 0.997002997002997 972 1 404 1 559 1 1046 1 521 1 547 0.8231768231768232 583 1
50 704 1 518 1 505 1 833 0.999000999000999 964 1 399 1 567 1 1041 1 521 1 561 0.999000999000999 578 1
51 709 1 526 1 518 1 846 1 982 1 403 1 563 0.999000999000999 1047 1 524 1 547 0.935064935064935 578 1
52 703 1 505 0.993006993006993 507 0.998001998001998 825 0.935064935064935 975 1 395 0.999000999000999 564 1 1045 1 517 1 548 0.9180819180819181 570 0.997002997002997
53 712 1 508 1 508 0.999000999000999 838 1 969 1 401 1 548 0.995004995004995 1060 1 519 1 549 0.9430569430569431 568 0.998001998001998
54 707 1 525 1 509 1 833 0.99000999000999 976 1 398 1 582 1 1045 1 511 0.999000999000999 545 0.8491508491508492 581 1
55 706 1 521 1 515 1 837 1 957 1 387 0.999000999000999 568 1 1063 1 519 1 547 0.951048951048951 579 1
56 705 1 525 1 506 1 843 1 953 1 399 1 556 0.999000999000999 1038 1 516 1 551 0.973026973026973 554 0.8171828171828172
57 722 1 514 1 518 1 841 1 966 1 395 0.999000999000999 561 1 1049 1 511 1 551 0.9760239760239761 571 1
58 728 1 521 1 493 1 838 1 966 1 389 0.993006993006993 573 1 1026 0.9560439560439561 522 1 557 0.997002997002997 575 0.998001998001998
59 707 1 510 0.999000999000999 517 1 829 0.996003996003996 972 1 398 1 562 1 1049 1 512 0.997002997002997 562 1 579 1
60 711 1 510 0.996003996003996 504 1 837 1 958 1 382 0.995004995004995 570 1 1020 0.8451548451548452 519 1 558 0.999000999000999 564 0.99000999000999
61 711 1 522 1 495 0.999000999000999 838 1 975 1 395 1 569 1 1036 0.994005994005994 519 1 538 0.6283716283716284 573 0.999000999000999
62 712 1 511 0.997002997002997 515 1 846 1 965 1 389 0.991008991008991 552 0.988011988011988 1058 1 521 1 559 1 582 1
63 713 1 515 0.998001998001998 507 1 844 1 954 1 405 1 559 0.998001998001998 1046 1 513 0.994005994005994 552 0.958041958041958 579 1
64 694 1 514 0.999000999000999 511 1 818 0.7702297702297702 968 1 384 0.994005994005994 559 1 1043 1 514 1 544 0.8061938061938062 585 1
65 700 1 522 1 512 1 841 0.999000999000999 956 1 389 0.999000999000999 563 1 1038 0.998001998001998 512 0.999000999000999 553 0.9760239760239761 567 0.984015984015984
66 722 1 514 0.997002997002997 510 1 833 0.981018981018981 973 1 393 1 572 1 1044 1 517 1 555 1 572 0.996003996003996
67 704 1 532 1 500 0.998001998001998 836 0.999000999000999 981 1 399 1 571 1 1045 1 491 0.8211788211788211 558 1 578 1
68 699 1 509 1 510 1 827 0.9500499500499501 985 1 400 1 555 0.997002997002997 1010 0.8861138861138861 522 0.999000999000999 553 0.999000999000999 575 0.998001998001998
69 712 1 517 0.999000999000999 504 1 843 1 960 1 392 1 550 0.998001998001998 1036 1 505 0.999000999000999 546 0.929070929070929 577 1
70 712 1 523 1 501 0.998001998001998 833 1 958 1 401 1 554 0.998001998001998 1037 0.999000999000999 510 0.998001998001998 550 0.961038961038961 576 0.999000999000999
71 705 1 515 1 513 1 844 1 983 1 405 1 552 0.998001998001998 1057 1 502 0.9600399600399601 559 0.999000999000999 579 1
72 697 1 512 1 510 1 813 0.7012987012987013 969 1 396 1 555 1 1039 0.999000999000999 513 1 546 0.957042957042957 582 1
73 718 1 514 1 511 1 823 0.919080919080919 968 1 391 1 556 1 1060 1 510 0.998001998001998 557 0.993006993006993 582 1
74 723 1 511 0.998001998001998 520 1 828 0.98001998001998 974 1 402 1 562 1 1047 0.999000999000999 498 0.955044955044955 557 0.996003996003996 590 1
75 716 1 522 1 516 1 827 0.9400599400599401 970 1 388 1 578 1 1050 0.999000999000999 512 0.997002997002997 553 0.985014985014985 584 1
76 717 1 517 0.998001998001998 512 1 840 1 974 1 404 1 569 1 1035 0.999000999000999 526 1 552 0.991008991008991 576 1
77 714 1 511 0.999000999000999 504 1 844 1 957 1 392 1 549 0.996003996003996 1057 1 508 0.997002997002997 562 1 577 1
78 720 1 522 1 513 1 823 0.939060939060939 941 1 397 0.999000999000999 566 1 1018 0.948051948051948 522 1 552 0.9590409590409591 582 1
79 708 1 504 0.919080919080919 510 1 833 0.9920079920079921 978 1 395 1 560 1 1053 1 500 0.9760239760239761 557 0.998001998001998 572 0.997002997002997
80 712 1 507 0.9920079920079921 502 1 822 0.951048951048951 965 1 398 1 572 1 1051 1 517 1 552 0.996003996003996 565 0.975024975024975
81 717 1 517 0.999000999000999 498 0.998001998001998 817 0.6073926073926074 965 1 394 1 561 1 1060 1 515 1 547 0.974025974025974 577 1
82 712 1 507 0.994005994005994 502 0.999000999000999 832 0.991008991008991 976 1 398 1 560 0.999000999000999 1053 1 506 0.989010989010989 562 1 572 1
83 687 1 511 0.996003996003996 505 1 837 1 979 1 394 1 557 1 1056 1 518 0.999000999000999 545 0.936063936063936 579 1
84 720 1 510 0.997002997002997 512 1 836 1 967 1 386 0.996003996003996 556 1 1039 1 507 0.999000999000999 563 1 580 1
85 693 1 502 0.994005994005994 512 1 829 0.9790209790209791 949 1 394 1 546 0.999000999000999 1061 1 510 0.999000999000999 538 0.4265734265734266 557 0.8851148851148851
86 725 1 511 0.994005994005994 498 0.9690309690309691 835 1 969 1 390 0.995004995004995 563 1 1049 1 512 1 553 0.987012987012987 581 1
87 706 1 528 1 519 1 827 0.975024975024975 966 1 398 1 575 1 1062 1 520 1 553 0.9820179820179821 579 1
88 726 1 520 1 512 1 834 0.993006993006993 973 1 393 0.998001998001998 565 1 1063 1 502 0.993006993006993 553 0.9920079920079921 571 1
89 729 1 518 1 489 0.995004995004995 837 1 948 1 400 1 562 1 1049 1 504 0.983016983016983 545 0.974025974025974 576 1
90 713 1 511 1 520 1 830 0.972027972027972 976 1 396 1 567 1 1053 1 514 1 555 0.996003996003996 565 1
91 702 1 519 0.999000999000999 507 1 842 1 961 1 396 1 565 0.999000999000999 1060 1 516 1 554 0.996003996003996 562 0.994005994005994
92 701 1 513 1 511 1 829 0.973026973026973 965 1 390 0.998001998001998 571 1 1057 1 515 0.999000999000999 557 0.997002997002997 584 1
93 718 1 522 1 512 1 833 0.997002997002997 986 1 400 1 556 1 1037 0.993006993006993 527 1 544 0.7242757242757243 580 0.999000999000999
94 707 1 512 0.999000999000999 504 0.999000999000999 840 1 966 1 393 0.998001998001998 557 0.997002997002997 1046 1 513 0.999000999000999 557 0.999000999000999 564 0.972027972027972
95 688 1 530 1 500 1 824 0.8411588411588412 971 1 399 1 563 1 1059 1 508 1 553 0.988011988011988 579 1
96 697 1 518 1 507 1 834 0.994005994005994 973 1 399 1 555 0.999000999000999 1059 1 507 0.995004995004995 552 0.9760239760239761 579 1
97 702 1 509 0.996003996003996 508 1 821 0.7282717282717283 969 1 399 1 572 1 1049 1 502 0.9760239760239761 549 0.983016983016983 555 0.7762237762237763
98 717 1 517 1 505 0.997002997002997 821 0.8451548451548452 957 1 392 0.998001998001998 559 0.999000999000999 1055 1 508 1 556 0.999000999000999 568 0.991008991008991
99 715 1 521 1 514 1 836 0.999000999000999 976 1 397 1 556 0.999000999000999 1045 0.999000999000999 523 1 547 0.8991008991008991 578 1
100 707 1 519 1 505 1 837 1 978 1 405 1 578 1 1028 0.962037962037962 508 0.99000999000999 545 0.8611388611388612 579 1
Percentage 
false 
postive 0 0 0 0 0 0 0 0 0 0 0
SVB026SVB025SVB021SVB012SVB008 SVB049SVB043SVB041SVB039SVB030SVB029
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2.3.20 Some clusters were heavily compartmentalized even in minimally compartmentalized 
donors 
Some previous studies had relied on visual inspection of phylogenetic trees to evaluate viral 
compartmentalization between blood and other anatomical sites [377, 380, 394, 529, 541]. 
However mere inspection of trees may not be entirely sensitive or accurate in detecting 
compartmentalization; especially when only some of the variants in anatomical tissues are 
compartmentalized [191, 277]; and when a very large number of sequences are analysed. In 
this report, phylogenetic trees revealed large clusters within blood  and semen that had 
identical sequences within them (Figure 20). Due to the huge amout of high thoughput data, 
other tree annotations were not possible. But the clustering of blood and semen sequences 
is clearly visible with SVB043 showing severe phylogenetic viral compartmentalization 
between blood and semen sequences. 
Figure 20: phylogenetic trees showing viral compartmentalization between  blood and the male genital compartment. 
clusters of either purely blood and semen are visible from the trees. Red represents PID-consensus sequences from blood while 
blue represent those from semen. 
To further understand the nature of blood and semen sequences within these clusters, the 
distribution of blood and semen sequences within the clusters of the phylogenetic trees  was 
analysed by counting the proportion of blood and semen sequences within them. To have a 
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meaningful result, only clusters carrying more than 10 sequences  were considered and 
bubble plots were drawn (Figure 21). Donors SVB021 and SVB026 did not have such clusters, 
so are not shown. Analysis revealed that some viral variants do not traffic well even among 
the minimally compartmentalized donors (Figure 21). For donor SVB043, who exhibited 
severe compartmentalization, the clusters were made of purely or almost purely blood or 
semen  sequences. In donors with lesser extent of compartmentalization, the majority of the 
clusters contained roughly equal number of blood and semen sequences. However, there 
were some clusters that had only blood or semen sequences (Figure 21). This suggest that 
some variants do not traffic well between the compartments and rather remain in the 
compartment of their production. These localized variants likely contributed to the 
compartmentalization signal observed within the minimally compartmentalized donors. 
Figure 21: Analysis of clusters with identical sequences from the phylogenetic trees. The analysis revealed that some variants 
do not traffic well between compartments. This was so even in donors showing lesser extent of compartmentalization where 
some clusters contained either purely blood or semen sequences. The y-axis on the graph represent the proportion of either 
blood or semen within the terminal nodes of the combined tree with blood and semen sequences from each the donors on 
the x-axis. Only donors whose tip nodes had clusters of 10 or more sequences were picked for this analysis (Donors SVB021 
and SVB026 did not have such clusters) 
To address the contribution of clonal amplification to compartmenatalization, sequences 
from all the donors were analyzed for viral compartmentalization in three ways; (1) using 
equal number of PID-consensus sequences, (2) collapsing the PID-consensus sequences into 
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haplotypes at 100% similarity and (3) taking equal number of haplotypes. 
Compartmentalization was observed in all the three situations for donor SVB043 who had the 
highest extent of clonal amplification Table 5. This observation was also consistent for donors 
SVB008 and not in others Table 5.  
Table 5: Role of clonal amplification in determining viral compartmentalization between blood and the male genital tract. 
primerID sequences Haplotypes 
equal number 
haplotypes 
SampleID FST Snn SMT FST Snn FST Snn 
SVB043 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
SVB008 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
SVB049 <0.001 <0.001 <0.001 0,429 0,999 0,245 0,554 
SVB026 <0.001 <0.001 <0.001 0,864 0,994 <0.001 <0.001 
SVB021 <0.001 <0.001 <0.001 0,995 0,99 0,005 <0.001 
SVB012 0,012 <0.001 <0.001 0,999 0,999 0,435 0,737 
SVB030 <0.001 <0.001 <0.001 0,108 0,999 <0.001 0,994 
SVB025 <0.001 <0.001 <0.001 0,021 0,159 0,339 0,531 
SVB029 <0.001 <0.001 <0.001 0,027 0,994 0,014 0,997 
SVB039 <0.001 <0.001 <0.001 0,747 0,998 0,169 0,979 
SVB041 <0.001 <0.001 <0.001 0,195 0,999 0,426 0,999 
2.3.21 Model of lower depth of sampling from Illumina Miseq data 
Previous studies reported viral compartmentalization between blood and the male genital 
tract in only about half of the donors [289, 381, 490, 529, 574]. This is a sharp contrast to the 
findings in this thesis where compartmentalization was found in every donor studied. These 
previous studies relied upon single genome analysis (SGA), for which the cost and labour-
intensiveness nature of the technique limit the depth of sampling to a few sequences. It is 
possible that the greater depth of sequencing was responsible for the apparent discrepancy 
between the proportion of study subjects with compartmentalization found in this thesis vs 
those found in previous studies. Alternatively, it is possible that the donors analysed were 
fundamentally different from the majority of donors previously analysed for blood/male 
genital tract compartmentalization in previous studies.  
To address this, a small number of sequences were randomly sampled from each 
compartment to simulate single genome analysis (SGA) and predict if compartmentalization 
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would have been detected if only 35 sequences from each compartment were sampled. This 
number corresponds approximately to the maximum number of amplicons per compartment 
used in previous studies (Table 8). This random set of sequences was resampled from each 
compartment 1000 times and compartmentalization analysed using Wright’s FST after each 
time. The proportion of iterations that achieved compartmentalization was noted (Table 6). 
This proportion should approximate the likelihood that compartmentalization would have 
been observed if SGA was used instead of deep sequencing.  
Only 5 out of the 11 donors exhibited a >50% likelihood that viral compartmentalization 
between blood and semen would have been detected had 35 sequences from each 
compartment  used (Table 6). This proportion agrees with previous studies. Thus, there is no 
evidence that supports the idea that the donors studied here were fundamentally different 
from those studied by other researchers. The high depth of sequencing used in this thesis 
therefore appears sufficient to explain why compartmentalization was observed in all the 11 
donors.  
Table 6: Simulation of lower depth of sequencing from Illumina Miseq data. A fraction of  50% and above was considered to 
have a high likelihood of being scored compartmentalized when using a random set of 35 sequences. 
SampleID Compartmentalized iterations (%)
SVB043 99.1
SVB008 99.5
SVB049 82.3
SVB021 50.0
SVB026 72.6
SVB012 15.8
SVB025 6.9
SVB030 27.1
SVB029 17.6
SVB039 8.1
SVB041 0.1
100 
2.3.22 Highly compartmentalized donors had viral populations with higher diversity in blood than 
in semen 
The median pairwise genetic distances varied between viral populations in blood and semen, 
but overall there was no significant differences between blood vs genital compartment 
sequences (p = 0.125) (Figure 22). In contrast, donors exhibiting the highest extent of 
compartmentalization, SVB043, SVB008 and SVB021 had high median pairwise genetic 
distances in blood compared to semen (Figure 22).  
Figure 22: Comparison of median pairwise genetic distances between variants from blood vs those from the male genital 
compartment. Donors with highest extent of compartmentalization, SVB043, SVB008 and SVB021 had blood variants with 
overall higher median pairwise genetic distances compared to their semen counterparts. 
2.3.23 Evidence suggesting purifying or diversifying selection 
Because selective pressures experienced by the virus in different anatomical sites may differ, 
codon sites under purifying and diversifying selection between blood and the genital 
compartment of each donor were evaluated using a maximum likelihood approach; Fixed-
Effect Likelihood (FEL) [575]. Though only a small section of the HIV-1 envelope (414bp, 
coding for 138 amino acids) was analysed, sites under selective pressures varied between the 
individuals (Table 7). There were more codon sites in blood than semen under both positive 
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(p=0.0195) and negative (p=0.002) selection suggesting higher selective pressures in blood as 
compared to semen by paired Wilcoxon test.  
Table 7: Sites under positive and negative selective pressures in blood and seminal compartments. There were significantly 
mores sites under positive (p=0.0195) and negative (p=0.002) selective pressures in the blood compartment than in the semen 
compartment. Sites under selective pressures were assessed using Fixed Effects Likelihood (FEL) as implemented in HYPHY. 
2.3.24 Movement of virus between blood and semen 
Previous studies showed that there were more virus movements from blood to the genital 
compartment [303, 530]. This observation was confirmed in this thesis using Slatkin-
Maddison test [564], where more inferred migration events were calculated from blood to 
semen than from semen to blood (Figure 18 C).  To support the SM test method, Bayesian 
phylogenetics were performed and the Root State Posterior Probabilitities of the resulting 
trees with blood and semen sequences were determined. High RSSP indicates the origin of a 
particular sequence was originally found in that compartment. Donors SVB043, SVB021 and 
SVB021 indicated the ancestral state of semen sequences were in blood Figure 23. 
SampleID
Sites under Negative / purifying 
selection
Sites under Positive / diversifying 
selection
Blood plasma Seminal plasma Blood plasma Seminal plasma
SVB008 51 27 13 6
SVB012 36 4 1 0
SVB021 53 16 14 0
SVB025 24 16 1 0
SVB026 70 25 3 0
SVB029 30 20 3 5
SVB030 44 29 3 0
SVB039 34 16 9 4
SVB041 36 22 0 0
SVB043 36 17 8 3
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Figure 23: Root State Posterior Probabilities (RSPP) for movement of viruses from blood to semen. Donors SVB043, SVB026, 
SVB021 had viral sequences the moved from blood into the genital tract. Donor SVB029 and donor SVB008 tip swap trees did 
not converge and hence the data is not available. 
2.3.25 Clonal amplification was found in all of the study participants 
Clonal amplification is the expansion of low diversity variants resulting in high proportional 
representation of these variants. These clonally amplified variants are localized and can 
substantially contribute to compartmentalization. Clonal amplification was evident in all the 
study participants and was a characteristic of both blood and semen populations. The clonally 
amplified variants were represented as bubbles in phylogenetic trees (Figure 24).  
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Figure 24: Clonal amplification was identified in both blood and the male genital compartment. The clonally amplified variants 
are represented here as bubbles, the size of the bubble being proportional to the number of sequences used to make that 
particular haplotype. Red bubbles represents variants from blood while green bubbles represent variants from semen. The 
trees are rooted by HIV-1 subtype C consensus of 2004 from Los Alamos. 
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2.4 Discussion 
In this thesis and for the first time, viral compartmentalization between blood and the male 
genital tract was studied in HIV-1 chronic infections using next generation sequencing. The 
use of primerID and high fidelity Taq polymerase allowed us to recover the sequences as close 
as possible to the way they appeared prior to the PCR amplifications. PrimerID technique has 
previously been used to study HIV-1 populations [532-537, 576]. The utilization of PrimerID 
not only helped to eliminate PCR-based artefacts, but in this study it gave two extra 
advantages. Firstly’ it allowed the use of individual PID-consensus sequences in analysis of 
compartmentalization as opposed to constructing haplotypes. Thus, the sequences were 
representative of the in vivo situation. Secondly, PID-consensus sequences allowed the study 
of clonal amplifications in more detail and with higher confidence.  
In evaluation of compartmentalization, three statistical techniques were used, two distance-
based methods, Wrights, measure of population subdivision (FST) [562, 563], and nearest 
neighbour statistic (Snn) [561] and one tree-based method Slatkin-Maddison Test (SMT) 
[564]. It is generally recommended that three techniques be used in evaluating 
compartmentalization [577]. Compartmentalization is said to exist when all the three 
techniques arrive at significant p values. When two techniques achieve significant p values, 
the viral populations are said to have partial compartmentalization and if only one or none 
achieve significant p values, the viral populations are said to be equilibrated. In this thesis, 
HIV-1 compartmentalization between blood and the male genital tract was found in all the 
study subjects. 
Previous studies working on compartmentalization of HIV-1 between blood and the male 
genital tract found compartmentalization in only about half of the study participants 
(summarized in Table 8). The results in this thesis, where viral compartmentalization between 
blood and semen was found in all the 11 subjects, are in sharp contrast to these earlier 
studies. The use of next generation sequencing in this thesis as opposed to techniques used 
in previous studies gave the advantage of increased depth of sequencing thereby explaining 
the discrepancy. Only one study had previously used next generation sequencing [530]. This 
particular study however worked on HIV-1 compartmentalization in blood and the male 
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genital compartment at acute phase of infection while participants involved in this thesis 
came from chronic infections. This study [530] found compartmentalization in 2 of the 6 study 
participants  at base line [530]. In addition, the study used 454 technology, which was among 
the first next generation technique. With 454, sequencing had to be preceded by a bulk PCR 
step which is known to alter the composition of viral populations through PCR recombination 
and amplification bias [550, 578, 579]. In this thesis, this is circumvented by using the 
PrimerID approach allowing use of viral sequences the way they existed in vivo.  
Table 8: Summary of the studies that have previously worked on compartmentalization of viral populations between blood 
and the male genital compartment. 
Other studies either used sequences derived from single genome amplification (SGAs) [289, 
381, 490, 529, 574], cloned from bulk PCR [377, 400, 401] or tracked sequence variation using 
Heteroduplex Tracking Assay (HTA) [292]. Each of these techniques have their own 
advantages and disadvantages. The main demerit of techniques that utilize SGAs data as far 
Article
Proportion of 
donors with 
compartmentaliza
tion, number (%)
Technique used
Mean number of 
amplicons per 
compartment
Region 
sequenced
Compartmentaliza
tion analysis 
Chaillon A. (2017) 7/14 time points(50) 454 22 haplotypes C2-V3 SMT, FST
Anderson J. A. 
(2010) 5/12 (42) SGA 27 env SMT
Chaillon A. (2014) 20/46 time points(43) SGA, cloned 29 C2-V3 SMT, Snn, FST
Diem K. (2008) 1/2 (50) SGA 13 C2-C5 SMT
Gupta Phalguni 
(2000) 3/5 (60) bulk, cloned 10 C2-V5 phylogeny
Butler DM (2010) 2/6 (33) SGA, cloned 20 C2-V3 FST
Pillai SK (2005) 6/12 (50) Database 27 C2-V3 SMT
Curran R. (2002) 7/10 (70) SGA 15 V1-V3 phylogeny
Boeras DI (2011) 1/1 (100) SGA 14 V1-V4 SMT, Snn
Paranjpe S. (2002) 3/3 (100) diluted, cloned 19 C2-V5 phylogeny, SMT, FST
Ghosn J. (2004) 1/3 (33) bulk 6 protease phylogeny
Brown RJ (2011) 3/4 (75) SGA 7 env phylogeny
Gianella S (2012) 7/14 (50) Bulk, cloned 25 C2-V3 SMT, FST
This thesis 11/11 (100) Illumina Miseq 549 V3 or C3-V5 SMT, FST,Snn
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as evaluation of compartmentalization is concerned, is limited sampling of the viral 
populations. This results from the high cost and the labour-intensiveness nature of the 
technique which limits the depth of sequencing to a few sequences. In addition, low 
prevelance sequences in SGAs get missed due to the small sequence sample.  Indeed, when 
a random set of 35 sequences was used in this thesis to mimic the result that would have 
been obtained if SGA was the technique of choice, only 5 out of the 11 had more than 50% 
likelihood of being reported to be compartmentalized. This identifies with what these 
previous studies found and underscores the importance of depth of sampling in studying HIV-
1 compartmentalization. In addition, this analysis shows no obvious fundamental 
discrepancies from the populations studied elsewhere for the purpose of blood vs male 
genital tract viral compartmentalization; since the results were identifiable. Heterodruplex 
tracking assays (HTA) lack the sequence information and cannot be compared easily to the 
study in this thesis. 
One potential limitation to our study is the choice of samples that had sufficient viral load in 
semen for deep sequencing (above 2500 copies). Coincidently, these also had high viral load 
in blood because the viral load in the two compartments were weakly associated [205]. 
However, two of the study participants (SVB012 and SVB026) who had the lowest viral loads 
in semen did not show obvious differences in compartmentalization of viral populations 
between blood and semen. Also on performing the tip swapping [572, 580], none of the 
donors including these two achieved compartmentalization (i.e. the three statistical tests 
achieving significant p values). This means that these two were not fundamentally different 
from the rest of the donors studied. 
Clonal amplification was observed in all of the study participants and in blood and in semen. 
Clonally amplified variants have a potential of being transmitted as evidenced in one study 
working on transmission of HIV-1 from infected mothers to infants [581]. This is possibly due 
to relative fitness of these variants in the anatomical sites where they achieve clonal 
amplification. Findings in this thesis of high clonal amplification in the male genital tract, are 
in line with the observations of Boeras et al , who showed that up to 86% of the genital tract 
variants were found in clusters of (near) identical sequences while the rest were intermingled 
with blood in the phylogenetic trees [490]. In addition, data in this thesis add to the work of 
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Anderson et al [381] who observed clonal amplification in semen in 8 out of the 12 study 
participants. However, unlike Anderson et al  where only 1 out of the 12 study subjects had 
clonal amplification in blood, all of the donors studied as part of this thesis showed clonal 
amplification in blood as well. This is possibly due to higher depth of sequencing afforded in 
this report. These clonally amplified variant could contribute to compartmentalization. 
Indeed, deconvoluting the phylogenetic trees and analysing the cluster composition at the 
terminal nodes, revealed that some clusters in minimally compartmentalized donors had 
purely blood or semen sequences. This suggest that  some viral quasispecies don’t move even 
in donors with little extent of compartmentalization and might contribute to 
compartmentalization signal. 
Another limitation of this study was the use of cross-sectional data; which limits the study of 
the movement of viruses between blood and semen and change in viral 
compartmentalization over time. This was hampered by the fact that the study subjects were 
introduced to antiretroviral therapy as soon as the first sample was collected. Nonetheless, 
using Slatkin-Maddison test, bidirectional movement of the virus between compartments was 
evident in all the study subjects. In addition, there were more inferred migration events from 
blood to semen than from semen to blood (Wilcoxon p = 0.0098) which is consistent with a 
previous studies that had used Bayesian-based Markov Jump Counts [303, 530]. These two 
studies also had previously confirmed that Inferred migration events from Slatkin-Maddison 
test correlated with Markov Jump Counts. 
Use of short reads (~400bp) is a limitation in interpretating phylogenetic data especially 
relating to clonaly amplification. The short read may have over estimated clonal amplification. 
It is difficult to know the contribution to viral diversity in the region outsided the 400bp that 
were sequenced. 
Unlike previous studies that suggest that presence of sexually transmitted infections 
increases the level of virus in semen [145, 251, 446, 447, 582], there was no relationship 
between sexually transmitted infections and semen or blood viral loads.  
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In summary, this is the first study to probe HIV-1 compartmentalization between the systemic 
circulation and the male genital tract in chronically infected individuals utilizing deep 
sequencing. In contrast to previous studies, we show compartmentalization was present in 
all individuals studied. In addition, deep sequencing revealed clonal amplification in blood in 
a higher proportion of donors than had previously been reported. Both apparent 
discrepancies are likely due to higher sensitivity to detect these phenomena using deep 
sequencing. The extent of compartmentalisation was not obviously related to CD4+ T cell 
count, viral load or history of sexually transmitted infections suggesting that it was 
independent of the overall state of immunodeficiency. This information furthers our 
understanding of how HIV-1 populations in the male genital tract are shaped prior to sexual 
transmission. 
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3 CHAPTER 3 
Genotypic and phenotypic 
characterization of HIV-1 variants 
compartmentalized in blood and the 
male genital compartment 
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3.1 Abstract 
Human Immunodeficiency Virus type 1 (HIV-1) transmission involves selection for particular 
genotypic and phenotypic characteristics whose understanding is critical for design of 
effective preventive interventions. Study of the characteristics of the virus establishing 
infection (Transmission /Founder virus) has produced mixed results. Majority of these studies 
had no information regarding the virus in the genital tract of the donors. Here we compared 
the variable loops characteristics and entry properties of HIV-1 envelope glycoproteins from 
blood and semen of three donors with compartmentalized viral populations in these two 
anatomical sites. The objective being to investigate whether there is change in function 
between HIV-1 populations in blood vs male genital tract. 
Full-length env sequences were amplified at limiting dilution of cDNA (single genome 
amplification) in order to avoid PCR-based recombination artefacts. The resulting sequences 
were examined for loop length and glycosylation differences. In addition, sensitivity of blood- 
and semen-derived envelopes in constructed psedoviruses was tested against CCR5 inhibitors 
Maraviroc and PSC-RANTES, CXCR4 inhibitor JM2897 and fusion inhibitor enfirvirtide (T-20). 
Differences in length and number of glycosylation sites were found between variants from 
blood and those from the genital tract: but the direction of the differences were inconsistent. 
Donor SVB043 (most severely compartmentalized) had semen variants that had longer and 
more glycosylated envelopes; while donor SVB008 (second most severely 
compartmentalized) had no difference in variable loop length, but semen variants were 
underglycosylated. The fourth variable loop (V4 loop) for donor SVB049 were longer and 
more glycosylated than those from donor SVB043 and SVB008. Differences in sensitivity to 
entry inhibitors between blood and semen variants were also observed and the direction of 
the differences varied as well. Semen variants for donor SVB043 were more insensitive to 
Maraviroc (CCR5 inhibitor) than the blood counter parts. The opposite was observed for 
donor SVB008 where the semen variants were more sensitive to inhibition by Maraviroc than 
the isolates from blood.  There was no difference in sensitivity to maraviroc between blood 
and semen variants for donor SVB049. Surprisingly, sensitivity of donor SVB043 variants to 
PSC-RANTES (another CCR5 inhibitor) did not correspond with the observation for Maraviroc. 
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These observations support that there are distinct blood and genital tract HIV-1 phenotypes, 
and that the selective milieu of the two compartments shapes HIV-1 populations differently. 
Thus, some of the features of the transmitted/founder (T/F) virus may already be selected in 
the transmitting donor before they are transmitted to the recipients. The differences 
between variants from blood and genital tract is important in understanding HIV-1 
transmission and in design of effective intervention strategies.  
3.2 Background 
The transmission of HIV-1 involves a genetic bottleneck irrespective of the mode of 
transmission [467] (reviewed in [508] and [468]). Some studies have suggested that the 
transmitted/founder (T/F) virus that establishes infection in the recipient is selected for 
leading to transmission of only one variant in 80% of heterosexual transmissions [456-458]. 
The biological determinants of the transmission bottleneck have not yet been fully 
determined. Most of the previous studies have characterized the nature of the T/F or acute 
vs chronic blood viruses [504, 506, 512, 583] as a source of information about the selective 
forces in play during transmission. Here we characterized the genetic and phenotypic features 
of the viruses compartmentalized in the male genital tract and compared these features to 
the virus found in the systemic circulation of the same donors. This information will dovetail 
the observations from previous studies that looked at the initially-infecting and/or acute 
viruses. Understanding these determinants will be important source of information for 
designing effective vaccine against HIV-1 and other interventions. 
The virus found in semen is phylogenetically distinct from that in blood due to tissue-specific 
characteristics and difference in immunologic and other selective pressures [205, 396, 409]. 
In addition, seminal viruses exist as cell-free or cell-associated which can either be produced 
locally or shipped from blood [381] and have been shown to sub-compartmentalize [380]. 
The unique selective milieu of the male genital tract shapes the virus differently than what 
happens in blood. Indeed, compartmentalized viral variants in the male genital tract have 
been observed to have a strong genetic signature at C2-V3 region with the most prominent 
signature at position 464 [409].  This therefore means that the features of the 
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transmitted/founder virus may begin much earlier in the donor during the transition to the 
recipient. Understanding these features of the potentially transmitted virus in the donor is 
important since this is the viral population that must be antagonized by a successful 
intervention strategy in the recipients.  
Previously, semen-derived variants were observed to have significant differences in the 
number of potential N-linked glycosylation sites (PNGS) at the C2-V3 region in subtype B-
infected subjects [409] compared to blood. The difference was not in any particular direction 
with 3/7 of the pairs having more PNGS in semen than plasma and 3/7 having the opposite, 
1/7 had no difference. This difference did not correspond well with observations in another 
study involving subtype B-infected individuals, where newly transmitted viruses were found 
to be underglycosylated in the V1-V4 region for only 1/6 of the transmitting pairs [525]. This 
however supports that there is likely to be local viral production, and that the HIV-1 
populations are shaped by the prevailing environment within its vicinity. In the context of 
subtype C infections, underglycosylation has been reported as a feature of T/F virus both in 
virus initiating infection (T/F) [459] or acute vs chronic viruses [506].  However, similar 
information regarding potential glycosylations or length of variable loops is not available for 
the HIV-1 populations found in the genital tract. In yet another study, the PNGS at position 
332 of the HIV-1 envelope was underrepresented in sequences of recently transmitted 
subtype C variants compared to variants existing one year post infection in the same donors 
[584]. This was not observed in subtype B viruses [509] suggesting a possibility that the 
selective conditions in the genital tract may impact the virus in a subtype-specific manner. 
This leaves it unresolved whether the selection for changes observed in PNGS happens within 
the donor’s genital tract or during transmission into a new recipient.  
Several studies have shown that HIV-1 entry inhibitors are efficient in preventing acquisitions 
of HIV-1 when used as microbicides or administered orally [585-589]. These compounds 
antagonize the virus entry in the initial stages of the lifecycle; i.e. prevent viral gp120 from 
interacting with the CD4 receptors or CCR5/CXCR4 coreceptors or prevent fusion of the virus 
with the cell membrane of host cells. When these compounds are used as topical 
microbicides, the virus they are required to antagonize during sexual transmission is the one 
that comes from genital tract of the infected donor. Additionally, the activity level of these 
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inhibitors against genital tract and blood HIV-1 may allow us to draw conclusions about the 
changes in function of the HIV-1 Env and systematic changes in viral properties. 
This chapter of the thesis therefore characterizes and compares the utilization of entry 
inhibitors between the variants from blood versus those from the male genital tract using a 
pseudovirion-based TZM-bl assay for three of the most compartmentalized donors. Since the 
early infecting virus are R5-tropic, semen derived viruses would be expected to be more 
sensitive to CCR5 inhibitors compared to isolates from blood. In addition, genotypic features 
relating to variable loop characteristics were assessed from the single genome amplification 
of env sequences of the same participants. 
3.3 Methods 
3.3.1 Study participants 
Blood and semen samples were collected from 44 HIV-infected men attending a health facility 
at ANOVA Health’s Health4Men clinic at Woodstock or Green Point, Cape Town, South Africa 
as previously described, or who were invited to the joint study at ANOVA Health’s mobile 
clinic in Khayelitsha, South Africa (Chapter 2). All samples were collected at one of the ANOVA 
Health facilities when the clinic was closed for normal business. Of eleven subjects who were 
analysed for level of compartmentalization by deep sequencing in chapter 2, three subjects 
who had the highest extent of compartmentalization were selected for this part of the 
experiment i.e. SVB043, SVB008 and SVB049 (Table 10 and chapter 2 figure 3). 
3.3.2 RNA extraction and cDNA synthesis 
From each blood or semen sample, RNA was extracted from the equivalent of approximately 
10,000 copies based on the viral load of the sample, except for semen samples with low viral 
loads, in which case the entire sample was used. RNA was extracted using QIAamp Viral RNA 
Mini Kit (Qiagen). The extracted RNA was eluted in a final volume of 50µl. Extracted RNA was 
reverse transcribed into cDNA using the SuperScript First-Strand Synthesis System Kit 
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(Invitrogen) and following the recommendations from the manufacturer. Briefly, the reaction 
contained 1 x Reverse transcriptase (RT) buffer, 5mM DTT, 2U/µl RNaseout which is an RNase 
inhibitor, 0.5mM each of the deoxynucleotide triphosphate (dNTP), 0.25µM Oligo(dT)20 and 
10 U/µl of the SuperScript III RT enzyme. Reverse transcription was performed at two 
temperatures, first at 45oC for an hour followed by another hour at 50oC. The enzyme was 
then deactivated by heating at 70oC for 15 minutes before holding at 4oC. The RNA was 
digested from RNA-DNA hybrids using RNAaseH by incubating at 37oC for 20 minutes. the 
cDNA was either used immediately or stored at -20oC for later use. 
3.3.3 Single genome amplification (SGA) of the HIV-1 envelope gene 
The single genome amplification (SGA) technique was used to amplify single genomes from 
cDNA generated from blood and semen. This was done by serial diluting the cDNA templates 
and distributing the dilutions in a 96-well plate followed by first and second stages of the 
nested PCR. The dilution of cDNA that resulted in less than 30% positive wells from the total 
reactions after gel electrophoresis was targeted. Assuming a poison distribution of cDNA 
templates and no binding between templates, when 30% of wells are positive, the likelihood 
that the PCR product in any one positive well was amplified from only one amplified template 
is approximately 84% [456-458]. Use of a single template was confirmed to the extent 
possible by sequencing of the amplicons and checking for mixed bases from the 
chromatograms. Clones were obtained from several independent PCRs for each sample to 
minimize the sampling bias. The PCR amplifications were performed using the Platinum HIFI 
Taq (Invitrogen) to keep the likelihood of PCR mismatch errors as low as was practical. The 
PCR conditions in a 20µl reaction contained 1x HIFI Buffer, 2mM MgSO4, 0.2mM each of 
dNTPs, 0.2µM of each primer and 0.025U/µl of Platinum HIFI Taq. The first-round primers 
were, forward VIF-1 5’– GGGTTTATTACAGGGACAGCAGAG-3’ and reverse OFM19 5’– 
GCACTCAAGGCAAGCTTTATTGAGGCTTA-3’ representing HXB2 positions 4903-4923 and 9604-
9632 respectively. The second-round primers were, forward ENV A 5’– 
GGCTTAGGCATCTCCTATGGCAGGAAGAA-3’ and reverse ENV N 5’– 
CTGCCAATCAGGGAAGTAGCCTTGTGT-3’ representing HXB2 positions 5954-5982 and 9145-
9171 respectively. This generated an amplicon of approximately 3kb. The PCR cycling 
conditions for first round PCR involved initial denaturation at 94oC for 2 mins, followed by 35 
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cycles at 94oC for 15 s denaturation, 55oC for 30 s primer annealing step and extension at 68oC 
for 4 mins. This was followed by a final extension at 68oC for 10 min. Two microliters of first 
round PCR were then added to second round PCR reaction and the same cycling conditions 
were used only that a total of 45 cycles were run this time. All the PCR reagent preparations 
and making of the master mixes were done in the PCR clean room. In addition, one sample 
was processed at a time to prevent cross-sample contaminations. 
3.3.4 Cloning and generation of pseudovirus plasmids 
PCR was first performed from 2µl of first stage PCR products in a reaction volume of 50µl.  
The primers used were, forward ENVARx 5’-CACCGGCTTAGGCATCTCCTATAGCAGGAAGAA-3’ 
and reverse ENV N 5’– CTGCCAATCAGGGAAGTAGCCTTGTGT-3’ representing HXB2 positions 
5954-5982 and 9145-9171 respectively. The special primer ENVARx improves expression of 
HIV-1 subtype C pseudotyped clones in expression cell lines by introducing a stop codon 
between the rev-vpu and env open reading frames [590].  In addition, the ‘CACC’ tag [457] 
allows for the directional cloning of the amplicon relative to CMV promoter into 
pcDNA3.1D/V5.His.TOPO vector which comes with a CTGG overhang (Figure 25). The cycling 
conditions were like the ones applied for first stage second-round PCR as detailed previously. 
The PCR products were then purified using QIAquick PCR purification kit (Qiagen), cloned into 
pcDNA3.1D/V5.His.TOPO vector (Invitrogen), and transformed into TOP 10 competent 
bacteria (Invitrogen). Bacterial clones containing inserts were identified by finding a PCR 
product using T7 and BGH primers that were supplied together with the kit (Figure 25). A band 
of around 3kb was indicative of a successful cloning. The positive colonies were then grown 
in Luria Broth (LB) supplemented with 100mg/ml of ampicillin overnight at 32oC in a shaking 
incubator at 200 revolutions per minute (rpm). The plasmids were then harvested from 
bacterial cultures using QIAprep Spin Miniprep Kit (Qiagen). After quantification of the DNA 
using the NanoDrop 2000 spectrophotometer (Thermo Scientific), the plasmids were used 
fresh or stored for later use at -20oC.  
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Figure 25: Schematic representation showing the map of pcDNA3.1D/V5-His-TOPO cloning vector. Figure obtained from Tarr 
et all [591] 
Pseudoviruses were constructed using established methods [592]. Briefly, the env-cassette 
plasmids and a HIV-1 subtype B backbone deficient of the envelope (pSG3Denv) were mixed 
in a mass ratio of 1:2, and co-transfected into HEK293T (packaging cell line) (Figure 26) cells 
using X-tremeGENE (Roche Diagnostics). The plasmids carrying the envelopes of interest 
(blood and semen strains envelopes) provided the envelope spikes in trans for the new 
psedoviruses while the rest of the HIV-1 proteins were provided by the pSG3Denv genome 
(Figure 26). The later lacked a functional envelope gene due to a four base pair insertion in 
the env open reading frame. After 48 hours incubation at 37oC, 5% CO2, the pseudoviruses 
were harvested from the supernatants, filtered through 0.45µM syringe filters to remove 
aggregates, and stored in single-use aliquots. The titre of the pseudoviruses was determined 
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in a TZM-bl assay. Titration of the pseudoviruses that resulted in approximately 50,000 
relative light units (RLU) was used for neutralization assays, except that if this was not 
achieved using undiluted supernatant, then the undiluted supernatant was used. 
Figure 26: Schematic representation of the pseudovirus construction process and the neutralization assay. The plasmid 
carrying the envelope of interest and the envelope-deficient plasmid (HIVDenv) were co-transfected into the packaging cell. 
The HIVDenv provides the accessory genes while the envelope spikes of the pseudoviruses comes from the env plasmid.  
During the neutralization assay, the antibodies may or may not bind to the envelope spike. If they bind, the pseudovirus is 
blocked from entering the detector cell line and if not, entry to detector cell line happens. (The diagram used with permission 
from Jeffrey R. Dorfman). 
3.3.5 Cell lines 
TZM-bl cells were used as the target cells for HIV-1 pseudoviruses. These cells are modified 
from a clone of a Hela cell that expresses high levels of DC4, CCR5 and CXCR4 and support 
single cycle virus entry [592]. In addition, they are engineered with a luciferase reporter gene 
whose transcription is driven by an HIV-1 LTR. HIV-1 Tat, when produced by an invading HIV-
1, activates transcription of luciferase, which is therefore indicative of infection of the cell. 
These cells were obtained through the National Institute of Health (NIH) AIDS Reagent 
Program from Dr John C. Kappes and Dr. Xiaoyun Wu. Transfection experiments to make the 
pseudoviruses were done using HEK 293T cells. Both types of cells were maintained at 1.0 x 
106 cells in DMEM supplemented with 5% heat-inactivated Fetal Bovine Serum (FBS), 25mM 
Step 1. make pseudovirus:
transfect Packaging cell line
Envelope 
producing 
plasmids
Envelope 
proteins
Pseudovirus RNA
All other viral proteins
Make more pseudovirus RNA
Lots of  pseudovirus 
ready for assay
HIVDenv plasmid
env plasmid
Step 2. assay:
Pseudovirus
+
Add test sample:
(from dilution of patient 
sample)
-> May contain antibodies
-> We wish to know:
Do antibodies block the 
Envelope used to make 
the pseudovirus?
These antibodies 
might block entry, 
or they might not.
Shows 
binding here, 
but might not 
always 
bind…
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(no virus entry)
Does not 
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(virus enters 
target cell)
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HEPES (Lonza) and 1% non-essential amino amino acids (Sigma-Aldrich). The cultures were 
split every 3-4 days after they obtained more >80% confluence. Medium used for the assay 
contained DMEM, 10% FBS, 25mM HEPES, 1% non-essential amino acids, 100µg/ml 
streptomycin, 100U/ml penicillin and 100µg/ml gentamicin. 
3.3.6 Entry inhibitors 
Sensitivity to entry inhibitors was done in a TZM-bl based assay in the absence or presence of 
varying concentrations of the entry inhibitors, Maraviroc, PSC-RANTES, JM2987 and 
enfuvirtide (T20). Maraviroc is an allosteric CCR5 antagonist and is already in use as a 
therapeutic drug against HIV-1 [585]. PSC-RANTES is a chemokine analogue which is a 
competitive inhibitor of CCR5 [589]. Enfuvirtide (T-20) is a fusion inhibitor made of a synthetic 
peptide mimicking the carboxyterminal heptad repeat sequence (HR2) of gp41 preventing the 
interaction with the aminoterminal heptad repeat sequence (HR1). This prevents the 
formation of the hairpin structure necessary for the fusion of the virus with the cell 
membrane of the target cell [593]. The JM2987 is a CXCR4 inhibitor. Each entry inhibitor was 
first serial diluted 5-fold in DMEM containing 10% FBS. TZM-bl cells were then added and a 1-
hour pre-incubation done. This was followed by addition of the virus. Each entry inhibitor was 
tested in duplicate and luciferase activity was measured after 48 hours of culture. The entry 
inhibitor antiviral activity was determined as a percentage of viral inhibition in the presence 
of the inhibitor compared to the controls with no inhibitor. Plotting of the concentrations and 
the percentage inhibition in GraphPad Prism (GraphPad Prism software, La Jolla, USA) allowed 
the determination of EC50. Tests were repeated at least 2 times, and the final EC50 was 
calculated by taking the geometric mean of the EC50 values for each test. The geometric mean 
EC50 of values of blood-derived isolates were then compared to those from semen-derived 
isolates. 
3.3.7 Sequencing of the SGA clones 
The full-length envelope gene was sequenced using a standard set of 12 primers (Table 9) in 
such a way that the contigs partially overlapped to provide one contiguous sequence after 
assembly. Sequencing was performed by the Stellenbosch University Central Analytical 
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Facility. The sequenced fragments were processed and assembled and edited using 
Sequencher DNA analysis software version 4.9 (Gene Codes Corporation, Ann Arbor, MI, 
USA). Sequences of all SGA clones will be submitted to GenBank. The timing of release of the 
sequences will be in accord with the requirements of the journal in which this work is 
accepted for publication. 
Table 9: Primers used for Single Genome Amplification (SGA) PCRs, cloning and sequencing of the PCR amplicons 
NAME SEQUENCE HXB2 POSITION 
FORWARD/ 
REVERSE 
Primers used for PCR amplification 
VIF1(VIF) 5’– GGGTTTATTACAGGGACAGCAGAG-3’ 4903-4923 Forward 
OFM19 5’– GCACTCAAGGCAAGCTTTATTGAGGCTTA-3’ 9604-9632 Reverse 
ENV A 5’– GGCTTAGGCATCTCCTATGGCAGGAAGAA-3’ 5954-5982 Forward 
ENV N 5’– CTGCCAATCAGGGAAGTAGCCTTGTGT-3’ 9145-9171 Reverse 
Primers used for sequencing of SGAs 
EF00 5’- GGGAAAGAGCAGAAGACAGTGGCAATGA-3’ 6204-6228 Forward 
REV15 5’-CTGCCATTTAACAGCAGTTGAGTTGA-3’ 7015-6990 Reverse 
FOR14 5’-TATGGGACCAAAGCCTAAAGCCATGTG-3’ 6556-6582 Forward 
E175 5’-TTTAGCATCTGATGCACAGAATAG-3’ 6378-6398 Reverse 
EF115 5’-AGAAAAATTCTCCTCTACAATTAA-3’ 7351-7371 Reverse 
EF55 5’-GCC CCA GAC CGT GAG TTG CAA CAT ATG-3’ 7914-7937 Reverse 
EF15 5’-CTTGCTCTCCACCTTCTTCTTC-3’ 8424-8442 Reverse 
FOR16 5’-TTTAATTGTGGAGGAGAATTTTTCTA-3’ 7350-7375 Forward 
REV19 5’-ACTTTTTGACCACTTGCCACCCAT-3’ 8820-8797 Reverse 
EF170 5’-AGC AGG AAG CAC TAT GGG-3’ 7802-7816 Reverse 
EF200 5’-GGG ATA ACA TGA CCT GGA TGC AGT GGG-3’ 8095-8118 Forward 
EF260 5’-TTCAGCTACCACCGATTGAGAGACT-3’ 8523-8544 Forward 
Primers used for cloning 
ENVARX 5'-CACCGGCTTAGGCATCTCCTATAGCAGGAAGAA-3’ 5954-5982 Forward 
ENV N 5’– CTGCCAATCAGGGAAGTAGCCTTGTGT-3’ 9145-9171 Reverse 
120 
3.3.8 Processing of the sequence data and phylogenetic analysis 
The sequenced contiqs were assembled into full HIV-1 envelope sequences using Sequencher 
Sequence Analysis software version 4.9 (Gene Codes Corporation, Ann Arbor, MI, USA). 
Alignments were done using MAFFT [594] and edited in Aliview [553]. Maximum likelihood 
phylogenetic trees were constructed under GTR model using FastTree [554] and visualized in 
FigTree [560]. 
3.3.9 Analysis of the length of HIV-1 variable loops 
The variable loop lengths were determined using an online tool found in Los Alamos HIV 
sequence database site 
(https://www.hiv.lanl.gov/content/sequence/VAR_REG_CHAR/index.html). The online tool 
takes the alignment as input. 
3.3.10 Analysis of the number of potential N-glycosylation sites (PNGS) 
The predicted N-glycosylation sites were counted using N-glycosite tool available as a web 
service at Los Alamos HIV sequence database site 
(https://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html). The site also takes 
an alignment as the input data and uses the HXB2 sequence to number the positions. 
3.3.11 Statistical Analysis 
The statistical analysis was done in STATA (STATACorp) and GraphPad Prism. The graphs were 
generated in GraphPad Prism. Significance testing were done using non-parametric methods 
with significant result cut off p-value set at 0.05.  
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3.4 Results 
3.4.1 Study participants 
This part of the thesis was done using three study participants who had the highest extent of 
compartmentalization as detailed in the previous chapter. The characteristics of these three 
study participants is available in Table 10 below.  
3.4.2 Compartmentalization analysis 
As indicated previously compartmentalization was assessed from deep sequencing data using 
three standard statistical tests as described in chapter 2. Using participants with the highest 
extent of compartmentalization enabled us to see the phenotypic differences more clearly. 
Table 10: Study participants with CD4 counts, viral loads in blood and semen, number of Single genomes amplifications (SGAs) 
from each compartment and status of compartmentalization. From Chapter 2 
SampleID CD4 count 
(cells/µl) 
Blood 
viral 
load 
(cp/ml) 
Semen viral 
load 
(cp/sample)a 
Number 
of SGAs 
from 
Blood 
Number 
of SGAs 
from 
Semen 
FSTb
pvalue 
Snnc
pvalue 
SMTd   
pvalue 
SVB043 509 122297 5556598 12 10 <0.001 <0.001 <0.001 
SVB008 257 309388 38640 13 10 <0.001 <0.001 <0.001 
SVB049 423 85711 7915 8 10 <0.001 <0.001 <0.001 
SVB021 148 183339 4435 0 0 <0.001 <0.001 <0.001 
SVB026 209 46202 4843 0 0 <0.001 <0.001 <0.001 
SVB012 586 145745 6365 0 0 0.012 <0.001 <0.001 
SVB025 368 440969 23356 0 0 <0.001 <0.001 <0.001 
SVB030 390 25781 235710 0 0 <0.001 <0.001 <0.001 
SVB029 149 20947 273305 0 0 <0.001 <0.001 <0.001 
SVB039 425 43191 132605 0 0 <0.001 <0.001 <0.001 
SVB041 567 89090 27540 0 0 <0.001 <0.001 <0.001 
aViral load assumes 100% yield upon filtration and ultracentrifugation 
bFST = Wright’s F-statistic 
cSnn = Nearest Neighbour statistic 
dSMT = Slatkin-Maddison Test 
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3.4.3 Genotypic characteristics 
Each study participant’s blood and semen sample full-length envelopes were amplified using 
the SGA technique [457, 458]. A median of 10 (range 8 - 13) sequences were generated per 
compartment from the three donors who showed the highest extent of 
compartmentalization; SVB043, SVB008 and SVB049 (Table 10). Genotypic comparisons for 
variants from blood and semen were done regarding the variable loop lengths (V1V2, V3, V4, 
V5) and predicted N-glycosylation sites (PNGS). In the individual phylogenetic trees, full-
envelope each donors’ sequences clustered together with high bootstraps supports (above 
70) suggesting that the individuals were infected by one variant or a number of related
variants (Figure 27). In addition, it shows that there was no cross-sample contamination
between the three donors.
Figure 27: Maximum likelihood trees for donors SVB043, SVB008, SVB049 arranged by the extend of compartmentalization. 
Red color represent sequences from blood and blue color represent sequences from semen.  Donor SVB043 had the highest 
extend of compartmentalization of viral variants between blood and semen while donor SVB049 had the least. 
3.4.3.1 Variation of lengths of variable loops between plasma- and semen-derived 
populations 
It has previously been reported that among the HIV-1 subtype C viruses, the transmitted 
founder viruses have short V1-V4 regions [459]. Here the degree of variable loop 
SVB043 SVB049SVB008
HIGH TO LOW EXTENT OF COMPARTMENTALIZATION
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polymorphisms between blood and genital tract sequences were evaluated from subjects 
infected with HIV-1 subtype C. The variable loop lengths between blood and semen 
sequences within each donor were compared using Mann-Whitney test while inter-group 
comparisons were done using Dunn’s multiple comparison test.  
Significance differences in length of V1V2 region were observed between blood and semen 
variants of donor SVB043 who had the most compartmentalization viral populations between 
blood and semen (Mann-Whitney P < 0.001) (Figure 28 A). This however was not the case for 
V1V2 region for donors SVB008 and SVB049 (Figure 28 A). Unexpectedly, donor SVB043 
difference was in the opposite direction i.e. semen variants had longer V1V2 variable loops 
than their blood counterparts (Figure 28). There were no significant differences in length of 
V3, V4 and V5 between blood and semen clones for all the three donors (Figure 28 B-D). The 
V3 region lengths among all the three donors and compartments remained constant at 37 
amino acid with one clone from SVB049 blood variants having 38 amino acids (Figure 28 B).  
Between donor variations also occurred in all the variable regions except the V3 region (Figure 
28 E-G). Compared with other donors, SVB049 had longer V4 loop lengths (Figure 28 F). In 
addition, donor SVB043 semen V5 loops were longer than those from blood and semen of 
other donors (Figure 28 G). 
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Figure 28: Variable loops polymorphisms. SVB043 had semen clones with overall longer V1V2 variable loops than those from 
blood  which was not observed in the other two donors (A). There were no significant differences in loop polymorphisms in 
other variable loops between blood and genital compartment (B-D) although between donor variations occurred except in 
V3 region (E-G). 
3.4.3.2 Predicted potential N-glycosylation sites (PNGS) in plasma- and semen-derived 
viral populations 
Previous study had observed that the transmitted/founder (T/F) virus was underglycosylated 
in subtype C [459] and not in subtype B [525] HIV-1. In this section of the thesis, this property 
was investigated for donor semen variants and compared to those in blood. Indeed, the 
number of PNGS varied between the two compartments among the different donors but the 
direction of the difference was inconsistent (Figure 29). For the most severely 
compartmentalized donor, SVB043, semen variants had significantly higher number of PNGS 
compared to the blood counterparts (Figure 29 A). In contrast, for the second most 
compartmentalized donor, SVB008, sequences from the genital tract had lower number of 
PNGS compared to the blood sequences (Figure 30 B). There was no differences in number of 
PNGS between semen and blood variants for  donor SVB049 (Figure 29 C).  
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Figure 29: Predicted N-glycosylation sites (PNGS) in the variable loops. The semen variants for donor SVB043 had more PNGS 
than the variants from blood. In contrast donor SVB008 who had the most compartmentalized viral populations between 
blood and semen after donor SVB043 had less PNGS in semen than in blood. There was no significant difference in the number 
of PNGS between blood and semen variants for donor SVB049 
Considering number of PNGS in individual variable loops, variations were also observed. 
Generally, there was no difference in the number of PNGS between blood and semen in all 
the variable loops except V3 of donor SVB008 (Figure 30). Similarly between donor variations 
of the variable loops were observed and mainly occurred in V3, V4 and V5 and rarely in V1V2 
(Figure 30 E-H).  
Figure 30: Within (A-D) and between (E-H) Predicted N-glycosylation sites (PNGS) in the variable loops. There were no within 
donor variations in number of PNGS between blood and semen in all the variable regions except V3 of donor SVB008 (A-D). 
Between donor variations majorly occurred in V3, V4 and V5 and rarely in V1V2 (E-H) 
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3.4.4 Blood and semen viral compartmentalization and susceptibility to entry inhibitors 
Entry of HIV-1 into the target cells occurs during the initial steps of the lifecycle. Entry 
inhibition assays allows understanding of the differences in change of viral envelope function 
for variants in blood versus those in the genital tract. The coreceptor tropism was studied 
through sensitivity to maraviroc (CCR5 antagonist), PSC-RANTES (CCR5 competitive inhibitor), 
JM2987 (CXCR4 inhibitor) and enfuvirtide (T-20). Sensitivity to maraviroc varied between 
blood and semen variants among the three donors. Donor SVB043 who had the most 
compartmentalized viral populations between blood and semen had semen variants that 
were more insensitive to maraviroc (Figure 31 A). This was the opposite of what was found 
for donor SVB008 where the semen variants were sensitive to maraviroc (Figure 31 B). There 
was however a wide range of sensitivities of blood clones to maraviroc for this donor (Figure 
31 B). In contrast, there was a narrow range of sensitivities of semen clones to maraviroc for 
this particular donor (Figure 31 B). On the other hand, there was no difference in sensitivities 
to maraviroc between variants derived from blood and those from semen for donor SVB049 
(Figure 31 C).  
Figure 31: Sensitivities of blood and semen variants to maraviroc (CCR5 allosteric inhibitor). Donor SVB043 had semen variants 
that were more resistant to maraviroc inhibition than the blood counterparts (A). In contrast, donor SVB008 had semen 
variants that were more sensitive to maraviroc inhibition (B). There was no difference in sensitivities to Maraviroc between 
variants from blood versus those from semen for donor SVB049 (C). 
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Sensitivities of blood and semen variants to another form of CCR5 inhibitor, PSC-RANTES 
varied among the three donors (Figure 32). There were no significant differences in sensitivity 
of blood and semen variants to PSC-RANTES for donors SVB043 and SVB049 (Figure 32 A & 
C). In contrast, semen variants for donor SVB008 were more sensitive to PSC-RANTES than 
the variants from semen (Figure 32 B). 
Figure 32: Sensitivities of blood and semen variants to PSC-RANTES (CCR5 competitive inhibitor). Only donor SVB008 had 
differences in sensitivity to PSC-RANTES where semen variants were more sensitive to PSC-RANTES than variants from blood. 
Of note, donor SVB043 blood variants had a strong correlation in potency between maraviroc 
and PSC-RANTES despite differences in their mode of action r2 = 0.5206; p = 0.008079) (Figure 
33 A). This however was not the case with the semen variants of the same donor (r2 = 0.07265; 
p = 0.4514) (Figure 33 B). Donor SVB008 did not show a correlation in potential between 
Maraviroc and PSC_RANTES for both blood and semen variants (Figure 33 C & D). On the other 
hand, donor SVB049 had strong correlation between potencies of PSC-RANTES and Maraviroc 
for both blood r2 = 0.5468; p = 0.03603) and semen (r2 = 0.8072; p = 0.0009940) (Figure 33 E 
& F).  
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Figure 33: Correlation analysis of sensitivities to Maraviroc and PSC-RANTES. Solid line is the regression line while the dotted 
line is the 95% confidence intervals. 
All the three donors’ variants from blood and semen were resistant to JM2987, a CXCR4 
inhibitor suggesting that they were all R5-tropic virus (Figure 34 A – C). 
Figure 34: Sensitivities of compartmentalized blood and semen variants to JM2987. All the clones from blood and semen in 
all the three donors were insensitive to CXCR4 inhibitor. 
There were no differences in sensitivities of blood and semen variants to enfirvitide (T-20), a 
fusion inhibitor (Figure 35). However, semen variants for donor SVB049 had wide ranges of 
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sensitivity to T-20 compared to blood variants (semen geometric mean EC50 3.9 - 28.4 vs 4.0 
– 17.4 for blood) (Figure 35 C).
Figure 35: Sensitivities of compartmentalized blood and semen variants to T-20 (fusion inhibitor). There were no differences 
in sensitivities to T-20 between blood and semen for all the three donors who had the highest extent of compartmentalization. 
In sum, all the viruses tested in this part of the experiment were R5-tropic and the sensitivities 
to the entry inhibitors varied in each donor and in each compartment. 
3.4.5 Phenotypic assays isolates were sampled from across the diversity found in the original HIV-
1 population 
To study the diversity of the clones used for phenotypic assays (neutralization and sensitivity 
to entry inhibitors) and how they fit within the overall population in an infected donor, the 
data generated from deep sequencing for the three study participants (Chapter 2 of this 
thesis) was combined with single genome amplification (SGA) sequencing data (Figure 36). 
The isolates used for phenotypic assay (chapter 3) and neutralization (chapter 4) were 
represented well in the diversity observed from deep sequencing of the individual donor’s 
blood and genital tract (Figure 36).  
Most of the clones (8 out of 10) from semen of donor SVB043 clustered around one semen 
variant from deep sequencing data (Figure 36 A). As would be expected, this was the most 
dominant variant found in the genital tract of this donor representing 66% of all the 
sequences from this compartment (Chapter 2, Figure 24). Similarly 4 out of the 12 blood 
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clones came from a variant represented at 38.6% (Figure 36). Clones from donors SVB008 and 
donor SVB049 did not form part of clonal amplification clusters. 
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Figure 36: Phylogenetic trees generated from combined deep sequencing data and the sequences of isolates used for 
neutralization experiment. The diversity of neutralization isolates was well represented within the overall population of the 
infected donors. 
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3.5 Discussion 
The viruses produced in the male genital tract are genetically distinct from the variants found 
in the blood [289, 377, 381, 396, 490]. This could reflect the tissue-specific differences or 
differential pressures experienced by the virus in these anatomical sites. Such changes may 
manifest in the variable loop characteristics (V1-V5 length and PNGS density). In addition, 
sensitivity to entry inhibitors provides information about the change of function of the HIV-1 
envelopes as the virus moves from systemic circulation into the genital compartment.  This 
information will dovetail the observations from study of transmitted/founder virus to find out 
if some of the changes might have started in the genital tract of transmitting donors. 
Several studies have shown that transmitted founder (T/F) or acute HIV-1 is compact [459, 
506, 510, 595] and underglycosylated [459, 506, 510, 525, 595]. Over the course of infection 
and disease progression, the length of the variable loops and the number of glycosylation 
sites increases [506, 596]. However only a handful of these studies managed to directly 
compare the viruses with those found in the genital tract of donors [292, 409, 490]. In order 
to completely understand the HIV-1 transmission bottleneck, the virus compartmentalized in 
the donor’s genital tract need to be understood as it is the source of the potential T/F virus. 
Here three donors infected with HIV-1 subtype C and with highly compartmentalized viral 
variants in blood and semen were studied for genotypic and phenotypic variations between 
viruses in blood and the male genital compartment. The objective in this part of the study was 
to investigate whether viral isolates compartmentalized in semen and blood vary in variable 
loop characteristics or in interaction with viral receptors by displaying differing sensitivities 
to entry inhibitors. 
Shorter variable loops have been reported to be a characteristic of the T/F viruses in HIV-1 
subtypes C [459], A [510, 595] and D [595] but not B [510, 520, 597]. Only donor SVB043 who 
had the most severe compartmentalization among the donors studied had significant 
difference in the length of V1V2 between blood and semen. Variants from semen had longer 
V1V2 loops compared to variants derived from blood. The difference was in the opposite 
direction from what had previously been reported for T/F virus among HIV-1 subtype C [459]. 
Nonetheless, our observation supports the theory of local production of the virus within the 
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genital tract and that it responds to local selective pressures which are distinct from those in 
blood. This observation however neither explains the previous observation that the T/F virus 
in heterosexual transmissions selects for shorter variable loops [459] nor expansion of V1-V2 
envelope loop over the course of infection [596]. The V1V2 region is known to contain sites 
important for immune recognition [598] and therefore it makes it difficult to interpret this 
result in this manner since as will be shown later in Chapter 4 of this thesis, semen isolates 
from this donor were sensitive to donor autologous antibodies. For the rest of the donors, 
there were no overall differences in variable loop-lengths between variants from blood and 
those found in the genital tract. However, multiple comparisons of inter-donor loop-lengths 
showed donor-to-donor variations in variable loops lengths except in the V3 region which had 
a constant 37 amino acids. This suggest that selective pressures within blood and semen vary 
from donor to donor and between anatomical sites.  
The HIV-1 extracellular domain contains approximately 30 glycosylation sites, which have 
both structural and immune evasion roles [599, 600]. The virus is under pressure to conserve 
them and therefore a dynamic nature of absence and presence of the glycans in certain sites 
is established, which has led to the term ‘evolving glycan shield’, which protect the vulnerable 
epitopes beneath [516]. Previous studies have shown that the T/F virus is underglycosylated 
in subtypes A, C and D [459, 510, 595]and not B [510, 525]. The explanation is that in an 
immunologically naïve recipient, the glycan shield is not necessary and therefore such viruses 
are outcompeted by strains with a more compact and less glycosylated envelope. In this 
study, variation in number of glycosylation sites varied both between blood and semen 
compartments as well as between donors. Considering blood-semen pairs from all donors in 
aggregate, there was no difference in overall number of PNGS between blood and semen 
variants. However, considering differences per individual loop, PNGS in the V3 region reached 
significance overall where the semen variants were underglycosylated (Mann-Whitney p = 
0.026). Considering donor pair-per-pair, differences in PNGS were observed for donor SVB043 
(Mann-Whitney p = 0.04648) and SVB008 (Mann-Whitney p = 0.01156) although in opposite 
directions and no difference for donor SVB049. SVB043 who had the most compartmentalized 
viral populations between blood and semen, had semen sequences with more PNGS overall 
than the blood counterparts. This is consistent with expansion of the variable loop of the 
same donor detailed above which accumulates PNGS as well. In contrast, donor SVB008 had 
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semen variants that were underglycosylated without significant reduction in loop lengths. 
These observations are consistent with previous observations involving database blood-
semen pairs for subtype B viruses where differences were observed in the majority of the 
pairs, but the direction of the difference was inconsistent [409]. Our findings are also 
consistent with observations of Frost et al in a subtype B cohort involving men-who-have-sex-
with-men (MSM) [525] where only 1/6 of the epidemiologically-linked recipients had variants 
that were underglycosylated. It is possible for the observed discrepancy in direction of the 
difference that fewer glycosylation and by extent shorter loop lengths are indirect 
modifications that provide the structural change to the backbone that benefit the T/F virus. 
In support of this idea, V1V2 is known to modulate the CD4 and coreceptor binding sites 
altering interaction of the virus with the target cells [601, 602]. In addition, our data differs 
with studies of T/F or acute vs chronic viruses in the sense that these viruses might be a step 
further in the selection phase than variants compartmentalized in the genital tract. The T/F 
has gone through the selective effect in the donor’s genital tract, recipient’s genital tract and 
mucosal surfaces as well as selection to produce the disseminated infection. Each of these 
environments contributes to the selective process [468, 508].  It is also difficult to rule out 
cohort-to-cohort variations. Derdeyn et al studied a Zambian cohort of heterosexual 
transmissions while this thesis worked on a South African cohort in a clinic that predominantly 
gives care to men who have sex with men. One explanation given is that glycosylation is 
affected by the mode of HIV-1 transmission [506]. The HIV-1 subtype B cohort studied by 
Frost  et al was dominated by male-to-male transmissions while the cohort studied by 
Derdeyn et al was subtype C and the transmissions were primarily heterosexual.  
After glycans are processed in the endoplasmic reticulum and the Golgi body, the final one 
left is mannose-rich which is known to be neutralized by mannose-binding lectin (MBL) 
dominant in the female genital tract [603].  While donor SVB043 contrasts what Derdeyn et 
al [459] observed for HIV-1 subtype C in a cohort of transmitting partners in a heterosexual 
transmission setting, our overall findings agrees with these findings when transmitting pairs 
involving a male donor were considered in isolation. Derdeyn et al found underglycosylation 
as a feature of T/F virus in 5/8 of the study participants i.e. in all the 4 female donors and one 
male donor. Indeed, a more stringent transmission bottleneck for female-to-male 
transmission was also confirmed by the work on Carlson et al [489]. Our data therefore adds 
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to the theory that underglycosylation feature is more of a female-to-male transmission 
feature and not the other way.  
We also considered the sensitivities of blood and semen variants to entry inhibitors by 
evaluating them against Maraviroc, PSC-RANTES, JM2987 and T-20. In HIV-1 subtype C virus, 
CXCR4 coreceptor usage is rare and our cohort was not an exception; we found that all the 
donors had variants that were insensitive to CXCR4 inhibitors suggesting that they were R5-
tropic. This is in line with previous studies that showed that the virus found in acute or early 
infection is CCR5-tropic as individuals with a defective CCR5 coreceptor are protected against 
HIV-1 infection [457, 465, 502, 505, 506, 511, 604, 605]. The X4 viruses have also been 
reported to be underrepresented in semen suggesting that they are CCR5-tropic [409].   
To evaluate whether semen- and blood-derived isolates vary in their dependence on CCR5 
coreceptors, we performed sensitivity analysis against Maraviroc and PSC-RANTES. There 
were differences in sensitivity of blood and semen variants to Maraviroc, but the direction of 
the difference varied from donor to donor. Donor SVB043 who had the most 
compartmentalized viral populations between blood and semen, had semen variants that 
were more insensitive to maraviroc compared to blood variants. A study by Ping et al [506] 
comparing pseudotyped viruses constructed from acute and chronic infections found that the 
transmitted viruses were sensitive to CCR5 antagonist. Similar observations had been 
reported in previous studies either working on acute or the T/F virus [137, 457, 465, 502, 505, 
605]; suggesting the virus establishing infection uses CCR5 coreceptor for entry which seems 
to contradict observations for donor SVB043 semen variants. On the other hand, SVB008 had 
semen variants that were sensitive to maraviroc suggesting the shaping of the potentially T/F 
virus may start in the genital tract. This is consistent with previous observations involving 
subtype C acute vs chronic viruses [502, 505, 506, 605] and also mother-to-infant 
transmission [606].  
Susceptibility to PSC-RANTES, another CCR5 competitive inhibitor only had significant 
differences with donor SVB008 where the semen variants were more sensitive to inhibition 
than blood variants. The discordance for donor SVB043 in sensitivity to CCR5 inhibitors 
(Maraviroc vs PSC-RANTES) could be attributed to the difference in the mechanism of action 
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[607]. Maraviroc is an allosteric non-competitive inhibitor of CCR5 while PSC-RANTES acts 
using several mechanisms such as competitive inhibition or downregulation via internalizing 
the CCR5 receptor [608]. In addition, the CCR5 receptor has been reported to exist in two 
forms, maraviroc-sensitive and resistant-forms when the target cells have high concentration 
of CCR5 [506]; TZM-bl cells used in this experiment had high concentrations of CCR5 [609]. 
The T/F virus is known to use the maraviroc-sensitive conformation of the receptor while the 
chronic viruses are more promiscuous in the use of this receptor [506]. Therefore, it is 
possible that the genital tract HIV-1 of donor SVB043 had the maraviroc-resistant CCR5-
trophic phenotype which is unlike what had been observed previously for transmitted viruses 
[506]. This means that they were able to use the maraviroc-bound CCR5 receptors or an 
alternative form that is not inhibited by maraviroc at all.  
There were no differences in sensitivities to inhibition by T-20 between variants from blood 
and those from the genital compartment in all the 3 donors. This suggest that the structural 
intermediate bound by T-20 does not vary between variants from blood and those from 
semen. 
Potential limitation of this study is the use of data from only three study participants. Even 
though these were the participants showing the highest extent of compartmentalization, 
generalization of the findings becomes a challenge. 
3.6 Conclusion 
The Transmitted/founder virus has been characterized with viral properties that include 
utilization of CCR5, reduction in lengths of the variable loops and underglycosylation. The 
findings have been inconsistent, and most studies lacked the information on the virus 
compartmentalized in the genital tract. Here we found variations in variable loop 
characteristics and viral entry phenotype between variants from blood and semen for three 
of the most compartmentalized donors; although the observed differences were not 
consistent in any direction. This is indicative of discordant selective pressures operating on 
the virus in the male genital compartment which are distinctive from the experiences in blood 
which also varied from donor to donor. This suggest that for a subset of the recipients, the 
features observed for the transmitted virus may be acquired in the genital compartment 
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before the virus establishes in the recipient. This information helps to understand the nature 
of the virus compartmentalized in semen and potentially transmitted to new recipients. 
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4 CHAPTER 4 
Increased neutralization sensitivity of 
genital tract HIV-1 isolates compared to 
blood-derived isolates: a shift in the 
selective milieu shapes the population 
available for transmission? 
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4.1 Abstract 
Human Immunodeficiency Virus type 1 (HIV-1) transmission by the sexual route is known to 
involve a transmission bottleneck, in which only one or a very few variants result in the 
disseminated infection in new recipients. Further, the new disseminated infection in a 
recipient often appears to be derived from a minor variant in the donor. This has led many 
scientists to the believe that the transmitted founder virus is selected to be better suited for 
successful transmission. Hence it might have some identifing features. Previous reports had 
indicated that the T/F virus is sensitive to transmitting donor antibodies in at least a portion 
of transmission events. Interestingly, it remains possible that selection for the traits 
associated with the T/F virus begins before transmission, in the transmitting donor. 
Therefore, we hypothesized that there may be a shift of selective milieu when the virus moves 
from systemic circulation into the genital tract of infected male donors. If the male genital 
tract is partially shielded from circulating antibodies, it would be expected that the virus 
found in the genital tract would be more sensitive to the donor’s systemic circulating 
antibodies. 
Blood and semen samples were collected from HIV-1 infected men. Pseudoviruses were 
constructed from blood and semen isolates of three donors who had the highest extent of 
viral compartmentalization between the two anatomical sites. Neutralization using 
autologous serum obtained from blood at the time of sampling was done. Heterologous 
neutralization using a pool of HIV-1 subtype C serum was also done. 
One of the three donors, donor SVB043 with marked compartmentalization between blood 
and genital tract (FST = 0.47, p = 0.001, Snn = 0.9838, p = 0.001, chapter 2) had semen variants 
that were 1.82 (95%CI 1.06-3.13) more sensitive to donor antibodies than blood variants 
(Mann-Whitney test, p = 0.004429). This however was not the case for the other two subjects 
who had lower genetic variation between variants from blood and semen.  
These results suggest that in a subset of the donors there is a shift of selective milieu when 
the virus moves from systemic circulation into genital tract. The change in selective milieu 
might result from partial shielding of the genital tract from circulating antibodies. In contrast, 
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the neutralization sensitivity of semen variants compared to blood variants to neutralization 
by antibodies from a pool of sera was not different in donor SVB043, suggesting little change 
in overall/global neutralization sensitivity.  
These results will help in understanding the shaping of the virus found in the male genital 
tract that is potentially transmitted to the recipients.   
4.2 Background 
The Human Immunodeficiency Virus type 1 (HIV-1) found in newly established infections 
following successful sexual transmission can be traced back to one or very few isolates that 
themselves are derived from the minor populations in the presumed donor [457, 458, 469, 
472]. Acutely infected subjects have a homogeneous viral population compared to the 
heterogenous populations found in the presumed donor which indicates a “transmission 
bottleneck” [459, 468, 508]. There has been continuous effort to study and characterize 
isolates before and after the HIV-1 transmission bottleneck, particularly to understand to 
what extent it reflects stochastic nonspecific barriers that restricts all isolates equally, versus 
selection for some identifiable traits that reflect relative advantage to establish disseminated 
infection in the recipients. Knowledge of such characteristics would be beneficial in 
understanding the process of establishing HIV-1 infections in newly-infected individuals, and 
perhaps in designing the HIV-1 intervention strategies.  
Traditionally, the bottleneck has been associated with the virus’s inefficiency in penetrating 
the mucosal surfaces of the recipient [164, 469]. However, more recent studies indicate that 
there are other processes that may play a role in selecting which virus from the donor’s 
circulating variants becomes the transmitted/founder (T/F) [468, 508]. The physical barriers 
and selective pressures act at various steps of the cycle of transmission by selecting the 
isolates that reach the donor’s genital and transmission fluid, shaping the virus within the 
recipient’s genital tract and when crossing the recipient’s genital mucosa and finally during 
the establishment of systemic infection in the recipient [468, 508]. Together, these barriers 
and selective pressures block the majority of the viruses at the transmission bottleneck [457, 
458, 472]. These bottlenecks are incompletely defined and many studies appear to disagree 
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as to precisely what features are associated with T/F viruses [457, 467, 468, 473, 504, 505, 
508, 511, 610-620]. Nonetheless, the transmitted/founder viruses appear to be heavily 
selected, as acute viruses tend to have different characteristics from chronic viruses in 
transmitting donors [459, 489, 525, 526, 621] or when acute and chronic viruses were 
compared [510, 511, 615].  
Genital tract virus comes from local sources or shipped from blood. Using macaque models 
infected with simian immunodeficiency virus (SIV), it has been demonstrated that the viral 
variants in semen and other tissues of the male genital tract are often shipped from blood 
[433]. In addition, viral variants in the male genital tract have also been shown to be produced 
locally in addition to being imported from blood [381]. Thus, it appears that the variants 
available in the male genital tract may reflect an equilibrium between local production and 
trafficking between compartments. Indeed, trafficking back and forth between blood and the 
male genital tract has been confirmed by analyses by Chaillon and colleagues [303, 530]. 
Nonetheless, HIV-1 populations within an infected donor’s blood and male genital tract 
compartmentalize [289, 292, 303, 377-379, 381, 385, 396, 490], meaning that the two 
populations are at least partially distinct. A lower genetic diversity and lower rate of molecular 
evolution in seminal sequences relative to those from blood have been observed [409]. In 
addition, blood plasma and seminal plasma viral loads correlate poorly, with some individuals 
having higher viral load in semen than blood suggesting independent replication of the virus 
in the genital compartment [205, 377, 392, 411, 622]. More surprising is that many or most 
of the sequences in the male genital tract are clonally amplified [381, 490]. This can explain 
the observation that the quasispecies in the blood of chronically infected individuals are very 
diverse, but the diversity seems to be reduced in the genital tract and within the transmission 
fluid [490, 508]. Compartmentalization may also reflect physical constraints against migration 
between the compartments. That there are physical constraints to migration between blood 
and the genital tract is suggested by the fact that some small molecules such as antiretroviral 
drugs appear not to readily penetrate into the genital tract compared to others [442, 444]. 
Together, these observations support the idea that there is independent replication of the 
virus in the genital tract possibly due to changed selective milieu as the virus moves from 
systemic circulation into the male genital tract.  
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There is evidence that isolates from the newly established infections are sometimes more 
sensitive to neutralization by antibodies from the presumed HIV-1 donor.  One prominent 
study observed that the newly transmitted viruses in the recipients in a Zambian heterosexual 
transmission cohort infected with HIV-1 subtype C were more sensitive to the donor’s 
antibodies compared to isolates derived from blood [459]. Similar observations were 
reported from the same cohort when infectious molecular clones were used [526]. In a similar 
study involving HIV-1 subtype B transmission among men who have sex with men (MSM), 
Frost et al observed 2/8 of the recipient’s isolates to be sensitive to donor antibodies [525]. 
The authors of Frost et al study suggest that the transmissions with a difference in 
neutralization sensitivity tend to be transmissions from donors with chronic HIV-1 infections, 
noting that there is much less variability of HIV-1 populations in transmission donors with 
acute infections. It is also possible that mode of transmission and inter-clade variation might 
have had a role. We considered the possibility that these neutralization sensitive variants may 
arise much earlier in the donor’s genital tract before they are transmitted into the new host.  
In this study, we proposed that HIV-1 from the seminal plasma is in a genital tract site 
relatively protected from the antibodies and can therefore evolve into more neutralization-
sensitive variants. That changes in the HIV-1 populations occur during partially separate 
evolution of the virus in the genital tract may explain some of the systemic changes that 
appear to occur during viral transmission to a new host. We are unaware of any neutralization 
study involving seminal HIV-1 isolates. Such information will add to the understanding of the 
transition from donor virus to early acute viruses in a recipient derived from the transmitted 
virus.  
4.3 Methods 
4.3.1 Study participants 
The same study participants described in chapter 3 of this thesis were used. These study 
participants had the highest extend of compartmentalization as described in chapter 2.  
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4.3.2 RNA extraction and complementary DNA (cDNA) synthesis 
The RNA extraction was done using QIAamp Viral RNA Mini Kit (Qiagen) and following the 
manufacturer’s instructions as described in chapter 3 of this thesis. The extracted RNA was 
transcribed to cDNA using SuperScript First-Strand Synthesis System Kit (Invitrogen) as 
described in Chapter 3 of this thesis. 
4.3.3 Single genome amplifications (SGA) 
The single genome amplification (SGA) technique was used to amplify single genomes as 
adapted from previous studies [456-458]. The description is as detailed in Chapter 3 of this 
thesis. 
4.3.4 Cloning and construction of pseudoviruses 
The generated envelope amplicons were cloned into a mammalian expression vector 
pcDNA3.1D/V5.His.TOPO (Invitrogen, Carlsbad, CA, USA) as described in Chapter 3 of the 
thesis. Pseudoviruses were constructed using established methods [592] as described in 
Chapter 3 of the thesis.  
4.3.5 Sequencing of the full-length envelopes from blood and semen isolates 
Sequencing of the clones obtained from blood and semen was done at Stellenbosch 
University Sequencing facility (SUN). Twelve primers encompassing the whole of the HIV-1 
envelope were used as described in Chapter 3 of the thesis.  
4.3.6 Sequence analysis 
The assembled sequences were aligned using MAFFT [594] and inspected in Aliview [553]. 
Blood and semen sequences were then combined in one alignment and maximum likelihood 
trees constructed using the generalized Time Reversible model (GTR) in FastTree [554]. In 
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order to determine how the pseudovirus env clones fit into the HIV-1 diversity of the study 
participant from which they came from, full-length envelope sequences were trimmed at 
either C3-V5 or V3 regions (depending upon the region analysed by Miseq deep sequencing 
from that study participant (see Chapter 2), combined with the sequences generated from 
the same donors by deep sequencing of these regions and a maximum likelihood tree was 
constructed. Trees were visualized in FigTree [560]. 
4.3.7 Serum for autologous neutralization 
Serum collected from blood at the same time blood and semen samples were collected was 
used as the source of the study participant’s own (autologous) neutralizing antibodies. The 
serum was heat-inactivated at 56oC for an hour and stored at -80oC for later use. For 
autologous neutralization patient-based antibodies were evaluated against same patient’s 
blood and semen pseudoviruses.  
4.3.8 Construction of HIV-1 subtype C sera pool for heterologous neutralization 
A pool of heterologous sera was constructed from HIV-1 subtype C-infected South African’s 
sera that had previously been mapped and published [623]. To make the subtype C pool, a 
total of 24 sera were selected from a total of 177 representing between 45th - 90th percentiles 
for potency, and a similar proportion of sera as the overall population of sera with dominant 
neutralizing antibodies specific for the membrane proximal external region (MPER), V2 apex 
and V3 glycans which has been previously reported [623]. TZM-bl-based neutralization assays 
were performed over a series of dilutions of serum in duplicate wells.  
4.3.9 Neutralization HIV-1 assays 
Neutralization assays were performed according to established methods [592]. Briefly, serum 
was first diluted 1:25 (for Donor SVB049 autologous neutralization, the isolated IgGs start 
concentration was 2150µg/ml) and put in duplicate in the first row of a flat-bottomed 96-well 
plate. A three-fold dilution was then performed down the 96-well plate. The serum was then 
pre-incubated for 1 hour with 50µl of the pseudovirus. Fifty microliters of freshly prepared 
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TZM-bl cells were then added at a final concentration of 10,000 cells/well. The cells were 
constituted in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% Fetal 
bovine serum (FBS), HEPES, antibiotics and 7.5µg/ml DEAE-dextran. Controls included TZM-
bl cells alone (cell controls) and TZM-bl cells with virus (virus controls). Unrelated Murine 
Leukaemia virus (MLV) and a lab-adapted neutralization sensitive strain SF-162 that is very 
sensitive to neutralization were also used. The MLV control helped to identify the presence 
of viral inhibitors in serum. Incubation was done for 48 hours and then developed in a 
luciferase assay system. To measure luciferase activity, 100µl of the supernatant was 
removed followed by addition of similar volume of Bright-Glo luciferase assay substrate 
(Promega, Madison, USA). After a 2-minute incubation, 100µl of the mixture was transferred 
to 96-well opaque plate, and luminescence was measured using a VERITAS luminometer 
(Turner Biosystems). 
4.3.10 Measurement of antiretroviral levels from donor SVB049 donor plasma 
Donor SVB049 serum inhibited unrelated Murine Leukaemia Virus (MLV). Therefore levels of 
the most common component of first line and protease inhibitor antiretroviral therapy (ART) 
used in South Africa at the time of sample collection were tested. A mass spectroscopy 
method was used to check for the commonly used antiretroviral drugs with the longest half-
lives in first line and second line antiretroviral therapy (ART), efavirenz, and lopinavir, 
respectively. The assay was qualitative with lower detection limits of 0.02µg/ml, substantially 
lower than the minimum trough blood plasma concentrations needed for efficacy, 1µg/ml for 
both drugs. 
4.3.11 Purification of immunoglobin G (IgG) from donor SVB049 
To remove the inhibitor (efavirenz) from the serum of donor SVB049, the IgGs from donor 
SVB049 were purified using Nab Protein G Spin Kit (Thermo Scientific) and following the 
recommendations of the manufacturer. Briefly, 0.5ml of serum was mixed with equal volume 
of PBS before loading into the provided affinity column with protein G agarose resin after 
equilibrating the column at room temperature. The column with the sample was then 
incubated at room temperature for 10 minutes with end-to-end mixing. Three washes with 
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the provided binding buffer were done with one-minute centrifugation after each wash. 
Elution was then done with the provided elution buffer into tubes containing (a tenth of the 
elution buffer volume) neutralization buffer. Multiple elution were done to make sure that 
most of the bound antibodies were eluted. Quantification of the IgGs from the elute fractions 
was then done using nanodrop by measuring the relative absorbance at 280nm. The fractions 
with the highest amount of antibody after quantification were combined and desalting done 
using Zeba Spin Desalting Columns (Thermo Scientific) and following the manufacturer’s 
instructions. The purified IgGs were used for the autologous neutralization assay for donor 
SVB049.  
4.3.12 Determination of ID50 values 
The 50% inhibitory dilution (ID50), defined as the dilution of serum that resulted in 50% 
inhibition of viral entry, was then determined using GraphPad Prism version 8 (GraphPad, La 
Jolla, USA) for donors SVB008 and SVB043. Values are displayed as the geometric mean of the 
ID50 from two independent experiments. Values for purified antibody from SVB049 are 
displayed as IC50 values, defined as the antibody concentration that resulted in 50% inhibition 
of viral entry. Lower IC50 and higher ID50 values indicate higher neutralization activity. 
4.4 Results 
4.4.1 Study participants 
RNA extracted from blood and semen samples of three study participants who showed the 
highest extent of compartmentalization after deep sequencing and compartmentalization 
analysis (Table 10, and Chapter 2 of this thesis) were used to construct the pseudoviruses. As 
previously indicated SVB043 had the most severe compartmentalized viral populations 
between blood and semen followed by SVB008 and SVB049. 
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Table 11: Study participants with CD4 counts, viral loads in blood and semen, number of SGAs from each compartment and 
status of compartmentalization. Three standard techniques were used to evaluate compartmentalization; FST = Wrights 
measure of population subdivision, Snn = Nearest neighbor statistic, SMT = Slatkin Maddison test. 
SampleID CD4 count 
(cells/µl) 
Blood 
viral 
load 
(cp/ml) 
Semen viral 
load 
(cp/sample) 
Number 
of SGAs 
from 
Blood 
Number 
of SGAs 
from 
Semen 
FST 
pvalue 
Snn p 
value 
SMT p 
value 
SVB043 509 122297 5556596 12 10 <0.001 <0.001 <0.001 
SVB008 257 309388 38640 13 10 <0.001 <0.001 <0.001 
SVB049 423 85711 7915 8 10 <0.001 <0.001 <0.001 
4.4.2 Donor SVB049 tested positive for efavirenz 
Donor SVB049 serum neutralized unrelated MLV control during the autologous neutralization 
assay which was not the case for donor SVB043 and SVB008 (Figure 37). On testing for drugs 
with long half-lives commonly used in combination for ART in South Africa, donor SVB049 was 
positive for efavirenz. On purification of IgGs, the inhibitor was successfully removed (Figure 
37 D). Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that prevent the 
reverse transcriptase enzyme from working. This means that the drug pressure will 
presumably reflect more on the pol and not the env where antibody pressure mainly targets. 
Nonetheless, it is difficult to rule out founder effects, in which partially random env genes are 
selected because they are in the same genome as the drug selected pol gene. It was possible 
to recover viruses from this donor’s blood and semen which may suggest that these viruses 
were resistant to efavirenz, although this was not empirically tested. It is therefore difficult 
to differentiate between antibody and drug pressure for donor SVB049. 
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Figure 37: Neutralization profiles using donor antibodies. Pseudoviruses expressing the envelope proteins from the HIV-1 
unrelated Murine Leukaemia virus (MLV) and from a neutralization-sensitive strain SF-162 pseudoviruses were used as 
internal controls in the neutralization experiments. The use of MLV also helped to identify the presence of viral inhibitor in 
donor sera (usually antiretroviral drugs). Panels A-C shows the neutralization profile for the three donors used in the 
neutralization experiments. Donor SVB049 serum inhibited MLV and therefore purification of IgGs was used to separate the 
neutralizing antibodies from other components of the serum, and neutralization repeated on successful purification (panel 
D). 
4.4.3 Increased sensitivity to autologous neutralization was observed for the most severe blood 
vs semen compartmentalized donor 
A total of 63 pseudoviruses were generated from blood and semen from the three donors 
who had the highest extent of compartmentalization determined using three standard 
statistical techniques as detailed in chapter 2 of this thesis. Here, pseudoviruses generated 
from blood and semen were tested for differences in sensitivities to autologous antibodies 
that were collected at the same time the samples were collected. The aim was to investigate 
if there was partial shielding of viral variants compartmentalized in the male genital tract 
viruses from autologous antibodies. This would test the change of selective milieu between 
variants from blood and the male genital compartment.  
Sensitivities of blood and genital tract pseudoviruses to autologous antibodies varied among 
the highly compartmentalized donors. Donor SVB043 who exhibited particularly severe 
compartmentalization (FST = 0.47, p = 0.001, Snn = 0.9838, p = 0.001) had semen variants that 
1.5 2.0 2.5 3.0 3.5
0
50
100
log10 Dilution
pe
rc
en
ta
ge
 n
eu
tra
liz
at
io
n
SVB043 autologous netralization
SVB043_BP_SGA_2
SVB043_BP_SGA_11
SVB043_BP_SGA_12
SVB043_BP_SGA_13
SVB043_BP_SGA_14
SVB043_BP_SGA_15
SVB043_BP_SGA_16
SVB043_BP_SGA_17
SVB043_BP_SGA_21
SVB043_BP_SGA_23
SVB043_BP_SGA_28
SVB043_BP_SGA_30
SVB043_SP_SGA_8
SVB043_SP_SGA_9
SVB043_SP_SGA_10
SVB043_SP_SGA_11
SVB043_SP_SGA_12
SVB043_SP_SGA_13
SVB043_SP_SGA_15
SVB043_SP_SGA_27
SVB043_SP_SGA_28
SVB043_SP_SGA_33
MLV
SF_162
2 3
0
50
100
Dilution
pe
rc
en
ta
ge
 n
eu
tra
liz
at
io
n
SVB008 autologous neutralization
SVB008BP_SGA_3
SVB008BP_SGA_5
SVB008BP_SGA_6
SVB008BP_SGA_8
SVB008BP_SGA_9
SVB008BP_SGA_10
SVB008BP_SGA_12
SVB008BP_SGA_16
SVB008BP_SGA_17
SVB008BP_SGA_18
SVB008BP_SGA_20
SVB008BP_SGA_21
SVB008BP_SGA_22
SVB008SP_PH_1
SVB008SP_PH_4
SVB008SP_PH_6
SVB008SP_SGA_1
SVB008SP_SGA_4
SVB008SP_SGA_5
SVB008SP_SGA_7
SVB008SP_SGA_8
SVB008SP_SGA_10
MLV
SF_1621.5 2.0 2.5 3.0 3.5
70
80
90
100
110
dilutions
pe
rc
en
ta
ge
 n
eu
tra
liz
at
io
n
SVB049 autologous neutralization
SVB049BP_SGA_5
SVB049BP_SGA_6
SVB049BP_SGA_9
SVB049BP_SGA_10
SVB049BP_SGA_11
SVB049BP_SGA_12
SVB049BP_SGA_13
SVB049BP_SGA_14
SVB049SP_SGA_1
SVB049SP_SGA_2
SVB049SP_SGA_3
SVB049SP_SGA_9
SVB049SP_SGA_11
SVB049SP_SGA_13
SVB049SP_SGA_15
SVB049SP_SGA_16
SVB049SP_SGA_17
SVB049SP_SGA_21
MLV
SF-162
Blood isolates
Semen isolates
MLV
SF-162
A
C D
B
150 
were 1.75 (95%CI 1.11-2.78) more sensitive to autologous antibodies (p = 0.004) (Figure 38 
A). Pseudoviruses generated from the genital tract and blood for donors SVB008 and SVB049 
had no differences in sensitivities to autologous antibodies (Figure 38).  
Of note is that donor SVB049 who was positive for efavirenz, had blood and semen isolates 
with similar sensitivities to autologous IgGs. It is however difficult to distinguish between 
genital vs blood compartmentalization and/or selection driven by partial shielding from drugs 
vs the one resulting from circulating antibodies. 
Figure 38: Sensitivities of pseudoviruses generated from blood and semen to autologous antibodies collected from donors at 
the same time the samples were obtained. Donor SVB043 who also showed severe compartmentalization had genital tract 
variants that were more sensitive to autologous antibodies compared to variants from blood. The other two donors, SVB008 
and SVB049 did not show differences in sensitivities to autologous antibodies between variants from blood and genital tract. 
The x-axis represents the compartment where the isolates came from while the y-axis represent the log to base ten of the 
geometric mean calculated from two replicates of the experiments. Red colour represents the isolates from blood and blue 
the isolates from semen. 
4.4.4 Genital tract HIV-1 isolates of SVB043 were not inherently more sensitive to neutralizing 
antibodies 
We considered that the genital tract variants were globally more sensitive to neutralizing 
antibodies. There is a range of overall sensitivity to neutralizing antibodies of HIV-1 isolates 
[624] which has led to characterising HIV-1 isolates by “tier,” with tier 1 being the most
sensitive and tier 3 isolates being the least sensitive. In order to address whether changes in
the overall neutralization sensitivity could explain the difference in neutralization sensitivity
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to autologous antibodies observed among the clones isolated from blood vs semen of donor 
SVB043 [624], a HIV-1 subtype C sera pool was constructed from a cohort recruited in South 
Africa as previously stated. There was no overall difference in neutralization sensitivities to 
the subtype C serum pool between blood and semen variants for donor SVB043 and SVB008 
(Figure 39). Unexpectedly, for donor SVB049, variants derived from semen were more 
sensitive to neutralization by heterologous antibodies compared to variants derived from 
blood (Figure 39). The meaning of this is not clear because in this case, there was no detected 
difference in sensitivity to neutralization by autologous antibodies. 
Overall, these results indicate that sensitivities of genital tract strains of SVB043 to antibodies 
is driven by autologous antibodies and does not reflect a change in overall neutralization 
sensitivity to common neutralizing antibodies.  
Figure 39: Sensitivities of blood and semen isolates to HIV-1 subtype C sera pool from a South African cohort. There were no 
differences in sensitivities of blood vs semen isolates to heterologous antibodies for donors SVB043 and SVB008. Donor 
SVB049 had semen variants that were more sensitive to heterologous antibodies compared to those from blood. The values 
on the y-axis represents the log to base 10 of the geometric mean of two replicate experiments while the x-axis represent the 
compartment from which the isolates came from. 
4.4.5 Phylogenetic analysis of viral isolates from blood and semen plasma 
The relationship between HIV-1 populations in blood and semen of the subjects who were 
used for neutralization experiments was done by comparing full-length envelope sequences 
(Figure 40). Phylogenetic reconstruction of donor SVB043 isolates from blood and semen 
revealed that seminal plasma isolates formed a monophyletic group that was distinct from 
the isolates from blood (Figure 40 A). This data is highly suggestive of a shift in the selective 
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milieu of the genital tract of donor SVB043, resulting from the partial shielding of genital tract 
HIV-1 variants from circulating antibodies. Alternatively, the monophyletic clade might have 
resulted from expansion of an infected T cell within the genital tract. This would mean that 
the observed selection is of the T cell receptor found on the infected T cell and not necessarily 
selction of HIV in them hence clonal amplification. The viral variants compartmentalized in 
the genital tract of donor SVB043 are evolving independently from those in blood due to 
possible  change in the selective environment between the two compartments.  
While donor SVB043 clustering was much more severe, donors SVB008 and SVB049 showed 
some intermingling of blood and semen sequences (Figure 40 B & C). Furthermore, donor 
SVB049 had more intermingled blood and semen sequences compared to donor SVB008, who 
had one cluster supported by a strong bootstrap value carrying more than 50% of the blood 
plasma sequences. The extent of phylogenetic compartmentalization represented here 
(SVB043 > SVB008 > SVB049) is very similar to the one shown in chapter 2 using deep 
sequencing data.  
The antibody pressure in donors SVB008 and SVB049 did not act perceptibly differently upon 
the isolates from blood and those from the genital compartment. This is suggestive that the 
variants are recent in one compartment and have not had enough time to evolve consistently 
in response to the changed selective environments.  Alternatively, it could also mean that 
there is movement of the variants between blood and the genital compartment such that any 
differential effect within either compartment is negated.  
Figure 40: Phylogenetic trees of full length env clones isolated from donors SVB043, SVB008 and SVB049. Donor SVB043 had 
the most compartmentalized viral sequences between blood and genital tract. Semen sequences formed a distinct cluster 
represented by high bootstrap supports from blood sequences of this donor. On the other hand, donors SVB008 and SVB049 
SVB043 SVB049SVB008
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had blood and semen sequences that were partially intermingled together. The red and blue colours represent variants from 
blood and semen respectively. Percentages at each node reflect the level of bootstrap support for the geometry of that node. 
4.5 Discussion 
The nature of the HIV-1 transmission bottleneck is mainly presumed to include effects from 
the integrity of the mucosal surfaces of the recipient’s genital tract [469]. However, other 
characteristics of the isolate may also be important in determining its transmissibility [468, 
508]. Three previous reports have suggested that the HIV-1 isolates found in the newly 
infected recipient are sometimes sensitive to neutralization by antibodies derived from 
transmitting donor [459, 525, 526]. These studies however did not test whether selection for 
the neutralization sensitivity phenotype of transmitted/ founder (T/F) virus might have 
started much earlier in the transmitting donor. The virus that must be antagonized by a 
successful vaccine or by mucosal interventions during sexual transmission is the one found in 
the genital tract.  
Donor SVB043 who had the most severe compartmentalized viral populations between blood 
and semen, had semen variants that were more sensitive to autologous neutralization than 
their blood counterparts. This observation supports the idea of partial shielding of the genital 
tract viral variants from circulating antibodies, i.e. that the release of antibody pressure from 
isolates in the genital tract leads to variants that are more sensitive to donor antibodies than 
circulating blood isolates. Importantly, it thus appears that neutralization sensitivity of 
transmitted isolates may arise in the donor’s genital tract before transmission to the new 
host, at least in some of the donors. To our knowledge, this has not been reported previously. 
Of the three reports of increased sensitivity of newly transmitted variants to neutralization 
by antibodies of the donor, one study observed it in all transmission pairs studied [459], one 
observed it in 2/8 transmission pairs studied [525] and the third study was only able to detect 
the difference by aggregating data from several transmission pairs [526]. It thus seems likely 
that not all transmission pairs exhibit a change in neutralization sensitivity upon transmission. 
This matches our results, in which only one out of three study participants exhibited increased 
autologous neutralization sensitivity of semen isolates compared to blood isolates. It is thus 
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possible (although speculative) that the increased sensitivity in recipients only occurs if there 
is increased sensitivity of the genital tract isolates in the transmission donor. 
This work therefore broadens the previous observations by Derdeyn et al [459], Deymier et 
al [526] and Frost et al [597] who observed neutralization sensitivity of recipient viruses to 
antibodies from the transmitting donor. In Derdeyn et al work [459], four of the transmitting 
pairs involved male donors and  two had envelope clones that were obtained from plasma 
(the other two came from PBMC source). Based on the observations in this thesis, it is possible 
that selection of the neutralization sensitivity to donor antibodies phenotype in some 
recipients might have started in the genital tract of the donors; at least for the two donors in 
Derdeyn et al  [459] whose source of clones was plasma.   
On the other hand, donors SVB008 and SVB049 who also had high extent of 
compartmentalization but less severe than that of SVB043, exhibited no detectable difference 
in sensitivities of blood and semen viruses to autologous antibodies. The discrepancy could 
be explained by the fact that the barrier between blood and the genital compartment was 
not completely tight as evidenced by the intermingling of some blood and semen sequences 
in the phylogenetic trees. It is possible that the semen variants of these donors were recent 
in the genital tract and had not had enough time to experience the changed selective milieu 
within the genital compartment. It is also possible that these donors are more recently 
infected and have less neutralising antibody with which to select viral populations in the 
blood, the reason that Frost et al [525] cited to explain why, in their study, only some of the 
HIV-1 transmissions were associated with an increased in sensitivity of isolates from the 
recipient’s disseminated infection.  An additional confounder for donor SVB049 might be the 
use of antiretroviral drug which makes it difficult to single out drug and antibody pressure. 
There was no difference in sensitivity of blood and semen variants to heterologous antibodies 
(from HIV-1 subtype C pool) for donor SVB043 who previously had semen variants that were 
sensitive to autologous antibodies. This suggest that the change in sensitivity to antibodies of 
semen-derived isolates versus those in blood does not reflect overall change in neutralization. 
Though the viruses were steps further in selection towards transmitted/founder viruses, the 
work of Derdeyn et al [459] and Ping et al [506] had reported lack of differences in sensitivity 
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of donor and recipient viral variants to heterologous subtype C sera in the context of 
heterosexual transmission. Our data therefore suggest that the overall sensitivities to 
antibodies for blood vs genital tract variants is donor-specific rather than a HIV-1 subtype C 
population-based feature. The only donor who exhibited a difference in inherent 
neutralization to a serum pool was donor SVB049, who was on antiretroviral therapy, which 
could have resulted in selective pressures that affected the inherent sensitivity of viruses in 
one or the other compartment. 
In conclusion, this study is the first to show that in some donors, the neutralization 
sensitivity feature of potentially transmitted/founder viruses begins in the donor’s genital 
tract. In addition, we show that the genital tract has altered antibody selective milieu that 
shape the virus on the way to becoming a transmitted/founder virus in one among the three 
study participants that we analysed. This strongly suggests that the selection of HIV-1 
populations in the genital tract can substantially and meaningfully alter which viral isolates 
can transmit. Therefore the trait of selection of donor antibody-sensitive viruses during 
transmission observed in previous studies may well had started in the genital tract of the 
transmitting donors in a subset of the cases. 
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sequencing) of which they are referenced in this thesis.  
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